Compositions comprising circular polyribonucleotides and uses thereof
Untranslatable cyclic polyribonucleotides with aptamer sequences form stable complexes to modulate gene expression and cellular processes, addressing the need for targeted interaction with nucleic acids and proteins, offering enhanced stability and reduced immunogenicity.
Patent Information
- Application Number
- JP2024159028
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-06-19
- Filing Date
- 2024-09-13
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing technologies lack effective methods for modulating gene expression and cellular processes using cyclic polyribonucleotides that are stable and have reduced immunogenicity, allowing for targeted interaction with nucleic acid molecules, proteins, and other cellular components.
The development of untranslatable cyclic polyribonucleotides with specific aptamer sequences that form stable complexes with targets such as nucleic acids, proteins, and small molecules, modulating gene expression and cellular processes while maintaining low immunogenicity and high stability.
The described cyclic polyribonucleotides effectively modulate gene expression, transcription, and cellular processes, demonstrating increased stability and reduced immunogenicity compared to linear counterparts, with detectable activity up to 10 days post-delivery.
Smart Images

Figure 2024169484000006 
Figure 2024169484000007 
Figure 2024169484000008
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a joint application of U.S. Provisional Patent Application No. 62 / 702, filed on July 24, 2018. ,714; 62 / 823,569, filed March 25, 2019 and priority to specification No. 62 / 863,670, filed June 19, 2019. and claims the benefit therefrom, the entire contents of each of which are incorporated herein by reference. To be incorporated. [Background technology]
[0002]
[0002] Certain cyclic polyribonucleotides are capable of binding to human tissues and cells, e.g., those of healthy individuals. It is ubiquitous in tissues and cells. Summary of the Invention
[0003] The invention described herein relates to compositions comprising cyclic polyribonucleotides and their Includes instructions for use.
[0004] In some embodiments, the method of binding a target in a cell comprises the step of: The aptamer sequence is an untranslatable circular polyribonucleic acid sequence that has a secondary structure that binds the target. and delivering untranslatable circular polyribonucleotides to cells to produce untranslatable The cyclic polyribonucleotides produced detectable complexes with the target at least 5 days after delivery. In some embodiments, the target is a nucleic acid molecule, a small molecule, a protein, In some embodiments, the target is selected from the group consisting of a carbohydrate, a lipid, and a genomic DNA. In some embodiments, the gene regulatory protein is a transcription factor. In some embodiments, the nucleic acid molecule is a DNA molecule or an RNA molecule. In some embodiments, the complex modulates gene expression. The complex mediates the directed transcription of DNA molecules and the epigenetic remodeling of DNA molecules. In some embodiments, the complex modulates the degradation of a target Modulates degradation of a target, translocation of a target, or target signaling. In some embodiments, gene expression is associated with the pathogenesis of a disease or condition. In some embodiments, the complex is detectable at least 7, 8, 9, or 10 days after delivery. In one embodiment, the untranslatable circular polyribonucleotide is In some embodiments, the non-translatable circular polyribonucleotide is less likely to be delivered. In some embodiments, the untranslatable circle is present after at least 6, 7, 8, 9, or 10 days. A circular polyribonucleotide is an unmodified, non-translatable circular polyribonucleotide. In an embodiment, the untranslatable circular polyribonucleotide is a quasi-double-stranded polyribonucleotide. In some embodiments, the aptamer sequence has a secondary structure that binds the target. In some embodiments, the cell is a eukaryotic cell. In an embodiment, the eukaryotic cell is a human cell.
[0004]
[0005] In some embodiments, the method of binding a transcription factor in a cell comprises binding the transcription factor. providing an untranslatable circular polyribonucleotide comprising an aptamer sequence that causes translation; Delivering untranslatable circular polyribonucleotides to cells, , forming a complex with a transcription factor and modulating gene expression.
[0005]
[0006] In some embodiments, the method of sequestering a transcription factor in a cell comprises: providing an untranslatable circular polyribonucleotide comprising an aptamer sequence that causes translation; a non-translatable circular polyribonucleotide is delivered to the cell, the non-translatable circular polyribonucleotide being This involves sequestering transcription factors by binding them to form a complex in the cell. In some embodiments, cell viability is decreased following formation of the complex.
[0006]
[0007] In some embodiments, the method of sensitizing a cell to a cytotoxic agent comprises administering to a subject a transcription factor providing an untranslatable circular polyribonucleotide comprising an aptamer sequence that binds; and delivering cytotoxic agents and untranslatable circular polyribonucleotides to cells and Polyribonucleotides form complexes with transcription factors in cells; they cause untranslatable Sensitizing cells to cytotoxic agents compared to cells lacking cyclic polyribonucleotides In some embodiments, sensitizing the cells to a cytotoxic agent comprises administering to the cells a cytotoxic agent and Decreased cell viability following delivery of untranslatable circular polyribonucleotides. In embodiments, the decreased cell viability is due to the administration of cytotoxic agents and untranslatable circular polyribonucleic acid. The decrease is by more than 40% at least two days after delivery of the chitin.
[0007]
[0008] In some embodiments, the method of binding a pathogenic protein in a cell comprises binding a pathogenic protein to a pathogenic protein in a cell. Providing an untranslatable circular polyribonucleotide containing an aptamer sequence that binds a protein and delivering the untranslatable circular polyribonucleotide to a cell and Polynucleotides form complexes with virulence proteins for their degradation This includes:
[0008]
[0009] In some embodiments, the method of binding a ribonucleic acid molecule in a cell comprises binding a ribonucleic acid molecule to a providing an untranslatable circular polyribonucleotide comprising a sequence complementary to the sequence of the nucleic acid; and Delivering untranslatable circular polyribonucleotides to cells and involves forming a complex with a ribonucleic acid molecule.
[0009]
[0010] In some embodiments, a method for binding genomic deoxyribonucleic acid molecules in a cell The present invention provides a method for the preparation of a non-translatable circular polynucleotide that contains an aptamer sequence that binds a genomic deoxyribonucleic acid molecule. and delivering untranslatable circular polyribonucleotides to cells. The untranslatable circular polyribonucleotide forms a complex with the genomic deoxyribonucleic acid molecule. and modulating gene expression.
[0010]
[0011] In some embodiments, the method of binding a small molecule in a cell comprises binding the small molecule. providing an untranslatable circular polyribonucleotide comprising an aptamer sequence that The translatable circular polyribonucleotides are delivered to the cells, whereas the non-translatable circular polyribonucleotides are delivered to the cells. In some embodiments, the compound forms a complex with a molecule and modulates a cellular process. In the present study, small molecules are organic compounds with molecular weights of 900 daltons or less that are involved in cellular processes. In some embodiments, the small molecule is a drug. In some embodiments, the small molecule is a fluorophore. It is a metabolic product.
[0011]
[0012] In some embodiments, the composition comprises an aptamer sequence, the aptamer sequence being It comprises an untranslatable circular polyribonucleotide having a secondary structure that allows it to bind a target.
[0013] In some embodiments, the pharmaceutical composition comprises an aptamer sequence, an untranslatable circular polyribonucleotide having a secondary structure that binds a target; and The composition includes a substantially acceptable carrier or excipient.
[0012]
[0014] In some embodiments, the cells express the untranslatable circular polyribonucleic acid described herein. Contains ochido.
[0015] In some embodiments, the method of treating a subject in need of treatment comprises the steps of any of the methods described herein. This includes administering a composition as described or a pharmaceutical composition as described herein.
[0013]
[0016] In some embodiments, the polynucleotide comprises an untranslatable circular polynucleotide as described herein. A polynucleotide that encodes a ribonucleotide.
[0017] In some embodiments, the method comprises the step of: A method for producing otides.
[0014]
[0018] In some embodiments, the pharmaceutical composition is directed to a target, e.g., RNA, DNA, protein. Cyclic polyribonucleotides containing binding sites for binding proteins, cell membranes, etc.; and pharmaceutical the target and the circular polyribonucleotide form a complex; In some embodiments, the pharmaceutical composition comprises a first target, and the target is not a microRNA. A circular polypeptide comprising a first binding site that binds a target and a second binding site that binds a second target. a ribonucleotide; and a pharma- ceutically acceptable carrier or excipient; a first binding site. The first and second binding sites are different from the second binding site, and both the first and second targets are microRNAs. In some embodiments, the binding site comprises an aptamer sequence. In the method, the first binding site comprises a first aptamer sequence and the second binding site comprises a second aptamer sequence. In some embodiments, the aptamer sequence comprises a bilayer that binds the target. In some embodiments, the first aptamer sequence binds the first target. The first aptamer sequence has a secondary structure that binds a second target, and the second aptamer sequence has a secondary structure that binds a second target. In some embodiments, the binding site is a first binding site and the target is a first target. In some embodiments, the circular polyribonucleotide is capable of binding to a second target. In some embodiments, the first target further comprises a second binding site that binds the first circular polypeptide. In some embodiments, the circRNA-binding motif comprises The second target comprises a second circular polyribonucleotide (circRNA)-binding motif In some embodiments, the first target, the second target, and the circular polyribonucleotide are In some embodiments, the first and second targets interact with each other to form a complex. In some embodiments, the complex modulates a cellular process. In an embodiment, the first and second targets are the same and the first and second binding sites are In some embodiments, the first target binds to a different binding site on the second target. In some embodiments, the target and the second target are different. In some embodiments, the nucleic acid further comprises one or more additional binding sites that bind a third or more targets. In the method, one or more targets are the same and one or more additional binding sites are located on one or more targets. In some embodiments, the formation of a complex is associated with a cellular process. In some embodiments, the cyclic polyribonucleotide comprises a first and and modulating a cellular process associated with the first or second target when contacted with the second target. In some embodiments, the first and second targets interact with each other in a complex. In some embodiments, the cellular process is associated with the pathogenesis of a disease or condition. In embodiments, the cellular process is different from translation of a circular polyribonucleic acid. In the method, the first target comprises a deoxyribonucleic acid (DNA) molecule and the second target comprises a protein. In some embodiments, the complex comprises a protein. It modulates the epigenetic remodeling of, or the degradation of, DNA molecules. In an embodiment, the first target comprises a first protein and the second target comprises a second protein. In some embodiments, the complex comprises a first protein, a second protein, a third protein, a fourth protein, a fifth protein, a sixth protein, a sixth protein, a seventh ... Modulating protein translocation or signal transduction or inhibiting natural proteins Modulates protein function through direct interaction between the first and second proteins In some embodiments, the compound inhibits or modulates the formation of the complex that is formed. In some embodiments, the first target or the second target is a ubiquitin ligase. The first target comprises a first ribonucleic acid (RNA) molecule and the second target comprises a second RNA molecule In some embodiments, the complex comprises a first RNA molecule that modulates degradation of the first RNA molecule. In some embodiments, the first target comprises a protein and the second target comprises an RNA. In some embodiments, the complex comprises a molecule that mediates protein translocation. Modulate or are formed by direct interactions between proteins and RNA molecules In some embodiments, the first target is a receptor and the second target is a The target of the complex is a substrate for the receptor. In some embodiments, the complex inhibits the activation of the receptor. To inhibit.
[0015]
[0019] In some embodiments, the pharmaceutical composition comprises a cyclic polypeptide that includes a binding site that binds a target. and a pharma- ceutical acceptable carrier or excipient; The leutide is non-translatable or translation-deficient and the target is not a microRNA. In the present invention, the pharmaceutical composition comprises a binding moiety that binds a target, and the target is a ribonucleic acid (RNA a circular polyribonucleic acid comprising a cyclic nucleotide sequence; and a pharma- ceutically acceptable carrier or excipient. the circular polyribonucleotide is non-translatable or translation-deficient and the target is a microRNA In some embodiments, the binding site is an antibody having a secondary structure that binds a target. In some embodiments, the target comprises a DNA molecule. In this state, binding of the target to the circular polyribonucleotide is monitored to interfere with the transcription of the DNA molecule. In some embodiments, the target comprises a protein. In this study, binding of targets to circular polyribonucleotides was demonstrated to mediate interactions between proteins and other molecules. In some embodiments, the protein is a receptor and is cyclic. Binding of the target to the polyribonucleotide activates the receptor. The protein is a first enzyme, and the cyclic polyribonucleotide is bound to a second enzyme. and a second binding site for binding the first and second enzymes to the circular polyribonucleotide. The binding modulates the enzymatic activity of the first and second enzymes. In some embodiments, the protein is a ubiquitin ligase. In some embodiments, the circular polyribonucleic acid (PNA) molecule is a Binding of the target to the tide modulates the interference with translation of the mRNA molecule. In some embodiments, the target comprises a ribosome. Binding of the target to the tide modulates interference with the translation process. In some embodiments, the target comprises a circular RNA molecule. Binding of the target to the polypeptide sequesters the circular RNA molecule. Binding of the target to the polynucleotide sequesters the microRNA molecule.
[0016]
[0020] In some embodiments, the pharmaceutical composition comprises a membrane of a cell (e.g., a cell wall membrane, organelle, The membrane of the cell contains a ribonucleic acid (RNA) binding motif. and a pharma- ceutically acceptable carrier or excipient. In an embodiment, the binding site binds a membrane of a cell (e.g., a cell wall membrane, an organelle membrane, etc.). In some embodiments, the aptamer comprises a secondary structure that binds to the cyclic polynucleotide. The polynucleotide further comprises a second binding site that binds to a second target, the second target being In some embodiments, the cyclic polyribonucleotide comprises a second RNA-binding motif. The circular polyribonucleic acid molecule binds to the membrane of the cell and to a second target. The oxidase further comprises a second binding site that binds to a second cellular target, Binding of the cellular target and the second cellular target to the oxidase induces a conformational change in the cellular target, which In some embodiments, the cyclic polynucleotide is a cyclic nucleotide that is a nucleotide sequence ... The ribonucleotide is non-translatable or translationally defective. Ribonucleotides are: a) encryptogens; b) splicing elements. c) regulatory sequences; d) replication sequences; e) quasi-double-stranded secondary structures; f) quasi-helical structures; and and g) at least one structural element selected from the group consisting of expression sequences. In some embodiments, the quasi-helical structure comprises at least one non-double-stranded segment. In some embodiments, the quasi-heterologous RNA comprises at least one double-stranded RNA segment having a The intermediate structure comprises a first sequence and a second sequence connected by a repeat sequence. In some embodiments, the encryptogen comprises a splicing element. In some embodiments, the circular polyribonucleic acid comprises at least one modified nucleic acid. In the present invention, at least one modified nucleic acid is 2'-O-methyl, 2'-O-methoxyethyl ( 2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, T-deoxy-2' -fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylamino Ethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DM AP), TO-Dimethylaminoethyloxyethyl (2'-O-DMAEOE), 2' -ON-Methylacetamide (2'-O-NMA), Locked Nucleic Acid (LNA), Ethylene Nucleic acid (ENA), peptide nucleic acid (PNA), 1',5'-anhydrohexitol nucleic acid ( HNA), morpholino, methylphosphonate nucleotides, thiolphosphonate nucleotides and 2'-fluoro N3-P5'-phosphoramidites. In some embodiments, the encryptogen comprises at least one modified nucleic acid. In some embodiments, the encryptogen comprises a protein binding site. In some embodiments, the encryptogen comprises an immunity protein binding site. In this study, circular polyribonucleic acid was found to bind to RIG-I, TLR-3, TLR-7, TLR-8, and MDA. -5, LGP-2, OAS, OASL, PKR, and / or IFN-β , signaling, or activation, as assessed by their counterparts lacking the cryptogen. In some embodiments, the circular polyribonucleic acid has a 20-fold lower immunogenicity. In some embodiments, the circular polyribonucleic acid has a size of about 20 kb. In some embodiments, the circular polynucleotide is synthesized via circularization of a linear polynucleotide. Ribonucleic acid is substantially resistant to degradation.
[0017]
[0021] In some embodiments, the pharmaceutical composition comprises a binding moiety that binds to a target, the target being a circular polyribonucleotide containing a ribonucleic acid (RNA) binding motif; and a pharma- ceutically acceptable and a suitable carrier or excipient, the circular polyribonucleotide comprising at least one modified nucleotide. leotide and at least about 5, 10, 20, 50, 100, 200, 300, 400, 5 00, 600, 700, 800, 900, or 1000 consecutive unmodified nucleotides. In some embodiments, the pharmaceutical composition comprises a binding moiety that binds to a target. the target is a circular polyribonucleotide containing a ribonucleic acid (RNA) binding motif; and The cyclic polyribonucleotide comprises at least one cyclic polyribonucleotide having a molecular weight of 100 or more and a pharmaceutical acceptable carrier or excipient. and at least about 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 consecutive nucleotides a first portion comprising: In some embodiments, the binding site is an aptamer having a secondary structure that binds the target. In some embodiments, the circular polyribonucleotide comprises the corresponding unmodified It has a lower immunogenicity than cyclic polyribonucleotides. Polyribonucleotides are involved in the regulation of RIG-I, TLR-3, TLR-7, TLR-8, and MDA- 5, at least one of the group consisting of LGP-2, OAS, OASL, PKR, and IFN-β The expression or signaling or activation of the corresponding unmodified circular polyribonucleic acid is evaluated. At least about 1.1, 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2 .2, 2.5, 2.8, 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5 , 4.8, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0 , 9.5, or 10.0 times less immunogenic. Polyribonucleotides have longer half-lives than the corresponding unmodified circular polyribonucleotides In some embodiments, the cyclic polyribonucleotide is a corresponding unmodified cyclic polyribonucleotide. At least about 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2 nucleotides , 2.5, 2.8, 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5, 4 .8, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9 In some embodiments, the half-life is longer than that of the cyclic polysaccharide. The modified cyclic polyribonucleotide or the corresponding unmodified cyclic polyribonucleotide is introduced into a cell, The introduced cyclic polyribonucleotide or the corresponding cyclic polyribonucleotide inside the cell In some embodiments, the at least one modification is measured by measuring the level of The modified nucleotides are N(6) methyladenosine (m6A), 5'-methylcytidine, and In some embodiments, at least one The modified nucleic acids are 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2 '-O-aminopropyl, 2'-deoxy, T-deoxy-2'-fluoro, 2'-O- Aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DM AOE), 2'-O-Dimethylaminopropyl (2'-O-DMAP), TO-Dimethyl Aminoethyloxyethyl (2'-O-DMAEOE), 2'-ON-methylacetate Amide (2'-O-NMA), locked nucleic acid (LNA), ethylene nucleic acid (ENA), peptide Polymorphonucleic Acid (PNA), 1',5'-anhydrohexitol nucleic acid (HNA), morpholino, Methylphosphonate nucleotides, thiolphosphonate nucleotides, and 2'-fulv In some embodiments, the N3-P5'-phosphoramidite is selected from the group consisting of: At least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% are modified nucleotides. In some embodiments, the cyclic polyribonucleotide is an unmodified nucleoside. The nucleotide sequence of the nucleotide sequence of the nucleotide sequence of the nucleotide a is a sequence that binds to a protein, DNA, RNA, or cellular target. In some embodiments, the cyclic polyribonucleotide comprises an inner nucleotide sequence consisting of unmodified nucleotides. In some embodiments, the binding site comprises an unmodified ribosome entry site (IRES). In some embodiments, the binding site is composed of unmodified nucleotides. In some embodiments, the first portion comprises an IRES consisting of a protein, DNA, In some embodiments, the first portion comprises a binding site that binds the RNA and the cellular target. In some embodiments, the circular polyribonucleotide comprises one or more In some embodiments, the circular polyribonucleotide comprises one or more expression sequences. The circular polyribonucleotide contains the current sequence and the IRES, and the 5'-methyl In some embodiments, the ring comprises a cytidine, a pseudouridine, or a combination thereof. One or more expression sequences of the cyclic polyribonucleotide may be expressed by the corresponding unmodified circular polyribonucleoside. In some embodiments, the cyclic polynucleotide is configured to have a higher translation efficiency than the cyclic polynucleotide. One or more of the expressed sequences of ribonucleotides are more easily synthesized than the corresponding unmodified circular polyribonucleotides. At least about 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.5, have 1.6, 1.8, 2, 2.2, 2.5, 2.8, or 3 times higher translation efficiency. In an embodiment, one or more of the expressed sequences of the circular polyribonucleotide comprises modified nucleotides. The polyribonucleotide has a higher translation efficiency than a corresponding circular polyribonucleotide having a first portion including a In some embodiments, the one or more expressed sequences of the circular polyribonucleotide are A corresponding circular polyribonucleotide having a first portion that contains more than 0% modified nucleotides. In some embodiments, one of the circular polyribonucleotides has a higher translation efficiency than the other. The expression sequences are then each synthesized from a corresponding circular polyribonucleotide having a first portion comprising a modified nucleotide. At least about 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2 nucleotides , 2.5, 2.8, 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5, 4 .8, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9 In some embodiments, the translation efficiency is 0.5, 10.0, or 20.0 times higher. in cells containing cyclic polyribonucleotides or the corresponding cyclic polyribonucleotides, is measured either in an in vitro translation system (e.g., rabbit reticulocyte lysate). In some embodiments, the cyclic polyribonucleotide is any one of the disclosed embodiments. It is a circular polyribonucleotide.
[0018]
[0022] In some aspects, the method of treatment comprises administering to a subject a therapeutic agent according to any one of the embodiments disclosed above. This involves administering the pharmaceutical composition to a subject having a disease or condition.
[0023] In some aspects, the method of producing a pharmaceutical composition comprises any of the disclosed embodiments. The method includes producing one or more circular polyribonucleotides.
[0019]
[0024] In some aspects, the composition of any one of the embodiments is provided on a carrier, e.g., a membrane. or formulated in a lipid bilayer.
[0025] In some aspects, the circular polyribonucleoside of any one of the disclosed embodiments is The method for producing a peptide includes producing a linear polyribonucleotide having a nucleic acid sequence as a circular polyribonucleotide. The method includes circularizing the polynucleotide.
[0020]
[0026] In some embodiments, the genetically engineered cells are Contains ingredients. Incorporation by Reference
[0027] All publications, patents, and patent applications mentioned herein are the property of their respective owners. All publications, patents, or patent applications are specifically and individually indicated to be incorporated by reference. No. 6,313,935, filed on Oct. 23, 2006, and is incorporated by reference herein to the same extent as if fully set forth herein.
[0021]
[0028] The patent or application contains at least one drawing in color. Copies of this patent or patent application publication will be provided by the Department upon request and payment of the necessary fee. The following detailed description of the embodiments of the present invention is best understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the invention, in the drawings, only exemplary embodiments are shown. However, the present invention does not depend on the precise arrangement and construction of the embodiment shown in the drawings. It should be understood that the present invention is not limited to stages. [Brief description of the drawings]
[0022] [Figure 1]
[0029] FIG. 1 illustrates an example of a circular polyribonucleotide molecular scaffold. [Diagram 2]
[0030] FIG. 2 illustrates an example of a trans-ribozyme circular polyribonucleotide. [Diagram 3]
[0031] FIG. 3 illustrates a schematic of protein expression by circular polyribonucleotides. [Figure 4]
[0032] FIG. 4 illustrates an example of a circular polyribonucleotide molecular scaffold for lipids, such as membranes. [Figure 5A-B]
[0033] FIG. 5A illustrates an example of a circular polyribonucleotide molecular scaffold for DNA.
[0034] FIG. 5B illustrates an example of a circular polyribonucleotide molecular scaffold with sequence-specific DNA binding motifs. circRNAs can bind to the major groove of a DNA duplex to form parallel or antiparallel triplex structures based on the orientation of the third strand. Exemplary parallel triplex structures include TA·U, CG·G, and CG·C (DNA DNA·RNA). Exemplary antiparallel triplex structures include TA·A, TA·U, and CG·G (DNA DNA·RNA). [Figure 5C-E]
[0035] FIG. 5C illustrates an example of a circular polyribonucleotide molecular scaffold with DNA-binding motifs specific for the enhancer region of the DHFR gene for transcription factor binding and / or interference with mRNA transcription.
[0036] FIG. 5D illustrates an example of a circular polyribonucleotide molecular scaffold with DNA-binding motifs specific for the enhancer region of the MEG3 gene for transcription factor binding and / or interference with mRNA transcription.
[0037] FIG. 5E illustrates an example of a circular polyribonucleotide molecular scaffold with DNA-binding motifs specific for the enhancer region of an EPS gene for transcription factor binding and / or interference with mRNA transcription. [Figure 6]
[0038] FIG. 6 illustrates an example of a circular polyribonucleotide molecular scaffold for RNA. [Figure 7]
[0039] FIG. 7A illustrates an example of a circular polyribonucleotide molecular scaffold for targeting RNA to sequester and / or degrade the target RNA.
[0040] FIG. 7B illustrates an example of a circular polyribonucleotide molecular scaffold for RNA and an RNA-targeting enzyme (eg, a decapping enzyme that induces degradation of the RNA).
[0041] FIG. 7C illustrates an example of a circular polyribonucleotide molecular scaffold for RNA, DNA, and proteins (e.g., to drive target gene translation). [Figure 8]
[0042] FIG. 8 illustrates an example of a circular polyribonucleotide molecular scaffold for a protein (e.g., FUS / TDP43 / ATXN2, PRPF8, GEMIN5, CUG BP1, and LIN28A). [Figure 9A]
[0043] FIG. 9A shows that modified circular RNAs bind the protein translation machinery in cells. [Figure 9B] FIG. 9B shows that modified circular RNAs bind the protein translation machinery in cells. [Figure 9C] FIG. 9C shows that modified circular RNAs bind the protein translation machinery in cells. [Figure 10A]
[0044] FIG. 10A shows that the modified circular RNAs have reduced binding to immune proteins compared to unmodified circular RNAs in cells as assessed by activation of immune-related genes (MDA5, OAS, and IFN-β expression). [Figure 10B] FIG. 10B shows that the modified circular RNAs have reduced binding to immune proteins compared to unmodified circular RNAs in cells as assessed by activation of immune-related genes (MDA5, OAS, and IFN-β expression). [Figure 10C] FIG. 10C shows that the modified circular RNAs have reduced binding to immune proteins compared to unmodified circular RNAs in cells as assessed by activation of immune-related genes (MDA5, OAS, and IFN-β expression). [Figure 11]
[0045] FIG. 11 shows that the hybrid modified circular RNAs have reduced immunogenicity in cells compared to unmodified circular RNAs as assessed by RIG-I, MDA5, IFN-β, and OAS expression. [Figure 12]
[0046] FIG. 12 demonstrates that circular RNA aptamers show increased intracellular delivery and improved binding to small molecule targets compared to linear aptamers. [Figure 13]
[0047] FIG. 13 illustrates binding of a circular RNA containing a protein-binding motif to a target protein. [Figure 14]
[0048] FIG. 14 demonstrates that a small molecule-circular RNA conjugate binds to a protein targeted by the small molecule. [Figure 15]
[0049] FIG. 15 demonstrates the interaction of a circular RNA-small molecule conjugate with a specific bioactive protein. [Figure 16]
[0050] Figure 16 illustrates, for example, a circRNA with two binding sites that can act as a scaffold to form a complex with an enzyme (Enz) and a target substrate (Substrate), facilitating modification of the target substrate (M) by the enzyme. [Figure 17]
[0051] FIG. 17 shows images from an electrophoretic mobility shift assay (EMSA) demonstrating that while an RNA with a scrambled binding aptamer sequence showed no binding affinity for the p50 subunit of NF-kB, both linear and circular RNAs with NF-kB binding aptamer sequences bound with similar affinity to the p50 subunit. [Figure 18]
[0052] FIG. 18 shows that treatment with circular RNA carrying an NF-kB binding aptamer sequence led to a decrease in cell viability of A549 cells compared to its linear counterpart. [Figure 19]
[0053] FIG. 19 shows that in doxorubicin (dox)-resistant A549 lung cancer cell lines, co-treatment with linear RNA and dox reduced cell viability on day 2, while co-treatment with cyclic aptamer and dox led to more cell death on both days 1 and 2. [Figure 20]
[0054] FIG. 20 is a schematic diagram showing an exemplary circular RNA that is delivered into a cell and tags a target BRD4 protein in the cell for degradation by the ubiquitin system. [Figure 21]
[0055] FIG. 21 shows Western blot images and quantification charts demonstrating that thalidomide and circular RNA containing JQ1 small molecule could degrade BRD4 in cells. [Figure 22]
[0056] Figure 22 shows aptamer fluorescence when bound to TO-1 biotin at different time points after delivery of circular RNA (endless aptamer) or linear RNA (linear aptamer) to HeLa cell cultures. Fluorescence images (top row) show aptamer fluorescence when bound to TO-1 biotin 6 hours, 1 day, and 10 days after delivery of circular RNA (endless aptamer) or linear RNA (linear aptamer). Graphs (bottom row) show the percentage of fluorescent cells in HeLa cell cultures 6 hours, 1 day, 3 days, 5 days, 7 days, 10 days, and 12 days after delivery of circular RNA (endless aptamer), linear RNA (linear aptamer), or TO-1 biotin alone (control). [Diagram 23]
[0057] FIG. 23 shows that HuR bound circular RNA with a HuR RNA-binding aptamer motif, and streptavidin pull-down yielded RNA with an RNA-binding aptamer motif compared to circular RNA without a binding aptamer motif, circular RNA with a HuR RNA-binding aptamer motif, and circular RNA with an RNA-binding aptamer motif. [Figure 24]
[0058] FIG. 24 shows that HuR bound circular RNA with a HuR DNA-binding aptamer motif, and streptavidin pull-down yielded RNA with a DNA-binding aptamer motif compared to circular RNA without a binding aptamer motif, circular RNA with a HuR DNA-binding aptamer motif, and circular RNA with DNA. [Diagram 25]
[0059] FIG. 25 shows lower secreted protein expression from circular RNAs without a HuR-binding motif compared to circular RNAs with 1×HuR-binding motif, 2×HuR-binding motif, and 3×HuR-binding motif. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0023]
[0060] The present invention relates generally to pharmaceutical compositions and formulations of cyclic polyribonucleotides and their Regarding their use.
[0061] Several aspects are described below with reference to illustrative example applications. Specific details, relationships, and methods are provided to provide a thorough understanding of the features described herein. However, it should be understood that the present invention is described in detail below. It is possible to practice the features without one or more of the specific details or in other manners. It will be readily appreciated that the features described herein may be implemented in a manner consistent with the described order of actions or events. The present invention is not limited to the order in which it is performed, and so some actions may be performed in different orders and / or in different ways. Further, the method according to the features described herein may be Not all illustrated acts or events are required to be performed.
[0024]
[0062] The terms used in this specification are for the purpose of describing specific cases. As used herein, the singular form "a" refers to any one of the following: "an" and "the" unless the context clearly indicates otherwise. In addition, the terms "including," "include," "includes," "common," "commonly" and "used" are used interchangeably. "s"), "having", "has", "with", or any of the above. To the extent that variants of the above are used in either the detailed description and / or claims, Such terms are intended to be inclusive in a manner similar to the term "comprising."
[0025] definition
[0063] As used herein, the term "circRNA" or "circular RNA" or "Cyclic polyribonucleotide" refers to a polyribonucleotide that forms a circular structure through covalent or non-covalent bonds. Refers to ribonucleotides.
[0026]
[0064] As used herein, the term "encryptogen" refers to a compound that is detected by immune cells. and / or to aid in the reduction, avoidance, and / or repelling of the release of cyclic polyribonucleotides. It refers to a nucleic acid sequence of a circular polyribonucleotide that reduces the induction of an immune response against a nucleic acid.
[0027]
[0065] As used herein, the term "expressed sequence" refers to a sequence that is capable of producing a product, e.g., a peptide or It also refers to a nucleic acid sequence encoding a polypeptide, or a regulatory nucleic acid.
[0066] As used herein, the term "immunity protein binding site" refers to a site that binds an immunity protein. It binds to proteins and helps mask non-endogenous circular polyribonucleotides. It refers to the nucleotide sequence.
[0028]
[0067] As used herein, the term "modified ribonucleotide" refers to a ribonucleotide that is a nucleotide sequence that is a sugar, a nucleobase, or a nucleotide sequence that is ... or a nucleotide having at least one modification of an internucleoside bond.
[0068] As used herein, the term "quasi-helical structure" refers to a circular polyribonucleic acid A circular polyribonucleotide in which at least a portion of the oligonucleotides fold into a helical structure. Refers to higher-order structure.
[0029]
[0069] As used herein, the term "quasi-double-stranded secondary structure" refers to a circular polyribonucleic acid A higher-order structure of a circular polyribonucleotide in which at least a portion of the nucleotide is double-stranded is formed. Point.
[0030]
[0070] As used herein, the term "regulatory sequence" refers to a nucleic acid sequence that modifies the expression product. Point to the column.
[0071] As used herein, the term "repetitive nucleotide sequence" refers to a repeat sequence in a DNA strand. In some embodiments, the repeats refer to repeated nucleic acid sequences within a genome or throughout the genome. The nucleotide sequence may include a polyCA or polyTG sequence. In this study, the repeated nucleotide sequence is a repeat sequence in the Alu family of introns. The columns are listed.
[0031]
[0072] As used herein, the term "replication element" refers to a circular polyribonucleic acid It refers to sequences and / or motifs useful for the replication of, or initiating the transcription of, a nucleotide sequence.
[0073] As used herein, the term "alternative translation sequence" refers to a circular polyribonucleic acid sequence. "Transcriptional primer" refers to a nucleic acid sequence that selectively initiates or activates the translation of an expression sequence in a gene.
[0032]
[0074] As used herein, the term "selective degradation sequence" refers to a sequence that is It refers to a nucleic acid sequence that initiates translation of an expression sequence in a nucleotide sequence.
[0075] As used herein, the term "staggered sequence" refers to a sequence that is In some embodiments, the ribosome positioning sequence is a nucleotide sequence that induces ribosome posing during The staggered sequence is a non-conserved sequence of amino acids with a strong α-helical tendency followed by The consensus sequence is -D(V / I)ExNPG P (where x is any amino acid). do.
[0033]
[0076] As used herein, the term "substantially resistant" refers to a material that is less susceptible to damage compared to a reference material. At least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 9 7%, 98% or 99% resistant.
[0034]
[0077] As used herein, the term "complex" refers to molecules that have an affinity for each other. It refers to an association between at least two moieties (e.g., chemical or biochemical substances) that The at least two moieties are a target (eg, a protein) and a circular RNA molecule.
[0035]
[0078] "Polypeptide" and "protein" are used interchangeably and are intended to mean any bond that is covalently bonded (e.g., It refers to a polymer of two or more amino acids linked together by bonds (e.g., amide bonds). The described polypeptides include full-length proteins (e.g., fully processed proteins). proteins) and shorter amino acid sequences (e.g., fragments of naturally occurring proteins or synthetic polypeptides). A polypeptide can be a peptide fragment of a naturally occurring amino acid (e.g., These are commonly found in peptides synthesized in the The 20 amino acids known as G, H, I, L, K, M, F, P, S, T, W, Y, and V (those commonly found in naturally synthesized peptides) and non-naturally occurring amino acids (e.g. Amino acids that are not among the 20 amino acids specified in the logs, and amino acid mimetics).
[0036]
[0079] As used herein, the term "binding site" refers to a binding site that binds to another entity, e.g., a compound The term refers to the region of a circular polyribonucleotide that interacts with a nucleic acid, protein, or nucleic acid. The site may comprise an aptamer sequence.
[0037]
[0080] As used herein, the term "binding moiety" refers to a molecule capable of being bound by a binding site. A region, e.g., a region, domain, fragment, epitope, or nucleic acid (e.g., RNA , DNA, RNA-DNA hybrids), compounds, small molecules (e.g., drugs), ptamers, polypeptides, proteins, lipids, carbohydrates, antibodies, viruses, virus particles , membranes, multicomponent complexes, organelles, cells, other cellular parts, any fragments thereof, and the like. It refers to any combination of these.
[0038]
[0081] As used herein, the term "aptamer sequence" refers to an aptamer that specifically binds to a target molecule. Aptamers refer to non-naturally occurring or synthetic oligonucleotides that bind to 0-250 nucleotides. Typically, aptamers are based on secondary structure rather than sequence homology. It binds to its target via this structure.
[0039]
[0082] As used herein, the term "small molecule" refers to a molecule having a molecular weight of less than 900 Daltons. Small molecules may modulate cellular processes or have a fluorochemical structure. It's forehand.
[0040]
[0083] As used herein, the term "conjugation moiety" refers to a conjugate. The term "modified nucleotide" refers to a modified nucleotide that contains a functional group for use in conversion methods.
[0084] As used herein, the term "linear counterpart" refers to a circular polyribonucleic acid. A polyribonucleic acid having the same nucleotide sequence and nucleic acid modification as the ribonucleic acid sequence and having two free ends. It refers to a ribonucleotide (i.e., a non-cyclized version of a circularized polyribonucleotide). In some embodiments, the linear counterpart further comprises a 5' cap. In some embodiments, the linear counterpart further comprises a polyadenosine tail. The counterpart further comprises a 3'UTR. In some embodiments, the linear counterpart comprises a 5'UTR. Further includes R. Circular Polyribonucleotides
[0085] Circular polyribonucleotides (circRNAs) as described herein are covalently or It is a polyribonucleotide that forms a continuous structure through non-covalent bonds.
[0041]
[0086] The invention described herein provides compositions comprising synthetic circRNAs and methods of using same. Due to their circular structure, circRNAs have improved cloning properties compared to their linear counterparts. Improved stability, increased half-life, reduced immunogenicity, and / or improved functionality (e.g. In some embodiments, the circular RNA may have a function as described herein. In some embodiments, the circular RNA is detectable at least 5 days after delivery to the Circular RNA is delivered to cells on days 6, 7, 8, 9, 10, 11, Circular RNA can be detected after 12, 13, 14, 15, or 16 days. Detection can be accomplished using any technique known in the art.
[0042]
[0087] In some embodiments, the circRNA is a circular aptamer. In some forms, circRNAs contain one or more binding sites that bind to one or more targets. In one embodiment, the circRNA comprises an aptamer sequence. CircRNAs bind both DNA and protein targets, e.g., regulating transcription. In another embodiment, circRNAs mediate protein complexes. For example, it mediates post-translational modification or signal transduction. A binds two or more different targets, e.g., proteins, and They shuttling proteins into the cytoplasm or mediating the degradation of one or more targets.
[0043]
[0088] In some embodiments, circRNAs are expressed as DNA, RNA, and protein. The method comprises the steps of: binding at least one of the proteins to a cellular process (e.g., a protein) and thereby regulating the cellular process (e.g., a protein). Alter protein expression, modulate gene expression, modulate cell signaling In some embodiments, synthetic circRNAs can be synthesized by cloning a target or selected DNA, RNA or or at least one portion of the protein, e.g., a binding moiety for interaction with the binding moiety. sites, thereby competing for binding with the endogenous counterparts.
[0044]
[0089] In some embodiments, the circular RNA regulates a cellular process (e.g., Alter protein expression, modulate gene expression, modulate cell signaling In some embodiments, the circular RNA forms a complex with a target (e.g., sensitize cells to cytotoxic agents (e.g., chemotherapeutic agents) by binding to cytotoxic receptors (e.g., transcription factors) For example, sensitization of cells to cytotoxic agents can result in reduced cell viability. This results in decreased cell viability following delivery of the cytotoxic agent and the circular RNA. The decreased cell viability was at least 10%, 20%, 30%, 40%, 50%, 60%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 210%, 220%, 230%, 240%, 250%, 260%, 2 It may be decreased by 0%, 70%, 80%, or 90%, or any percentage therebetween.
[0045]
[0090] In some embodiments, the complex is administered 6, 7 days after delivery of the circular RNA to the cell. , 8, 9, 10, 11, 12, 13, 14, 15, or 16 days later It is possible.
[0046]
[0091] In one embodiment, the synthetic circRNA binds a miRNA and / or In another embodiment, the synthetic circRNA binds or sequesters a protein. In another embodiment, the synthetic circRNA binds and / or sequesters the mRNA. In another embodiment, the synthetic circRNA binds and / or sequesters the ribosome. In another embodiment, the synthetic circRNA is In another embodiment, the synthetic circRNA is is a long non-coding RNA (lncRNA) or any other non-coding RNA, such as miRNA, RNA, tRNA, rRNA, snoRNA, ncRNA, siRNA, long non-coding RNA NAs bind and / or sequester shRNAs. circRNAs bind and / or In addition to the sequestration site, degradation enzymes that result in the degradation of bound and / or sequestered RNA and / or protein The component may include elements.
[0047]
[0092] In one embodiment, the circRNA is a lncRNA or a sequence of a lncRNA. For example, circRNAs include sequences of naturally occurring non-circular lncRNAs or fragments thereof. In one embodiment, the sequence of the lncRNA or the lncRNA comprises a spacer sequence The RNA is circularized with or without the addition of ribozyme to form a synthetic circRNA.
[0048]
[0093] In one embodiment, the circRNA has ribozyme activity. In this embodiment, circRNA acts as a ribozyme to target pathogenic or endogenous RNA, It can be used to cleave DNA, small molecules, or proteins. In one embodiment, the circRNA has enzymatic activity. A is capable of specifically recognizing and cleaving RNA (e.g., viral RNA). In another embodiment, the circRNA can specifically recognize and cleave a protein. In this study, circRNAs can specifically recognize and degrade small molecules.
[0049]
[0094] In one embodiment, circRNAs are self-immolating or self-opening. In one embodiment, the circRNA is an RNA, For example, miRNA, tRNA, rRNA, snoRNA, ncRNA, siRNA, long In one embodiment, the vector can be used to deliver non-coding RNA, such as shRNA. In this study, synthetic circRNAs were developed that contain (1) self-cleaving elements (e.g., hammerhead, splicing elements), (2) cleavage recruitment sites (e.g., ADARs), (3) a degradable linker (e.g., glycerol), (4) a chemical linker, and / or (5 ) The microRNAs are separated by spacer sequences. Therefore, synthetic circRNAs contain (1) self-cleaving elements (e.g., hammerhead, spindle, etc.) splicing element), (2) cleavage recruitment site (e.g., ADAR), ( 3) a degradable linker (e.g., glycerol); (4) a chemical linker; and / or (5) It is composed of siRNAs separated by spacer sequences.
[0050]
[0095] In one embodiment, the circRNA is a transcribable / replicable circRNA. This circRNA can encode any type of RNA. In one embodiment, In one embodiment, the synthetic circRNA comprises an antisense miRNA and a transcriptional element. In one embodiment, linear functional miRNAs are generated from circRNAs after transcription. In some embodiments, circRNAs are untranslatable circular polyribonucleotides.
[0051]
[0096] In one embodiment, the circRNA is in combination with a translation element. Possess one or more of the above characteristics.
[0097] In some embodiments, the circRNA comprises at least one modified nucleotide. In some embodiments, the circRNA comprises at least 10%, 20%, Contains 30%, 40%, 50%, 60%, 70%, or 80% modified nucleotides. In some embodiments, the circRNA is substantially all (e.g., 80%, 85%, 90%, %, 95%, 97%, 98%, or more than 99%, or about 100%) of the In some embodiments, the circRNA comprises modified nucleotides and unmodified consecutive It contains a portion of nucleotides, which can be referred to as hybrid modified circRNA. Some of the unmodified consecutive nucleotides are involved in the protein binding in hybrid modified circRNAs. , or an unmodified binding site configured to bind DNA, RNA, or a cellular target. Some of the unmodified consecutive nucleotides are unmodified IR in the hybrid modified circRNA. In other embodiments, the circRNA lacks modified nucleotides and This can be referred to as unmodified circRNA.
[0052] target
[0098] circRNAs may contain at least one binding domain for a target, e.g., a binding moiety for the target. A circRNA may contain at least one binding site that binds to a target. In some embodiments, the circRNA may comprise a tammer sequence. Targets include, but are not limited to, nucleic acids (e.g. For example, RNA, DNA, RNA-DNA hybrids), small molecules (for example, drugs, fluoro lophores, metabolites), aptamers, polypeptides, proteins, lipids, carbohydrates, antibodies , viruses, virus particles, membranes, multicomponent complexes, organelles, cells, other cellular parts, and any combination thereof. l., (2002) Nat Biotech20: 473-77; Gullberg et al., (2004) PNAS, 101: 8420-24. For example, the target may be single-stranded RNA, double-stranded RNA, single-stranded DNA, double-stranded DNA, DNA or RNA containing one or more double-stranded regions and one or more single-stranded regions, RNA-DNA Hybrids, small molecules, aptamers, polypeptides, proteins, lipids, carbohydrates, antibodies , antibody fragments, antibody mixtures, virus particles, membranes, multicomponent complexes, cells, cell parts, etc. or any combination thereof.
[0053]
[0099] In some embodiments, the target is a polypeptide, a protein, or a polypeptide thereof. For example, the target may be a purified polypeptide, an isolated polypeptide, a fusion tagged polypeptide, or a polypeptide fragment. A polypeptide that is attached to or penetrates the membrane of a cell or a virus or virion. peptides, cytoplasmic proteins, intracellular proteins, extracellular proteins, kinases, tyrosine kinases, serine / threonine kinases, phosphatases, aromatases, phosphodiesterases, Esterases, cyclases, helicases, proteases, oxidoreductases, reductases Glutases, transferases, hydrolases, lyases, isomerases, glycosylases , affecting extracellular matrix proteins, ligases, ubiquitin ligases, and post-translational modifications Any ligase, ion transporter, channel, pore, or apoptotic protein that Proteins, cell adhesion proteins, pathogenicity proteins, abnormally expressed proteins, transcription factors, transcriptional regulation Sectional factors, translation proteins, epigenetic factors, epigenetic regulators, Matin regulators, chaperones, secreted proteins, ligands, hormones, cytokines, Mokine, nuclear protein, receptor, transmembrane receptor, receptor tyrosine kinase, G protein Plasma-coupled receptors, growth factor receptors, nuclear receptors, hormone receptors, signal transduction factors, antibodies , membrane proteins, integral membrane proteins, peripheral membrane proteins, cell wall proteins, globular proteins Proteins, fibrous proteins, glycoproteins, lipoproteins, chromosomal proteins, carcinogens A gene, an oncogene, a tumor suppressor gene, any fragment thereof, or any combination thereof. In some embodiments, the target is a heterologous polypeptide. In this method, the target is a protein that is overexpressed in cells using molecular techniques, e.g., transfection. In some embodiments, the target is a recombinant polypeptide. For example, The target may be in a sample produced from bacterial (e.g., E. coli), yeast, mammalian, or insect cells. In some embodiments, the protein is present in an organism (e.g., a protein that is overexpressed by the organism). In some embodiments, the target is a polypeptide having a mutation, insertion, deletion, or polymorphism. In some embodiments, the target is a cell (e.g., a healthy cell or a cell associated with a disease or pathology). In some embodiments, the target is a polypeptide that is naturally expressed by an organism. Used to immunize an organism or to generate an immune response in an organism, e.g., for antibody production. The antigen to be treated is, for example, a polypeptide.
[0054]
[0100] In some embodiments, the target is an antibody. An antibody binds to a specific space on another molecule. The antibodies may be monoclonal, polyclonal, or The antibody may be a recombinant antibody and may be produced by techniques well known in the art, such as by immunizing a host and extracting serum. The secreted proteins are then isolated by collection (polyclonal) or by continuous hybrid cell lines. By recovering proteins (monoclonal), or at least specific binding of natural antibodies A nucleotide sequence encoding the amino acid sequence required for Naturally occurring antibodies can be prepared by cloning and expressing a sequence similar to that described above. It consists of at least two heavy (H) chains and two light ( Each heavy chain can be a protein comprising a heavy chain variable region (V H ) and heavy chain The heavy chain constant region can be composed of three domains, C H1 , C H2 , and C H 3 Each light chain may comprise a light chain variable region (V L ) and a light chain constant region. The light chain constant region consists of one domain, C L V H and V L Area: Framework The complementarity determining regions (CDRs) are interspersed with more conserved regions called FRs. Each V can be further subdivided into hypervariable regions. H and V L Ami The three CDRs and four FRs arranged from the amino terminus to the carboxy terminus are in the following order: Introduction: FR 1 , CDR 1 , F.R. 2 , CDR 2 , F.R. 3 , CDR 3 , and may be constructed of FR4. The constant region of an antibody binds to host tissues or factors, such as various cells of the immune system (e.g., It mediates the binding of immunoglobulins to the first component of the classical complement system (C1q) and to the effector cells. The antibody may be of any isotype (e.g., IgG, IgE, IgM, IgD, IgE ... gA and IgY), class (e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , lgA 1 and lgA 2), subclass, or modified versions thereof. Examples of antibody fragments include complete immunoglobulins or fragments thereof. Antibody fragments include a binding portion, For example, it may refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. In addition, aggregates, polymers, and conjugates of immunoglobulins or fragments thereof may also be used for specific molecular weights. As long as the binding affinity for the antibody is maintained, examples of antibody fragments include Fab fragments. , V L , V H , C L and C H1 F(ab) is a monovalent fragment of a domain. 2 Fragment, hinge area A bivalent fragment containing two Fab fragments linked by a disulfide bridge in the V region; H and C H1 Fd fragment consisting of domain; V of a single arm of an antibody L and V H From the domain Fv fragment; V H Single domain antibody (dAb) fragments consisting of domains (Ward et al., (19 89) Nature 341:544-46); and isolated CDR and V L and V H The domain is paired to form a single valence Single chain fragments (scFv) forming fragments (known as single chain Fv (scFv); see, e.g., Bird e See Huston et al., (1988) Science 242: 423-26; and Huston et al., (1988) PNAS 85: 5879-83. Thus, antibody fragments include Fab, F(ab) 2 , scFv, Fv, dAb, etc. Two domains V L and V H is coded by a separate gene However, they can be made as a single protein chain using recombinant methods. Such single chain antibodies can be linked by an artificial peptide linker that can The antibody may comprise one or more antigen-binding portions. The antibody may be a multivalent antibody, e.g., a bivalent, trivalent, tetravalent, pentavalent, It may be a hexavalent, heptavalent, or octavalent antibody. The antibody may be a multispecific antibody. For example, Multispecific, trispecific, tetraspecific, pentaspecific, hexaspecific, heptaspecific, or octaspecific The heterologous antibodies can be, for example, any two or more antigen binding agents (e.g., Fab, F(ab) 2 , s A combination of multiple Fvs (cFv, Fv, IgG) can be produced by recombinantly combining multiple Fvs. Polyspecific antibodies can target two or more targets, e.g., a degradation mechanism and a target substrate for degradation, or a ubiquitin These can be used to bring ubiquitin ligases and substrates for ubiquitination into close proximity. Antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the fragments may be obtained from intact antibodies. Antibodies can be screened for benefits in the same manner as antibodies. Synthetic, chimeric, isolated, canine, feline, donkey, ovine, any plant, animal, or mammalian antibody. could be.
[0055]
[0101] In some embodiments, the target is a ribonucleotide and / or a deoxyribonucleotide. A polymeric form of nucleotides (adenine, guanine, thymine, or cytosine), such as DNA or RNA (e.g., mRNA). DNA includes linear DNA molecules (e.g., Examples include double-stranded DNA found in restriction fragments, viruses, plasmids, and chromosomes. In some embodiments, the polynucleotide target may be a single stranded, double stranded, small molecule interferon, or a combination thereof. Interfering RNA (siRNA), messenger RNA (mRNA), transfer RNA ( tRNA), chromosomes, genes, non-coding genomic sequences, genomic DNA (e.g., fragmented genomic DNA), purified polynucleotides, isolated polynucleotides, hybridized polynucleotides ocide, transcription factor binding site, mitochondrial DNA, ribosomal RNA, eukaryotic polynucleotide Nucleotides, prokaryotic polynucleotides, synthetic polynucleotides, ligated polynucleotides nucleotides, recombinant polynucleotides, polynucleotides containing nucleic acid analogs, methylation A polynucleotide, a demethylated polynucleotide, any fragment thereof, or any In some embodiments, the target is a recombinant polynucleotide. In some embodiments, the target is a heterologous polynucleotide. For example, the target is Polynuclear antibodies produced from bacteria (e.g., E. coli), yeast, mammalian, or insect cells. In some embodiments, the polynucleotide is a heterologous polynucleotide (e.g., a polynucleotide heterologous to the organism). In this case, the target is a polynucleotide that has a mutation, insertion, deletion, or polymorphism.
[0056]
[0102] In some embodiments, the target is an aptamer. Aptamers have high specificity. Isolated nucleic acid molecules that bind binding moieties or target molecules, such as proteins, with isomerism and affinity An aptamer provides the chemical contacts to specifically bind its given target. Aptamers are nucleic acid-based molecules that are capable of binding to a specific target molecule. There are fundamental differences between aptamers and other nucleic acid molecules, e.g., genes and mRNAs. In the latter case, the nucleic acid structure encodes information through its linear base sequence and thus The sequence of the nucleosome is important for its function of storing information. In complete contrast, the nucleosomes are based on specific binding of target molecules. Aptamer function does not depend entirely on conserved linear base sequences (non-coding sequences); Any coding potential that an aptamer may have depends on the specific secondary / tertiary / quaternary structure. These results suggest that the aptamer is highly specific and unlikely to play a role in binding of the aptamer to its cognate target. Aptamers are distinct from naturally occurring nucleic acid sequences that bind to a protein. These naturally occurring nucleic acid sequences are useful for coding for proteins involved in the transcription, translation, and transport of naturally occurring nucleic acids. Embedded within the genome of an organism that binds to specialized subgroups (e.g., nucleic acid-binding proteins) Aptamers, on the other hand, are non-naturally occurring nucleic acid molecules. While it is possible to identify aptamers that bind proteins, in most cases Such aptamers share sequence identity with sequences recognized by nucleic acid binding proteins in nature. More importantly, aptamers have virtually no binding affinity to any target molecule. Proteins (not just nucleic acid binding proteins) and almost any target partner, e.g. For most partners, the TA can be attached to small molecules, carbohydrates, peptides, etc. For the protein, there is no naturally occurring nucleic acid sequence to which it binds. For a partner with a nucleic acid binding protein, such an arrangement would be tightly coupled. As a result of the relatively low binding affinity of naturally occurring aptamers compared to the aptamers they bind Aptamers differ from aptamers in that they specifically bind to a partner of choice and inhibit the activity or activity of that partner. can modulate the binding interaction, for example, through binding, and the aptamer can The functional property of specific binding to a partner is the ability of an aptamer to function. Aptamers can be between 6 and 35 kDa. Aptamers can be between 20 Aptamers can be up to 250 nucleotides in length. Aptamers can be used in micromolar to sub-nanomolar concentrations. can bind its partner with lower affinity and can distinguish between closely related targets (e.g. Aptamers can selectively bind related proteins from the same gene family. In some cases, the aptamer binds only one molecule. Binding members of a family of molecules. In some cases, aptamers bind multiple different molecules. Aptamers bind to molecules that bind to the nucleotides of interest, such as those found in common intermolecular interactions, e.g., hydrogen bonds, electrostatic interactions, etc. They can bind to specific partners using complementarity, hydrophobic contacts, and steric exclusion. The compounds have many desirable characteristics for use as therapeutic and diagnostic agents, including high specificity and Aptamers have excellent affinity for mAbs, low immunogenicity, biological potency, and excellent pharmacokinetic properties. The hybridization of covalently linked complementary polynucleotides results in a The peptide may comprise a molecular stem and loop structure (e.g., a hairpin loop structure). The hybridizing polynucleotide comprises a loop that shares two complementary polynucleotides. An aptamer is a linear ribonucleic acid (e.g., a linear ribonucleic acid) that contains an aptamer sequence. aptamer) or a circular polyribonucleic acid containing an aptamer sequence (e.g., a circular aptamer) It could be.
[0057]
[0103] In some embodiments, the target is a small molecule. For example, the small molecule is a macrocyclic The small molecule may be a molecule, an inhibitor, a drug, or a compound. In some embodiments, the small molecule contains 10 or fewer hydrogen bond donors. In some embodiments, the small molecule has a molecular weight of 500 daltons or less. In some embodiments, the small molecule has a molecular weight of about 180 to 500 daltons. In some embodiments, the small molecule has an octanol / water partition coefficient lo of 5 or less. In some embodiments, the small molecule has a partition coefficient l of -0.4 to 5.6. og P. In some embodiments, the small molecule has a molar refractive index of 40 to 130. In some embodiments, a small molecule contains from about 20 to about 70 atoms. In an embodiment, the small molecule is less than 140 angstroms. 2 It has the following polar surface area:
[0058]
[0104] In some embodiments, the target is a cell. For example, the target is an intact cell. The cells may be cells, cells treated with a compound (e.g., a drug), fixed cells, lysed cells, or any of the above. In some embodiments, the target is a single cell. In some embodiments, the target is a plurality of cells.
[0059]
[0105] In some embodiments, circRNAs may be single-targeted or multiple (e.g., 2 In one embodiment, the single circRNA comprises binding sites for a target of Contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or more distinct binding sites for a single target In one embodiment, a single circRNA contains two or three identical binding sites for a single target. , 4, 5, 6, 7, 8, 9, 10 or more. A is 2, 3, 4, 5, 6, 7, 8, 9, 10 or more distinct In one embodiment, the two or more targets are present in a sample, e.g., a mixture or are present in a library of targets, and the sample contains two or more binding moieties that bind to two or more targets. Contains circRNAs containing the position.
[0060]
[0106] In some embodiments, the single target or multiple (e.g., two or more) targets are: In one embodiment, the single target has 2, 3, 4, 5, 6, 7, In one embodiment, two or more targets are In a sample, e.g., a mixture or library of targets, the sample contains two or more binding moieties. In some embodiments, the single target or multiple targets comprise multiple different binding moieties. For example, a plurality may be at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 , 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 500, 1,0 00, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8 ,000, 9,000, 10,000, 11,000, 12,000, 13,000, 1 4,000, 15,000, 16,000, 17,000, 18,000, 19,000 , 20,000, 25,000, or 30,000 binding moieties.
[0061]
[0107] A target may comprise multiple binding moieties, including at least two different binding moieties. For example, the binding moiety may be at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 , 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 90 0, 1,000, 2,000, 3,000, 4,000, 5,000, 6,000, 7, 000, 8,000, 9,000, 10,000, 11,000, 12,000, 13, 000, 14,000, 15,000, 16,000, 17,000, 18,000, 1 9,000, 20,000, 21,000, 22,000, 23,000, 24,000 , or a plurality of binding moieties, including up to 25,000 different binding moieties. Binding Sites and Binding Moieties
[0108] In some instances, the circRNA comprises one binding site. The binding site is In some examples, the circRNA may contain at least two binding sites. For example, circRNAs contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 may contain 1, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more binding sites In some embodiments, the circRNAs described herein are capable of targeting one or more targets, or is a molecular scaffold that binds one or more binding moieties of one or more targets. Each target is , including but not limited to, different or the same nucleic acid (e.g., RNA, DNA, RNA- DNA hybrids), small molecules (e.g., drugs), aptamers, polypeptides, proteins Substances, lipids, carbohydrates, antibodies, viruses, virus particles, membranes, multicomponent complexes, cells, cell parts In some embodiments, the compound may be a part of the amine, any fraction thereof, and any combination thereof. In some embodiments, one or more binding sites bind to the same target. A binding site binds to one or more binding moieties of the same target. The binding moieties bind to one or more different targets. The binding site above binds to one or more binding moieties of different targets. , circRNAs act as scaffolds for one or more binding to one or more targets. In some embodiments, circRNAs are characterized by their ability to bind one or more binding moieties to one or more targets. In some embodiments, the circRNA acts as a scaffold for one or more By specifically binding to the above targets, the cellular processes are modulated. In this form, circRNAs specifically bind to one or more binding moieties of one or more targets. In some embodiments, the circR NAs modulate cellular processes by specifically binding to one or more targets In some embodiments, the circRNAs described herein are capable of detecting one or more specific In some embodiments, the circRNA comprises multiple binding sites for the target. In some embodiments, the nucleotide sequence includes a binding site or a combination of binding sites for each of the intended targets. In general, circRNAs contain multiple binding sites or sets of binding sites for each of the binding moieties of interest. For example, a circRNA may contain one or more binding sites for a polypeptide target. In some embodiments, the circRNA may comprise a polynucleotide target, e.g. For example, DNA or RNA, mRNA target, rRNA target, tRNA target, or genomic DNA. It contains one or more binding sites for a target.
[0062]
[0109] In some instances, circRNAs contain binding sites for single-stranded DNA. In some instances, circRNAs contain binding sites for double-stranded DNA. In some examples, the circRNA contains a binding site for an antibody. The rcRNA contains a binding site for a viral particle. A comprises a binding site for a small molecule. In some instances, the circRNA is In some instances, the circRNA comprises a binding site that binds to the RNA- In some instances, circRNAs contain binding sites for DNA hybridization. In some instances, the circRNA comprises a binding site for a transcriptionally encoded polynucleotide. , which contains a binding site for an unmethylated polynucleotide. The NA contains a binding site for an aptamer. In some instances, the circRNA In some instances, the circRNA contains a binding site for a polypeptide. , proteins, protein fragments, tagged proteins, antibodies, antibody fragments, small molecules, viruses a virus particle that contains a transmembrane protein, or a binding site for a cell In some instances, the circRNA comprises a binding moiety for a binding moiety on a single-stranded DNA. In some instances, the circRNA contains a binding site for a binding moiety on double-stranded DNA. In some instances, the circRNA contains a binding site for a binding moiety on an antibody. In some instances, the circRNA contains a binding site for a binding moiety on a viral particle. In some instances, the circRNA comprises a binding site for a binding moiety on a small molecule. In some instances, the circRNA contains a binding moiety in or on a cell. In some instances, the circRNA contains a binding site for an RNA-DNA hybrid. In some instances, the circRNA comprises a binding site for the above binding moiety. In some embodiments, the circR The NA contains a binding site for a binding moiety on an unmethylated polynucleotide. In some cases, the circRNA contains a binding site for a binding moiety on an aptamer. In the present invention, the circRNA contains a binding site for a binding moiety on a polypeptide. In some examples, circRNAs can be polypeptides, proteins, protein fragments, tagged Proteins, antibodies, antibody fragments, small molecules, virus particles (e.g., containing transmembrane proteins) The virion comprises a binding site for a binding moiety on the virion (e.g., a virus particle) or cell.
[0063]
[0110] In some instances, the binding site is a portion of the target that contains at least two amide bonds. In some instances, the binding site binds to a portion of the target that contains a phosphodiester bond. In some cases, the portion of the target is neither DNA nor RNA. In some embodiments, the linking moiety comprises at least two amide bonds. The moiety does not contain a phosphodiester bond. In some instances, the linking moiety may be either DNA or R It's not NA either.
[0064]
[0111] The circRNAs provided herein contain one or more binding moieties for the binding moiety on the complex. The circRNAs provided herein may contain the above binding sites to form a complex. For example, the cir can include one or more binding sites for a target for a given gene. cRNA may act as a scaffold to form a complex between circRNA and target In some embodiments, the circRNA forms a complex with a single target. In embodiments, the circRNA forms a complex with two targets. In some embodiments, the circRNA forms a complex with three targets. In some embodiments, the circRNA forms a complex with four targets. The circRNA forms a complex with five or more targets. The ircRNA forms a complex with two or more target complexes. In some embodiments, In some embodiments, the circRNA forms a complex with three or more targets. In some embodiments, two or more circRNAs form a complex with a single target. In some embodiments, two or more circRNAs form a complex with two or more targets. In one embodiment, the first circRNA comprises a first binding portion of a first target and a second binding portion of a second target. In some embodiments, the first c The ircRNA forms a complex with a first binding moiety of a first target and binds to a second circRNA A forms a complex with a second binding moiety of a second target.
[0065]
[0112] In some embodiments, the circRNA is Complex, polypeptide-polypeptide complex, polypeptide-DNA complex, polypeptide -RNA complex, polypeptide-aptamer complex, virus particle-antibody complex, virus Virus particle-polypeptide complex, virus particle-DNA complex, virus particle-RNA complex Conjugation, virus particle-aptamer complex, cell-antibody complex, cell-polypeptide complex , cell-DNA complex, cell-RNA complex, cell-aptamer complex, small molecule-polypeptide complex Peptide complexes, small molecule-DNA complexes, small molecule-aptamer complexes, small molecule-cell complexes , small molecule-virus particle complexes, and combinations thereof.
[0066]
[0113] In some embodiments, the circRNA is Complex, polypeptide-polypeptide complex, polypeptide-DNA complex, polypeptide -RNA complex, polypeptide-aptamer complex, virus particle-antibody complex, virus Virus particle-polypeptide complex, virus particle-DNA complex, virus particle-RNA complex Conjugation, virus particle-aptamer complex, cell-antibody complex, cell-polypeptide complex , cell-DNA complex, cell-RNA complex, cell-aptamer complex, small molecule-polypeptide complex Peptide complexes, small molecule-DNA complexes, small molecule-aptamer complexes, small molecule-cell complexes Binding for one or more binding moieties on the small molecule-virus particle complex, and combinations thereof. It may contain a binding site.
[0067]
[0114] In some instances, the binding site is a polypeptide, protein, or fragment thereof. In some embodiments, the binding site binds to a target polypeptide, protein or a fragment thereof. For example, The binding site may be an isolated polypeptide, a cellular polypeptide, a purified polypeptide, or a recombinant polypeptide. Binds to a domain, fragment, epitope, region, or portion of a polypeptide. For example, binding The site binds to a domain, fragment, epitope, region, or portion of an antibody or fragment thereof. For example, a binding site may be a region, fragment, epitope, or portion of a transcription factor. For example, a binding site may bind to a domain, fragment, epitope, region, or portion of a receptor. For example, a binding site may be a domain, fragment, epitope, region, or fragment of a transmembrane receptor. The binding site may be a domain, fragment, or fragment of an isolated, purified, and / or recombinant polypeptide. The binding site may bind to a fragment, epitope, region, or portion of an analyte. For example, binding to a domain, fragment, epitope, region, or portion of a polypeptide (e.g., lysate). The sites may be domains, fragments, epitopes, regions, or fragments from multiple cells or from a single cell lysate. The binding moiety may bind to a binding portion of a target. The binding moiety is present on a polypeptide, protein, or fragment thereof. In some embodiments, the binding moiety may be a domain, fragment, or fragment of a polypeptide, protein, or fragment thereof. For example, a binding moiety may be an isolated polypeptide, a cell, A domain, fragment, epitope, or polypeptide of the present invention, a purified polypeptide, or a recombinant polypeptide of the present invention For example, a binding moiety may be a domain, fragment, or portion of an antibody or fragment thereof. For example, the binding moiety may be a domain, fragment, or portion of a transcription factor. For example, a binding moiety may be a domain, fragment, or portion of a receptor. For example, a binding moiety may be a domain, fragment, or portion of a transmembrane receptor. The binding moiety may be an isolated, purified, and / or recombinant polypeptide. It may be present on or comprise a domain, fragment, epitope, region, or portion of a polypeptide. The binding moiety may be a domain, fragment, epitope, or fragment of an analyte mixture (e.g., a lysate). For example, the binding moiety may be a binding moiety for binding to a plurality of cells. or on a domain, fragment, epitope, region, or portion from a single cell lysate. , or includes them.
[0068]
[0115] In some instances, the binding site may be a domain, fragment, or a portion of a compound (e.g., a small molecule). For example, binding may occur to a domain, fragment, epitope, region, or portion of a drug. For example, a binding site may be a domain, fragment, or portion of a compound. Binds to an epitope, region, or portion. For example, a binding moiety can be a domain of an organic compound, In some embodiments, the binding site is 900 A domain, fragment, epitope, region, or portion of a small molecule having a molecular weight of less than a Dalton. In some instances, the binding site binds to a small molecule having a molecular weight of 500 Daltons or greater. A small molecule that binds to a domain, fragment, epitope, region, or portion of Some of the methods include, for example, libraries of naturally occurring or synthetic molecules, e.g., combinatorial A library of compounds produced via the means, i.e., a compound diversity combinatorial Combinatorial Libraries and Their Production and screening methods are known in the art, the disclosures of which are incorporated herein by reference. Incorporated U.S. Patent Nos. 5,741,713 and 5,734,018 Specification No. 5,731,423; Specification No. 5,721,099; No. 5,70 Specification No. 8,153; Specification No. 5,698,673; Specification No. 5,688,997 Specification No. 5,688,696; Specification No. 5,684,711; No. 5,64 Specification No. 1,862; Specification No. 5,639,603; Specification No. 5,593,853 Specification No. 5,574,656; Specification No. 5,571,698; No. 5,56 Specification No. 5,324; Specification No. 5,549,974; Specification No. 5,545,568 Specification No. 5,541,061; Specification No. 5,525,735; No. 5,46 Specification No. 3,564; Specification No. 5,440,016; Specification No. 5,438,119 The binding site is a small molecule binding portion as described in US Pat. No. 5,223,409. In some instances, the binding moiety may bind to a domain, fragment, epitope, or For example, the binding moiety may be present on or comprise a region or portion of a drug domain, The binding moiety is present on or comprises a fragment, epitope, region, or portion of , on or including a domain, fragment, epitope, region, or portion of a compound For example, a binding moiety may be attached to a domain, fragment, epitope, region, or portion of an organic compound. In some embodiments, the binding moiety is a molecule of 900 daltons or less. on or in the vicinity of a domain, fragment, epitope, region, or portion of a small molecule having an amount In some instances, the binding moiety is a small molecule having a molecular weight of 500 daltons or greater. The binding site is located on or comprises a domain, fragment, epitope, region, or portion of The molecules can be, for example, libraries of naturally occurring or synthetic molecules, e.g. ... A library of compounds produced through the method, i.e., a compound diversity combinatorial library Combinatorial libraries and their production and Methods for screening are known in the art, the disclosures of which are incorporated herein by reference. Incorporated U.S. Patent Nos. 5,741,713; 5,734,018; Specification No. 5,731,423; Specification No. 5,721,099; No. 5,708, Specification No. 153; Specification No. 5,698,673; Specification No. 5,688,997; Specification No. 5,688,696; Specification No. 5,684,711; Specification No. 5,641, Specification No. 862; Specification No. 5,639,603; Specification No. 5,593,853; Specification No. 5,574,656; Specification No. 5,571,698; Specification No. 5,565, Specification No. 324; Specification No. 5,549,974; Specification No. 5,545,568; Specification No. 5,541,061; Specification No. 5,525,735; Specification No. 5,463, Specification No. 564; Specification No. 5,440,016; Specification No. 5,438,119; It is described in US Pat. No. 5,223,409.
[0069]
[0116] A binding site is a domain or fragment of a member of a specific binding pair (e.g., a ligand). A binding site may be monovalent (monoepitope) or can bind to a multivalent (polyepitopic) domain, fragment, epitope, region, or portion A binding site may bind to an antigenic or haptenic portion of a target. A binding site may be a single molecule or is a set of domains of molecules that share at least one common epitope or determinant site. The binding site may bind to an polypeptide, fragment, epitope, region, or portion of a polypeptide. a domain, fragment, epitope, region, or portion of a gene of a human or animal cell (e.g., a bacterial cell, a plant cell, or an animal cell); The binding site may be in the natural environment (e.g., tissue), in cultured cells, or in microorganisms (e.g., For example, a target present in a bacterial, fungal, protozoan or viral vector, or in a lysed cell, may be bound to the target. The binding site may be modified (e.g., chemically) to provide one or more additional binding sites. The portion of the target that is being detected, such as, but not limited to, a dye (e.g., a fluorescent dye) , a polypeptide modifying moiety, e.g., a phosphate group, a carbohydrate group, or the like, or a polynucleotide The binding site may be a member of a specific binding pair. A binding moiety can bind to a binding moiety of a specific binding pair (e.g., a ligand). It may be present on or comprise a domain, fragment, epitope, region or portion of The binding moiety may be a monovalent (monoepitope) or polyvalent (polyepitope) domain, fragment, epitope, or The binding moiety may be present on or comprise a topope, region, or portion of the The binding moieties may be single molecules or may be at least one common epitope or or domains, fragments, epitopes, regions, or portions of molecules that share a common determinant site. The binding moiety may be present on or comprised within a cell (e.g., a bacterial cell, a plant cell, on a domain, fragment, epitope, region, or portion of a portion of a human or animal cell; The binding moieties may include those found in the natural environment (e.g., tissues), cultured cells, or microorganisms (e.g., For example, bacteria, fungi, protozoa, or viruses) or in lysed cells. The binding moiety may include one or more additional binding sites, such as, but not limited to, a dye. (e.g., fluorescent dyes), polypeptide modifying moieties, e.g., phosphate groups, carbohydrate groups, etc., or is (e.g., chemically) modified to provide a polynucleotide modifying moiety, e.g., a methyl group. It may be modified.
[0070]
[0117] In some instances, the binding site corresponds to a domain of a molecule found in a sample from a host. The binding site binds to a polypeptide, fragment, epitope, region, or portion of the polypeptide found in a sample from a host. In some instances, the binding moiety can bind to a binding moiety of a molecule delivered to a sample from a host. on or within a domain, fragment, epitope, region, or portion of a molecule found in Samples from a host include body fluids (e.g., urine, blood, plasma, serum, saliva, semen, etc.) Samples may be directly tested. Alternatively, the sample may be pretreated to make the binding moiety more easily detectable. A sample may be natural, recombinant, synthetic, or non-natural. The binding sites may be naturally occurring. or cell culture medium, in vitro translation samples, or immunofluorescence from samples (e.g., cell lysates). The binding moiety may be any of the above present in the immunoprecipitate. recombinantly expressed, cell lysate or cell culture medium, in vitro translation sample, or sample The antibody may be any of the above present in an immunoprecipitate from (eg, a cell lysate).
[0071]
[0118] In some instances, the binding site is located on a target expressed in a cell-free system or in vitro. For example, the binding moiety binds to a target in a cell extract. The binding sites are then incubated in a cell extract containing a DNA template and reagents for transcription and translation. The binding site binds to a binding portion of a target expressed in a cell-free system or in vitro. In some instances, the target binding portion may be expressed in a cell-free system or in vitro. For example, the binding moiety of the target is present in a cell extract. The fusion portion is incubated in a cell extract containing a DNA template and reagents for transcription and translation. Exemplary sources of cell extracts that can be used include wheat germ, large intestine, and the like. Bacteria, rabbit reticulocytes, hyperthermophilic bacteria, hybridomas, Xenopus oocytes Cells, insect cells, and mammalian cells (e.g., human cells). to express (e.g., to produce a target polypeptide on an array) Exemplary cell-free methods that can be used include protein in situ arrays. itu arrays (PISA), Multiple spotting technique que) (MIST), self-assembly mRNA translation, Nucleic Acid Programmable Protein Array (Nuc leic acid programmable protein array (NAPPA), Nanowell NAPPA, DN A-array - DNA array to protein array (DAPA), membrane Membrane-free DAPA, nanowell copying and μIP-microinterface opprinting, and pMAC-protein microarray copying ( (See Kilb et al., Eng.Life Sci. 2014, 14, 352-364).
[0072]
[0119] In some instances, the binding sites are generated in situ (e.g., from a DNA template). The binding sites bind to targets that are synthesized (e.g., on a solid substrate in an array). The target can be synthesized and bound to a binding moiety. In some instances, the target can be bound to a binding moiety of DNA. They are synthesized in situ from templates (e.g., on a solid substrate in an array). In an example, multiple binding moieties are synthesized in parallel or in a single reaction from multiple corresponding DNA templates. An exemplary method for in situ target polypeptide expression is Stevens, Structure 8(9): R177-R185 (2000); Katzen et al., Trends Biotechnol. 23(3):150-6. (2005);He et al., Curr. Opin. Biotechnol. 19(1): 4-9. (2008);Ra machandran et al., Science 305 (5680): 86-90. (2004);He et al., Nucleic Acids R es. 29(15):E73-3 (2001); Angenendt et al., Mol. Cell Proteomics 5(9): 1658-66 ( 2006);Tao etal, Nat Biotechnol 24(10): 1253-4 (2006);Angenendt et al., Anal. Chem. 76(7):1844-9(2004);Kinpara et al., J. Biochem. 136(2): 149-54 (2004);Ta kulapalli et al., J. Proteome Res. 11(8): 4382-91 (2012);He et al., Nat. Method s 5(2): 175-7(2008);Chatterjee and J. LaBaer, Curr Opin Biotech 17(4): 334-336 (2006); He and Wang, Biomol Eng 24(4): 375-80 (2007); and He and Taussig, J. Im munol. Methods 274(1-2):265-70 (2003).
[0073]
[0120] In some instances, the binding site comprises at least 6 nucleotides, e.g., at least Also 8, 9, 10, 12, 15, 20, 25, 30, 40, 50, or 100 nucleotides In some instances, the binding site binds to a nucleic acid target that contains a span of nucleotides. In some instances, the binding site binds to a protein target that contains a continuous stretch of nucleic acid. In some embodiments, the binding A site is a mutation or functional mutation of a nucleotide in a nucleic acid sequence, e.g., a deletion, addition, The binding site binds to a nucleic acid target that contains a site of addition, swap, or truncation. In some instances, the binding moiety of the nucleic acid target can bind to at least 6 nucleotides, e.g., at least 8, 9, 10, 12, 15, 20, 25, 30, 4 In some instances, the protein target comprises a span of 0, 50, or 100 nucleotides. The binding portion of the target protein comprises a continuous stretch of nucleotides. In some instances, the binding portion of the nucleic acid target comprises a non-contiguous stretch of nucleotides. The binding moiety may be a mutation or functional mutation of a nucleotide in a nucleic acid sequence, e.g., a deletion. This includes sites of deletion, addition, swapping, or truncation.
[0074]
[0121] In some instances, the binding site comprises at least six amino acids, e.g., at least Spa with 8, 9, 10, 12, 15, 20, 25, 30, 40, 50, or 100 amino acids In some instances, the binding site is a contiguous sequence of amino acids. In some instances, the binding site is the amino acid sequence In some instances, the binding site binds to a protein target that contains a non-continuous stretch. Amino acid mutations or functional mutations in the polypeptide sequence, e.g., deletions, additions, substitutions The binding site is a protein target that contains a site of amplifica- tion or truncation. In some instances, the binding moiety of the protein target can be , at least 6 amino acids, e.g., at least 8, 9, 10, 12, 15, 20, 25, In some embodiments, the protein comprises a span of 30, 40, 50, or 100 amino acids. The binding portion of the target comprises a contiguous stretch of amino acids. In some instances, the binding portion of the target comprises a non-contiguous stretch of amino acids. The target binding moiety may be an amino acid mutation or a functional mutation in the polypeptide sequence, e.g. This includes sites of deletion, addition, swapping, or truncation.
[0075]
[0122] In some embodiments, the binding site is a domain, fragment, or fragment of a membrane-associated protein. Binds to an epitope, region, or part of a membrane-bound protein. In some embodiments, the binding moiety may be a domain, fragment, or a polypeptide of a membrane-associated protein. On or including an epitope, region, or portion. Exemplary Membrane-Associated Proteins Examples of the receptors include, but are not limited to, GPCRs (e.g., adrenergic receptors, angiogenic receptors, etc.) Otensin receptor, cholecystokinin receptor, muscarinic acetylcholine receptor, neurotransmitter - Lotensin receptors, galanin receptors, dopamine receptors, opioid receptors, erotonin receptors receptors, somatostatin receptors, etc.), ion channels (e.g., nicotinamide acetylcholine receptors, sodium channels, potassium channels, etc.), non-excitatory and and excitatory channels, receptor tyrosine kinases, receptor serine / threonine kinases, receptor Somatic guanylate cyclase, growth factor and hormone receptors (e.g., epidermal growth factor (EGF) The binding site may be a mutant or modified variant of a membrane-bound protein. The binding site may bind to a domain, fragment, epitope, region, or portion of the ant. The binding moiety of the mutant or modified variant of the fusion protein may bind to a membrane Domains, fragments, epitopes, regions of mutant or modified variants of binding proteins; or a portion thereof. For example, a single or multiple GPCRs Point mutations in the ribosome conserve function and are associated with disease (e.g., Stadel et al., (1997) Trends inPharmacological Review 18: 430-37).
[0076]
[0123] The binding site may be, for example, a domain, fragment, epitope, or region of a ubiquitin ligase. The binding site may be, for example, a ubiquitin adaptor, a proteasome, or a portion of the A domain, fragment, epitope, region of an adaptor or proteasome protein, or The binding sites include, for example, endocytosis, phagocytosis, lysosomal pathways, Autophagy pathway, macroautophagy, microautophagy, chaperone-mediated Domains, fragments, and sequences of proteins involved in autophagy, the multivesicular body pathway, or a combination thereof In some instances, the binding site is a binding moiety. The binding moiety may, for example, be a domain, fragment, epitope, or fragment of a ubiquitin ligase. The binding moiety may include, for example, a ubiquitin adaptor, a proteasome or a domain, fragment, epitope, region, or fragment of a proteasome protein. The binding moiety may include, for example, a portion of the endocytosis, phagocytosis, lysosomal pathway. , Autophagy pathway, Macroautophagy, Microautophagy, Chaperone mediator domains of proteins involved in endothelial cell-mediated autophagy, the multivesicular body pathway, or a combination thereof; It may include a fragment, epitope, region, or portion.
[0077]
[0124] The binding site may be, for example, a domain, fragment, or fragment of a protein associated with a disease or pathology. Binds to an epitope, region, or portion of a gene. Binding sites include, for example, a domain of a protooncogene, The binding site may be, for example, a fragment, epitope, region, or portion of an oncogene. The binding site may be, for example, a fragment, epitope, region, or portion of a tumor suppressor gene. The binding site may be, for example, a fragment, epitope, region, or portion of a nucleic acid molecule. The antibody binds to a domain, fragment, epitope, region, or portion of a disease gene (e.g., a cytokine). The binding site may bind to a binding moiety. The binding moiety may, for example, be associated with a disease or pathology. The binding moiety may include a domain, fragment, epitope, region, or portion of a protein that binds to the For example, the binding site may include a domain, fragment, epitope, region, or portion of a proto-oncogene. The portion can include, for example, a domain, fragment, epitope, region, or portion of an oncogene. The binding moiety may, for example, bind to a domain, fragment, epitope, region, or portion of a tumor suppressor gene. The binding moiety may include, for example, a domain, fragment, or fragment of an inflammatory gene (e.g., a cytokine). , epitope, region, or portion.
[0078]
[0125] FIG. 1 shows sequence-specific RNA-binding motifs, sequence-specific DNA-binding motifs, and An example of a circular polyribonucleotide having a protein-specific binding motif is shown in FIG. In this embodiment, the circRNA may have other binding motifs for binding other intracellular molecules. Non-limiting examples of circRNA applications are listed in Table 1.
[0079] [Table 1]
[0080] RNA binding site
[0126] In some embodiments, the cyclic polyribonucleotide comprises one or more RNA bonds. In some embodiments, the circular polyribonucleotide comprises a binding site that is linked to an endogenous gene and and / or an RNA binding site that modulates expression of the exogenous gene. The RNA binding site modulates the expression of host genes. Genes (e.g., miRNAs, siRNAs, mRNAs, lncRNAs, Hybridize to a sequence for RNA, DNA, antisense RNA, or gRNA A sequence that hybridizes to an exogenous nucleic acid, e.g., viral DNA or RNA; Sequences that hybridize to RNA, sequences that interfere with gene transcription, sequences that interfere with RNA translation Stabilizing RNA through targeted degradation or destabilizing RNA Some of the sequences may include sequences that modulate a DNA or RNA binding factor. In an embodiment, the cyclic polyribonucleotide comprises an aptamer sequence that binds to RNA. The aptamer sequence may be a sequence that is encoded by an endogenous gene (e.g., an miRNA, siRNA, or a combination thereof, as described herein). A. About mRNA, lncRNA, RNA, DNA, antisense RNA, and gRNA (sequence), to an exogenous nucleic acid, e.g., viral DNA or RNA, to RNA, to a gene To sequences that interfere with transcription, to sequences that interfere with RNA translation, for example, through targeting for degradation, NA-stabilizing or RNA-destabilizing sequences, or DNA or RNA The secondary structure of the aptamer sequence can be determined by the RNA. The circular RNA can bind to the RNA by binding the aptamer sequence to the RNA. A coalescence may be formed.
[0081]
[0127] In some embodiments, the RNA binding site is a tRNA, an lncRNA, a li ncRNA, miRNA, rRNA, snRNA, microRNA, siRNA, piR NA, snoRNA, snRNA, exRNA, scaRNA, Y RNA, and hnR The RNA binding site may be that of an NA binding site. RNA binding sites are well known to those skilled in the art.
[0082]
[0128] Certain RNA-binding sites mediate the biological process of RNA interference (RNAi). In some embodiments, the cyclic polyribonucleotide can be a cyclic polyribonucleotide having a structure similar to that of the Typically, the nucleic acid has 15 to 50 base pairs (e.g., about 18 to 25 base pairs) and is expressed in cells. Nucleobases that are identical (complementary) or nearly identical (substantially complementary) to a coding sequence in a target gene The RNAi molecule includes an RNA having a sequence or an RNA-like structure. These include, but are not limited to, small interfering RNA (siRNA), double-stranded RNA (dsRNA), NA), microRNA (miRNA), short hairpin RNA (shRNA), meloduline Examples include the ribosome-specific ribosome cleavage domain, meroduplex, and Dicer substrate.
[0083]
[0129] In some embodiments, the RNA binding site comprises an siRNA or an shRNA. siRNA and shRNA are known to mediate the processing pathway of endogenous miRNA genes. The intermediates are similar. In some embodiments, siRNAs can function as miRNAs. MicroRNAs, e.g., siRNAs, can be targeted using RISC and vice versa. Unlike siRNAs, most animal miRNAs can down-regulate target genes. Instead, miRNAs mediate translational repression or polyA removal and mRNA transcription. Reduces protein output through degradation. Known miRNA binding sites are NA 3'-UTR; miRNAs are located 5 nucleotides from the 5' end of the miRNA It is believed that the targeting site has almost perfect complementarity with 2 to 8. This region is Since siRNA and miRNA are interchangeable, exogenous siRNA NAs can downregulate mRNAs that have seed complementarity with the siRNA. Multiple target sites within may confer even stronger downregulation.
[0084]
[0130] MicroRNAs (miRNAs) bind to the 3'-UTR of nucleic acid molecules and mediate the function of nucleic acid molecules. Downregulate gene expression by reducing gene stability or by inhibiting translation Circular polyribonucleotides are small non-coding RNAs that bind to one or more miRNA targets. Such sequences may include any target sequence, miRNA sequence, or miRNA seed. It may correspond to a miRNA.
[0085]
[0131] The miRNA sequence is a "seed" region, i.e., a region whose sequence is identical to the miRNA target sequence. The miRNA sequence includes sequences in the region of positions 2 to 8 of the mature miRNA that have Watson-Crick complementarity of The miRNA seed may comprise positions 2-8 or 2-7 of the mature miRNA. In the present study, the miRNA seed is a sequence of 7 nucleotides (e.g., 1 nucleotide of a mature miRNA). 2 to 8), and the seed complementary site in the corresponding miRNA target is In some embodiments, m is flanked by an adenine (A) opposite m The iRNA seed consists of 6 nucleotides (e.g., nucleotides 2-7 of the mature miRNA). a seed complementary site in the corresponding miRNA target that is complementary to the miRNA at position 1 It is flanked by opposing adenines (A).
[0086]
[0132] The bases of the miRNA seed can be substantially complementary to the target sequence. A target sequence is engineered into the circular polyribonucleotide to form a circular polyribonucleotide. The nucleotides are capable of evading or being detected by the host's immune system and modulating This process involves the synthesis of circular polyribonucleotides (CPNs), which are then converted to cyclic polyribonucleotides (CPPs), or modified translation. This may reduce the risk of off-target effects during delivery.
[0087]
[0133] The circular polyribonucleotide is a nucleotide sequence of about 5 to about 25 consecutive nucleotides of the target gene. In some embodiments, the miRNA sequence may be identical to the mRNA sequence. Targeting NA, starting with the dinucleotide AA, about 30%-70%, about 30%-60% , about 40% to 60%, or about 45% to 55% GC content, e.g., standard BL Any nucleic acid other than the target in the genome of the mammal into which it is to be introduced, as determined by AST searches. It does not have a high percentage of identity with the nucleotide sequence.
[0088]
[0134] Conversely, miRNA binding sites can be engineered from circular polyribonucleotides It can be eliminated (i.e., removed) to modulate protein expression in specific tissues. Modulation of expression in multiple tissues can be achieved by introducing one or several miRNA binding sites or This can be achieved through removal.
[0089]
[0135] miRNAs regulate mRNA and thereby protein expression. Examples of known tissues include, but are not limited to, liver (miR-122), muscle ( miR-133, miR-206, miR-208), endothelial cells (miR-17-92, miR-126), bone marrow cells (miR-142-3p, miR-142-5p, miR- 16, miR-21, miR-223, miR-24, miR-27), adipose tissue (le t-7, miR-30c), heart (miR-ld, miR-149), kidney (miR-1 92, miR-194, miR-204), and lung epithelial cells (let-7, miR-13 miRNAs play important roles in complex biological processes, e.g. It may also regulate angiogenesis (miR-132). In such a process, binding sites for miRNAs involved in the process are removed or introduced. and inducing expression from the circular polyribonucleotide in biologically relevant cell types or in In some embodiments, the miRs can be tailored to the context of the biological processes involved. NA binding sites include, for example, miR-7.
[0090]
[0136] Through understanding the expression patterns of miRNAs in different cell types, The cyclic polyribonucleotides described herein are capable of being synthesized in specific cell types or under specific biological conditions. Only under these conditions can the gene be engineered for more targeted expression. Through the introduction of RNA binding sites, circular polyribonucleotides can be expressed in tissues or biological conditions. The vectors can be designed for optimal protein expression in various contexts.
[0091]
[0137] In addition, miRNA seed sites are incorporated into circular polyribonucleotides to produce Expression of certain proteins in cells can be modulated to result in biological improvements. Incorporation of the miR-142 site into the circular polyribonucleotide described herein. Incorporation of the miR-142 site in the IL-14 protein may not only modulate expression in hematopoietic cells, but also also reduces the immune response to proteins encoded in the circular polyribonucleotide, Or it may be stopped.
[0092]
[0138] In some embodiments, the cyclic polyribonucleotide comprises at least one m In some embodiments, the iRNAs include, for example, 2, 3, 4, 5, 6 or more. The circular polyribonucleotide may be either a nucleotide sequence or a sequence complementary to a target sequence. At least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about miRNs with 97%, about 98%, about 99%, or 100% nucleotide sequence identity Contains A.
[0093]
[0139] Lists of known miRNA sequences are available from research institutions, such as the Wellcome Trust San Gorgoniovascular Center. r Institute,Penn Center for Bioinformatics, Memorial Sloan Kettering Cancer Center ter, and the database maintained by the European Molecule Biology Laboratory. RNAi molecules can be readily designed using techniques known in the art. In addition, computational tools can be used to generate effective and specific sequence motifs. It can be determined.
[0094]
[0140] In some embodiments, the cyclic polyribonucleotide is a long non-coding RNA. Long noncoding RNAs (lncRNAs) are non-coding RNAs longer than 100 nucleotides. Longer lengths distinguish lncRNAs from small regulatory RNAs, e.g. For example, lncRNAs are distinguished from miRNAs, siRNAs, and other short RNAs. The majority (approximately 78%) are characterized as tissue-specific. Diverse lncRNAs transcribed in the opposite direction to the parent (total lncRNAs in mammalian genomes) A significant proportion (approximately 20%) can regulate the transcription of adjacent genes.
[0095]
[0141] The length of the RNA binding site is about 5 to 30 nucleotides, about 10 to 30 nucleotides, or about 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 , 23, 24, 25, 26, 27, 28, 29, 30 or more nucleotides. The degree of identity of the RNA binding site to the target is at least 75%, at least 80%, It may be at least 85%, at least 90%, or at least 95%.
[0096]
[0142] In some embodiments, the cyclic polyribonucleotide comprises one or more long chain genetic fragments. It contains intercellular non-coding RNA (lincRNA) binding sites. LincRNAs are long non-coding RNAs that bind to LincRNAs are non-coding transcripts and in some embodiments In some embodiments, the lincRNA is greater than about 200 nucleotides in length. has an exon-intron-exon structure similar to that of protein-coding genes, but It does not contain an open reading frame and does not code for a protein. Expression can be significantly tissue specific compared to the coding gene. Generally, the degree of similarity between their neighboring genes and those of adjacent protein-coding gene pairs In some embodiments, the circular polyribonucleotide is co-expressed with the circularized li Contains ncRNAs.
[0097]
[0143] In some embodiments, the cyclic polyribonucleotides disclosed herein are , one or more lincRNAs, e.g., FIRRE, LINC00969, PVT1, L INC01608, JPX, LINC01572, LINC00355, C1orf13 2, C3orf35, RP11-734, LINC01608, CC-499B15.5 , CASC15, LINC00937, and RP11-191.
[0098]
[0144] Lists of known lincRNA and lncRNA sequences are available from research institutions, e.g., Institute of Genomics and Integrative Biology, Diamantina Institute at the Unive maintained by the City of Queensland, Ghent University, and Sun Yat-sen University. LincRNA and lncRNA molecules can be found in the databases available in the art. They can be easily designed and produced by techniques known in the art. The tool can be used to determine effective and specific sequence motifs.
[0099]
[0145] The RNA binding site is located in all of the endogenous genes or gene products (e.g., mRNA). A complementary sequence may comprise a sequence that is substantially complementary to a specific sequence or a fragment thereof. Prevents the maturation of newly generated nuclear RNA transcripts of target genes into mRNA for transcription The complementary sequence may be at the boundary between an intron and an exon for the purpose of , which is specific for a gene by hybridizing to the mRNA for that gene; The RNA binding site may bind to an endogenous gene or gene product, e.g., DNA, preventing its translation. Antisense oligonucleotides for all or a fragment of A, RNA, or their derivatives or hybrids. The nucleic acid may comprise a sequence that is sense or substantially antisense.
[0100]
[0146] In some embodiments, the cyclic polyribonucleotide typically comprises about 5 to about 10 nucleotides. 5000 base pairs (depending on the specific RNA structure, e.g., miRNA 5-30 bp, ln cRNA (200-500bp) containing RNA or RNA-like structure with an RNA-binding site The coding sequence is identical (complementary) or nearly identical (substantially identical) to the coding sequence in the target gene that is expressed in the cell. The nucleic acid sequence of the nucleic acid sequence is substantially complementary to that of the nucleic acid sequence ...
[0101] DNA binding site
[0147] In some embodiments, the cyclic polyribonucleotide comprises a DNA binding moiety, e.g. For example, the sequence for a guide RNA (gRNA) is included. The ribonucleotide comprises a complementary strand to the guide RNA or gRNA sequence. Short synthetic RNAs contain the "scaffold" sequences necessary for binding to defective effector moieties and the user The nucleic acid sequence comprises a targeting sequence of about 20 nucleotides for a genomic target defined by: The guide RNA sequence may be 17 to 24 nucleotides (e.g., 19, 20, or 21 nucleotides). The length of the guide RNA may be 100 bp (100 bp) and is complementary to the nucleic acid sequence to be targeted. In this study, custom gRNA generators and algorithms can be used. Gene editing is performed using chimeric "single guide RNA" ("sgRNA"), a naturally occurring crRNA- Mimicking the tracrRNA complex, it binds tracrRNA (for nuclease binding) and at least Both genes are encoded by a single crRNA (to guide the nuclease to the sequence targeted for editing). This can be achieved using a genetically engineered (synthetic) single RNA molecule that contains both Chemically modified sgRNAs can be effective in genome editing.
[0102]
[0148] gRNAs are designed to encode specific DNA sequences (e.g., promoters, enhancers, and The nucleic acid may recognize a sequence adjacent to or within a transcription factor, silencer, or repressor.
[0149] In some embodiments, the gRNA is a CRISPR system for gene editing. For gene editing, the circular polyribonucleotide is a part of the desired target DNA sequence. The guide RNA can be designed to include one or more guide RNA sequences corresponding to the gRN The A sequence is a sequence for interaction with Cas9 or other exonucleases that cleave DNA. At least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30 or more nucleotides For example, Cpf1 is a gene that is capable of detecting DNA cleavage at least about 1 ms after the gRNA sequence. 6 interacts with nucleotides.
[0103]
[0150] In some embodiments, the cyclic polyribonucleotide is capable of binding to DNA The secondary structure of the aptamer sequence is capable of binding to DNA. In this form, the circular polyribonucleotide is transformed into a DNA fragment by binding of the aptamer sequence to the DNA. It forms a complex with NA.
[0104]
[0151] In some embodiments, the cyclic polyribonucleotide is a major component of the double-stranded DNA. In one such example, a circular polyribonucleotide and The specificity and stability of triplex structures created by double-stranded DNA and the anti- Hoogsteen hydrogens distinct from those formed in classical Watson-Crick base pairing In one example, the cyclic polyribonucleotide binds to the target via the major groove. It binds to the purine-rich strand of the duplex.
[0105]
[0152] In some embodiments, triplex formation involves a purine-rich strand of the target duplex. It occurs in two motifs that are distinguished by the orientation of the circular polyribonucleotides. In an example, the polypyrimidine sequence stretch in the circular polyribonucleotide is (i.e., in the same 5'-3' orientation as the purine-rich strand of the duplex) While it binds to polypurine stretches of double-stranded DNA via Retsch (R) binds to the purine strand of the duplex in an antiparallel manner via reverse Hoogsteen hydrogen bonds. In the antiparallel configuration, the purine motif is G:GC, A:AT, or T:A- In parallel, the pyrimidine motif contains a triplet of T, while in parallel, the pyrimidine motif is C+:GC or Canonical for T:AT triplet (C+ represents a protonated cytosine at the N3 position) The antiparallel GA and GT sequences in the circular polyribonucleotides are at neutral pH. While a stable triplex can be formed in the presence of a cyclic nucleotide, the parallel CT sequence in the circular polyribonucleotide The N3 on the cytosine in the cyclic polyribonucleotide is a protease that can bind at acidic pH. Substitution of C with 5-methyl-C is preferred over cytosine because 5-methyl-C is more likely to be rotonized. The high pK of cyclic polyribonucleotides prevents the formation of CT sequences at physiological pH. For both purine and pyrimidine motifs, at least 10 base pairs are acceptable. The continuous homopurine-homopyrimidine sequence stretch of aids in nucleotide binding because shorter triplexes are unstable under physiological conditions. In some embodiments, the triplex structure may be destabilized by interrupting the sequence. Thus, a DNA duplex target for triplex formation contains consecutive purine bases in one strand. In one embodiment, the target for triplex formation is a homozygous nucleotide in one strand of a DNA duplex. It includes the homopyrimidine sequence in the complementary strand and the homopyrimidine sequence in the complementary strand.
[0106]
[0153] In some embodiments, the triplexes comprising the cyclic polyribonucleotides are stable. In some embodiments, the triplex comprising the cyclic polyribonucleotide has an increased structure. Half-life, e.g., about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% %, 45%, 50% or more increased half-life, e.g., at least 1 hour to about 30 days; or at least about 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days The duration may be days, 30 days, 60 days or more, or any time in between.
[0107] Protein binding sites
[0154] In some embodiments, the cyclic polyribonucleotide is a In some embodiments, the protein binding site comprises an aptamer sequence. In one embodiment, the circular polyribonucleotide comprises a reference compound, e.g., a protein. Responses induced by circular polyribonucleotides lacking protein-binding sites, e.g., linear RNA The antibody comprises a protein binding site for reducing an immune response from the host compared to the antibody.
[0108]
[0155] In some embodiments, the cyclic polyribonucleotides disclosed herein are , one or more protein binding sites for binding a protein, e.g., a ribosome Protein binding sites, e.g., ribosome binding sites, are included in the circular polyribonucleotide. By genetically engineering the cyclic polyribonucleotides, they can evade the host immune system and has reduced detection thereby, modulated decomposition, or modulated translation It may have a translation.
[0109]
[0156] In some embodiments, the cyclic polyribonucleotide may be used to enhance, for example, the immunity of a host. To mask the cyclic polyribonucleotides from components of the system, e.g., CTL responses In some embodiments, the antibody comprises at least one immunity protein binding site to avoid In this case, the immunity protein binding site binds to the immunity protein and is a non-endogenous component of the environment. It is a nucleotide sequence that assists in the masking of polyribonucleotides.
[0110]
[0157] The conventional mechanism of ribosome engagement on linear RNA is the RNA capsid. The ribosome binds to the 5' end of the loop. From the 5' end, the ribosome moves to the start codon. At that point, the first peptide bond is formed. Internal initiation of transcription (i.e., cap-independent) or translation can occur at either free or capped ends. Rather, the ribosome binds to a non-capped internal site, thereby In some embodiments, the cyclic nucleotide sequence begins polypeptide elongation at the initiation codon. A polyribonucleotide is a ribosome binding site, e.g., one or more R Contains NA sequence.
[0111]
[0158] In some embodiments, the cyclic polyribonucleotides disclosed herein are In some embodiments, the protein comprises a protein binding sequence that binds to the protein. The substrate-binding sequence targets or localizes the circular polyribonucleotide to a specific target. In some embodiments, the protein binding sequence binds to an arginine-rich region of the protein. Binds specifically.
[0112]
[0159] In some embodiments, the cyclic polyribonucleotides disclosed herein are , each of which contains one or more protein binding sites that bind to a target protein, e.g., In some embodiments, the ribozyme acts as a scaffold to bring one or more proteins into close proximity. The circular polynucleotides disclosed herein each comprise two nucleotides each of which binds to a target protein. In some embodiments, the target protein is brought into close proximity with the protein binding site. In the present specification, the circular polynucleotides each bind to a target protein. It contains three protein-binding sites that bind to each other, thereby bringing three target proteins into close proximity. In some embodiments, the circular polynucleotides disclosed herein are Each of the four proteins contains four protein-binding sites that bind to the target protein. In some embodiments, the circular polynucleotides disclosed herein are contains five or more protein binding sites that each bind to a target protein, and In some embodiments, the target proteins are the same. In some embodiments, the target proteins are different. The proximity of the proteins promotes the formation of a protein complex. Nucleotides can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more target proteins. In some embodiments, the endothelial cell may act as a scaffold to promote the formation of a complex containing the endothelial cell. The proximity of two or more target proteins promotes the interaction of two or more target proteins. In some embodiments, the proximity of two or more target proteins modulates an enzymatic reaction. In some embodiments, the binding of two or more target proteins is inhibited, promoted, or inhibited. The prodrug may modulate, promote, or inhibit a signal transduction pathway.
[0113]
[0160] In some embodiments, the protein binding site includes, but is not limited to, However, proteins such as ACIN1, AGO, APOBEC3F, and APOBEC3 G, ATXN2, AUH, BCCIP, CAPRIN1, CELF2, CPSF1, CP SF2, CPSF6, CPSF7, CSTF2, CSTF2T, CTCF, DDX21, DDX3, DDX3X, DDX42, DGCR8, EIF3A, EIF4A3, EIF4 G2, ELAVL1, ELAVL3, FAM120A, FBL, FIP1L1, FKBP 4, FMR1, FUS, FXR1, FXR2, GNL3, GTF2F1, HNRNPA1 , HNRNPA2B1, HNRNPC, HNRNPK, HNRNPL, HNRNPM, H NRNPU, HNRNPUL1, IGF2BP1, IGF2BP2, IGF2BP3, I LF3, KHDRBS1, LARP7, LIN28A, LIN28B, m6A, MBNL 2, METTL3, MOV10, MSI1, MSI2, NONO, NONO-, NOP5 8, NPM1, NUDT21, p53, PCBP2, POLR2A, PRPF8, PTB P1, RBFOX1, RBFOX2, RBFOX3, RBM10, RBM22, RBM2 7, RBM47, RNPS1, SAFB2, SBDS, SF3A3, SF3B4, SIR T7, SLBP, SLTM, SMNDC1, SND1, SRRM4, SRSF1, SRS F3, SRSF7, SRSF9, TAF15, TARDBP, TIA1, TNRC6A, TOP3B, TRA2A, TRA2B, U2AF1, U2AF2, UNK, UPF1, W DR33, XRN2, YBX1, YTHDC1, YTHDF1, YTHDF2, YWHA G, ZC3H7B, PDK1, AKT1, and any other protein that binds RNA Examples of binding sites include
[0114]
[0161] In some embodiments, the protein binding site is a nucleic acid that binds to the protein. Sequences such as transcription factors, enhancers, repressors, polymerases, nucleases, It is a sequence that can bind histones or any other proteins that bind DNA. In some embodiments, the protein binding site is an aptamer sequence that binds to the protein. In some embodiments, the secondary structure of the aptamer sequence allows the aptamer to bind the protein. In some embodiments, the circular RNA is amplified by binding of the aptamer sequence to a protein. Forms complexes with proteins.
[0115]
[0162] In some embodiments, the circular RNA is conjugated to a small molecule or a portion thereof. The small molecule or a portion thereof binds to a target, e.g., a protein. Conjugated to the circular RNA via modified nucleotides, e.g., by click chemistry Examples of small molecules that can bind to proteins include, but are not limited to, However, 4-hydroxytamoxifen (4-OHT), AC220, afatinib, and ampicillin were Nopyrazole analogs, AR antagonists, BI-7273, bosutinib, ceritinib , chloroalkanes, dasatinib, foretinib, gefitinib, HIF-1α-derived (R )-Hydroxyproline, HJB97, Hydroxyproline-based ligand, IACS- 7e, ibrutinib, ibrutinib derivatives, JQ1, lapatinib, LCL161 derivatives, Lenalidomide, Nutlin small molecule, OTX015, PDE4 inhibitors, pomalidomide, rip k2 inhibitor, RN486, Sirt2 inhibitor 3b, SNS-032, Steel factor, T BK1 inhibitors, thalidomide, thalidomide derivatives, thiazolidinedione-based ligands , VH032 derivatives, VHL ligand 2, VHL-1, VL-269, and their derivatives The body is mentioned.
[0116]
[0163] In some embodiments, the circular RNA comprises two or more small molecules, e.g., two, three , 4, 5, 6, 7, 8, 9, 10 or more small molecules. In some embodiments, the circular RNA is a mixture of two or more different small molecules, e.g., 2, 3, 4, 5, 6, 7 , 8, 9, 10 or more different small molecules. Two or more small molecules conjugated to the circular RNA can be linked to their respective target proteins. The target protein is then recruited to the target site, which acts as a target protein-protein complex. For example, circular RNA can induce cellular and / or molecular changes. and thalidomide, or their derivatives, which Therefore, target proteins of JQ1, such as BET family proteins and thalids, In some instances, the target protein of the amide may be recruited, for example, an E3 ligase. The circular RNA conjugated with JQ1 and thalidomide is Recruiting BET family proteins through the body to transport thalidomide or its derivatives BET family proteins are ligated to ubiquitin by E3 ligases recruited via This results in the tagging of the protein and thus the degradation of the tagged BET family protein.
[0117] Other binding sites
[0164] In some embodiments, the cyclic polyribonucleotide is a non-RNA or non-DNA A comprises one or more binding sites for a target. In some embodiments, the binding site is a small molecule. molecule, aptamer, lipid, carbohydrate, virus particle, membrane, multicomponent complex, cell, cell part, or any fragment thereof. The ribonucleotide comprises one or more binding sites for a lipid. Thus, a circular polyribonucleotide contains one or more binding sites for carbohydrates. In an embodiment, the cyclic polyribonucleotide comprises one or more binding sites for a carbohydrate. In some embodiments, the cyclic polyribonucleotide comprises one or more In some embodiments, the circular polyribonucleotide comprises a multicomponent complex. , e.g., one or more binding sites for ribosomes, nucleosomes, transcription machinery, etc. nothing.
[0118]
[0165] In some embodiments, the cyclic polyribonucleotide comprises an aptamer sequence. Aptamer sequences can be used to target any of the targets described herein (e.g., nucleic acid molecules, small molecules, protein molecules, The aptamer sequence is a set of two molecules that can bind to the target. In some embodiments, the aptamer sequence has a tertiary structure that is capable of binding a target. In some embodiments, the aptamer sequence has a quaternary structure that is capable of binding a target. The circular polyribonucleotide binds to the target via the aptamer sequence and forms a complex. In some embodiments, the complex is detectable for at least 5 days. In some embodiments, the complex is incubated for at least 2 days, 3 days, 4 days, 5 days, 6 days, days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, It is detectable for 15 to 16 days.
[0119] isolation
[0166] In some embodiments, the circRNAs described herein can be used to target, e.g. , sequestering DNA, RNA, proteins, and other cellular components to regulate cellular processes. circRNAs that contain binding sites for a target of interest can be used to identify endogenous binding partners and targets. In some embodiments, the circRNAs described herein may compete for binding to the In some embodiments, the circRNAs described herein are In some embodiments, the circRNAs described herein sequester mRNA. In some embodiments, the circRNAs described herein are In some embodiments, the circRNAs described herein In some embodiments, the circRNAs described herein sequester other circRNAs. RNA includes non-coding RNA, lncRNA, miRNA, tRNA, rRNA, and snoR. In some embodiments, the nucleic acid sequence of the present invention is sequestered to a nucleic acid sequence of the target nucleic acid, such as a nucleic acid sequence of the target nucleic acid, a ncRNA, a siRNA, or a shRNA. The circRNAs described herein are intended to be useful for identifying sequestering targets bound to the circRNA, e.g., DNA A, contains degradative elements that degrade RNA, proteins, or other cellular components. Non-limiting examples of rcRNA isolation applications are listed in Table 2.
[0120] [Table 2]
[0121]
[0167] In some embodiments, the methods of using circRNAs described herein Any of these may be in combination with a translation element. The described circRNAs can translate RNA into proteins. Binding motifs, sequence-specific DNA binding motifs, protein-specific binding motifs (protein facilitated by circRNAs containing regulatory RNA motifs (RNA1) and Schematic diagram of protein expression by RNA transcription and transcription factor ... It can initiate protein expression.
[0122] Untranslated Regions
[0168] In some embodiments, the circRNAs disclosed herein are In some embodiments, the encryptogen may include a non-translated region (UT The UTR of a gene can be transcribed but not translated. In some embodiments, Thus, a UTR can be included upstream of the translation initiation sequence of the expressed sequences described herein. In some embodiments, a UTR can be included downstream of the expression sequences described herein. In some instances, a UTR for a first expressed sequence can be a UTR for a second expressed sequence. It is the same as, contiguous with, or overlapping with another UTR in In embodiments, the intron is a human intron. The intron is a full-length human intron, for example, ZKSCAN1.
[0123]
[0169] In some embodiments, the encryptogen provides improved stability. In an embodiment, the regulatory features of the UTRs are included in the cryptogen to produce a circular polylysine. The stability of polynucleotides can be improved.
[0124]
[0170] In some embodiments, the circular polyribonucleotide comprises an embedded amino acid sequence. Contains UTRs with one or more stretches of deoxyribonucleic acid and uridine. Char may increase the turnover rate of the expression product.
[0125]
[0171] The introduction, removal, or modification of UTR AU-rich elements (AREs) results in the formation of circular polypeptides. These may be useful for modulating the stability or immunogenicity of ribonucleotides. When engineering a heterologous circular polyribonucleotide, one or more copies of an ARE are introduced. The ARE copies can then be used to destabilize the circular polyribonucleotide, thus terminating translation. Similarly, AREs can be identified and removed to reduce the expression of the target gene and / or reduce production of the expression product. or mutated to increase intracellular stability, thus improving translation and the resulting protein can increase the production of
[0126]
[0172] The UTR from any gene is composed of each fragment of the circular polyribonucleotide. In addition, multiple wild-type UTs of any known gene can be incorporated into the king region. In some embodiments, R can be used that is not a variant of the wild-type gene. Artificial UTRs can be used. These UTRs or parts of them can be The nucleic acid sequence of the transcript can be arranged in the same orientation as the transcript that was generated, or the orientation or location can be changed. Thus, a 5'- or 3'-UTR can be linked to one or more other 5'- or 3'-UTRs. The TR can be inverted, shortened, extended, or chimeric. The term "alteration" as used herein, when referring to a UTR sequence, refers to a modification of the UTR to a reference sequence. For example, the 3'- or 5'-UTR is The above teachings may be modified relative to the wild-type or native UTR by changing the orientation or location. or by the inclusion of additional nucleotides, deletion of nucleotides, swapping of nucleotides, etc. The "modified" UTR (whether 3' or 5') can be modified by a repeat or transposition. Any of these alterations that produce a waxy gene involve a variant UTR.
[0127]
[0173] In some embodiments, a double UTR, a triple UTR, or a quadruple UTR, e.g. , 5'- or 3'-UTR can be used. A UTR is one in which two copies of the same UTR are encoded contiguously or substantially contiguously. For example, a double β-globin 3'-UTR is used in some embodiments of the invention. It can be used. Encryptogen
[0174] As described herein, cyclic polyribonucleotides can be used to stimulate cellular innate immune responses. In some embodiments, the compound may include an encryptogen to reduce, avoid, or repel. In the present specification, the cyclic polyribonucleotides provided herein are represented by the following formula: A linear polynucleotide or encryptogen corresponding to the above circular polyribonucleotide is reduced immunity from the host compared to responses elicited by a non-cyclic cyclic polyribonucleotide In some embodiments, the cyclic polyribonucleotide provides an encoding response. It has lower immunogenicity than its counterpart lacking the gen.
[0128]
[0175] In some embodiments, the cyclic polyribonucleotide is derived from a mammal, e.g., In some embodiments, the cyclic polyribonucleotide is , capable of replicating in mammalian cells, for example human cells.
[0129]
[0176] In some embodiments, the cyclic polyribonucleotide comprises a sequence or an expression product. include.
[0177] In some embodiments, the cyclic polyribonucleotide is at least The half-life of a product, e.g., a linear expression sequence, or a linear circular polyribonucleotide. In one embodiment, the cyclic polyribonucleotide has an increased In some embodiments, the half-life is about 5%, 10%, 15%, 20% , 25%, 30%, 35%, 40%, 45%, 50% or more. In the method, the cyclic polyribonucleotide is Also about 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days , 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days The compound has a half-life or persistence in the cells of 10 to 20 days, 60 days or more, or any time in between. In one embodiment, the cyclic polyribonucleotide is cleaved for about 10 minutes to about 7 days, or for about 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 24 hours, 36 hours, 48 hours, 60 hours, In cells for up to 72 hours, 4 days, 5 days, 6 days, 7 days, or any time in between It has a half-life or duration of action.
[0130]
[0178] In some embodiments, cyclic polyribonucleotides can enhance cellular function, e.g. In some embodiments, the cell function is stably altered. For example, the modulation may be for at least about 1 hour to about 30 days, or for at least Also about 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days , 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days In one embodiment, the cells persist for 10 days, 60 days or more, or any time in between. The function is changed transiently, e.g., the modulation lasts from about 30 minutes to about 7 days or less; Approximately 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours hours, 19 hours, 20 hours, 21 hours, 22 hours, 24 hours, 36 hours, 48 hours, 60 hours hours, 72 hours, 4 days, 5 days, 6 days, 7 days, or any time in between; last.
[0131]
[0179] In some embodiments, the cyclic polyribonucleotide comprises at least about 20 bases. at least about 30 base pairs, at least about 40 base pairs, at least about 50 base pairs, At least about 75 base pairs, at least about 100 base pairs, at least about 200 base pairs, At least about 300 base pairs, at least about 400 base pairs, at least about 500 base pairs, or at least In some embodiments, the circular polyribonucleotide is at least about 1,000 base pairs. may be of sufficient size to accommodate a binding site for a ribosome. The authors report that the maximum size of cyclic polyribonucleotides is determined by the production and / or that the circular polyribonucleotide may be as large as possible within the technical constraints of use Without being bound by theory, multiple segments of RNA can be recognized. The strands are generated from DNA and their 5' and 3' free ends are annealed to form RNA strands. When only one 5' and one 3' free end remain, it is called the final In some embodiments, the circular polyribonucleic acid may be circularized. The maximum size of a nucleotide determines its ability to package RNA and deliver it to a target. In some embodiments, the size of the circular polyribonucleotide may be more limited. The length of the nucleic acid sequence is sufficient to code for a useful polypeptide, and therefore is about 20,000 amino acids long. less than about 15,000 base pairs, less than about 10,000 base pairs, about 7,500 base pairs less than about 5,000 base pairs, less than about 4,000 base pairs, less than about 3,000 base pairs , less than about 2,000 base pairs, less than about 1,000 base pairs, less than about 500 base pairs, less than about 400 base pairs Lengths of less than about 300 base pairs, less than about 200 base pairs, and less than about 100 base pairs are useful. It could be.
[0132] Cleavage sequence
[0180] In some embodiments, the cyclic polyribonucleotide comprises at least one open nucleotide. In some embodiments, the cleavage sequence flanks the expression sequence. In the form of a circular polyribonucleotide, for example, a self-immolating circRNA or a cleavable In some embodiments, the cleavage sequence in a specific circRNA or a self-cleaving circRNA. In the present invention, the circular polyribonucleotide contains two or more cleavage sequences, Multiple products of the peptide, such as miRNA, linear RNA, smaller circular polyribonucleoside, This results in separation into chids, etc.
[0133]
[0181] In some embodiments, the cleavage sequence comprises a ribozyme RNA sequence. RNA enzymes (from ribonucleic acid enzymes, also called RNA enzymes or catalytic RNAs) catalyze chemical reactions. Many natural ribozymes are RNA molecules that bind to their own phosphodiester bonds. They catalyze either the hydrolysis of one or the other bond in RNA. It has also been found to catalyze the aminotransferase activity of ribosomal R NAs can be "evolved" by in vitro methods. Similarly, ribozymes and their reaction products can regulate gene expression. In this study, catalytic RNA or ribozymes are used for the purpose of chemical conversion of molecules from bulk volumes. Larger non-coding RNAs such that ribozymes exist in many copies within cells In some embodiments, the aptamer and the ribozyme can both be located within Both can be encoded in the same non-coding RNA.
[0134] Self-Sacrifice Array
[0182] In some embodiments, the circRNAs described herein are self-sacrificing ci Includes rcRNA, cleavable circRNA, or self-cleaving circRNA. A is a cellular component, e.g., RNA, lncRNA, lincRNA, miRNA, RNA, tRNA, rRNA, snoRNA, ncRNA, siRNA, or shRNA In some embodiments, the circRNA may comprise (i) a self-cleaving element. (ii) a cleavable recruitment site; (iii) a degradable linker; (iv) a chemical phosphorus and / or (v) miRNAs separated by spacer sequences. In terms of morphology, circRNAs can be characterized as having (i) self-cleaving elements; (ii) cleavage recruiting elements; (iii) a degradable linker (e.g., glycerol (iv) a chemical linker; and / or (v) a siRNP separated by a spacer sequence. Non-limiting examples of self-cleaving elements include hammerhead, splice binding element, hairpin, hepatitis delta virus (HDV), barked satellite (Vark ud Satellite (VS), and glmS ribozyme. Non-limiting examples of sacrifice applications are listed in Table 4.
[0135] [Table 3]
[0136] Expression sequence Peptide or Polypeptide
[0183] In some embodiments, the cyclic polyribonucleotide is a peptide or polypeptide. The peptide coding sequence is
[0137]
[0184] The polypeptide may be linear or branched. The polypeptide may be from about 5 to about 400 0 amino acids, about 15 to about 3500 amino acids, about 20 to about 3000 amino acids, about 25 to about 2 It may have a length of about 500 amino acids, about 50 to about 2000 amino acids, or any range therebetween. In some embodiments, the polypeptide is less than about 4000 amino acids, about 3500 amino acids, or less than about 4000 amino acids. less than about 3000 amino acids, less than about 2500 amino acids, or less than about 2000 amino acids less than about 1500 amino acids, less than about 1000 amino acids, less than about 900 amino acids, Less than 800 amino acids, less than about 700 amino acids, less than about 600 amino acids, about 500 amino acids having a length of less than about 400 amino acids, less than about 300 amino acids, or less than that number. and may be useful.
[0138]
[0185] In some embodiments, the cyclic polyribonucleotides each comprise a polypeptide. The polypeptides are produced in significant amounts. Thus, a polypeptide can be any protein that can be produced. The polypeptide may be secreted from the cell or may be present in the cytoplasm, nucleus or other part of the cell. can be a polypeptide that is capable of localizing to a membrane compartment.
[0139]
[0186] In some embodiments, the cyclic polyribonucleotide can be a protein, e.g. , and sequences encoding therapeutic proteins. Some examples of therapeutic proteins include, but are not limited to, Protein replacements, protein supplements, vaccinations, antigens (e.g. For example, tumor antigens, viruses, and bacteria), hormones, cytokines, antibodies, immunotherapeutic agents ( cancer), cell reprogramming / transdifferentiation factors, transcription factors, chimeric antigen receptors, transposases or nucleases, immune effectors (e.g., immune response / signaling) and regulatory death receptor proteins (e.g., those that regulate apoptosis or necrosis). inducers), tumor lytic inhibitors (e.g., inhibitors of oncoproteins), epigenetic modifying agents, epigenetic enzymes, transcription factors, DNA or protein modifying enzymes, DNA Intercalating agents, efflux pump inhibitors, nuclear receptor activators or inhibitors, proteases asome inhibitors, competitive inhibitors for enzymes, protein synthesis effectors or inhibitors, Nucleases, protein fragments or domains, ligands or receptors, and CRISPR systems Or a component thereof.
[0140] Regulatory Sequences
[0187] In some embodiments, the regulatory sequence is a promoter. In the method, the circular polyribonucleotide is at least one sequence adjacent to the expression sequence. In some embodiments, the circular polyribonucleotide comprises: Each expression sequence includes a promoter adjacent thereto. The target is present on one or both sides of each expression sequence and is used to express the expression product, e.g., a peptide or and / or resulting in the separation of the polypeptide.
[0141]
[0188] Circular polyribonucleotides modulate the expression of RNA encoded by genes. Multiple genes may share some sequence homology with each other, resulting in a circular Polyribonucleotides are designed to target classes of genes with which they have sufficient sequence homology. In some embodiments, the cyclic polyribonucleotide can be designed to have different Complementarity to sequences shared among gene targets or unique to a specific gene target. In some embodiments, the circular polyribonucleotide may contain a sequence having any of the following: By targeting conserved regions of RNA sequences that share homology among several genes, It can be designed to target several genes in a family. In the present study, circular polyribonucleotides are synthesized by cloning the RNA sequences of specific genes. The rows can be designed to be targeted.
[0142]
[0189] In some embodiments, the expressed sequence is less than 5000 bp (e.g., about 500 0bp, 4000bp, 3000bp, 2000bp, 1000bp, 900bp, 80 0bp, 700bp, 600bp, 500bp, 400bp, 300bp, 200bp, 100bp, 50bp, 40bp, 30bp, 20bp, less than 10bp, or less) In some embodiments, the expression sequence may independently or additionally comprise: More than 10bp (e.g., at least about 10bp, 20bp, 30bp, 40bp, 50bp , 60bp, 70bp, 80bp, 90bp, 100bp, 200bp, 300bp, 4 00bp, 500bp, 600bp, 700bp, 800bp, 900bp, 1000k b, 1.1kb, 1.2kb, 1.3kb, 1.4kb, 1.5kb, 1.6kb, 1. 7kb, 1.8kb, 1.9kb, 2kb, 2.1kb, 2.2kb, 2.3kb, 2. 4kb, 2.5kb, 2.6kb, 2.7kb, 2.8kb, 2.9kb, 3kb, 3. 1kb, 3.2kb, 3.3kb, 3.4kb, 3.5kb, 3.6kb, 3.7kb, 3.8kb, 3.9kb, 4kb, 4.1kb, 4.2kb, 4.3kb, 4.4kb, Length of the fragment (4.5kb, 4.6kb, 4.7kb, 4.8kb, 4.9kb, 5kb or more) Yes.
[0143]
[0190] In some embodiments, the expression sequence exhibits one or more of the features described herein. For example, one or more peptide or protein coding sequences, one or more regulatory sequences, The nucleic acid may be a nucleic acid sequence, one or more non-coding RNAs, and other expressed sequences.
[0144] Internal ribosome entry site (IRES)
[0191] In some embodiments, the cyclic polyribonucleotides described herein include The preferred IRES element is a In some embodiments, the nucleic acid sequence may contain an RNA sequence capable of engaging a nuclear ribosome. Typically, the IRES element is at least about 50 base pairs, at least about 100 base pairs, At least about 200 base pairs, at least about 250 base pairs, at least about 350 base pairs, or In some embodiments, the IRES element is located in an organism, e.g. Examples include, but are not limited to, viruses, mammals, and Drosophila hila) DNA. Viral DNA is derived from, for example, picornavirus cDNA, brain It can be derived from myocarditis virus (EMCV) cDNA and poliovirus cDNA. In one embodiment, the Drosophila DNA from which the IRES element is derived is For example, the antennapedia gene from Drosophila melanogaster can be mentioned. .
[0145]
[0192] In some embodiments, the cyclic polyribonucleotides described herein are At least one (e.g., 2, 3, 4, 5 or more) expression sequence flanking the In some embodiments, the IRES comprises at least one (e.g., In some embodiments, the expression sequence may be flanked on either side by at least one of the following: In the present invention, the circular polyribonucleotide is one or more on one or both sides of each expression sequence. The nucleic acid sequence may include an IRES sequence, which provides for isolation of the resulting peptide and / or polypeptide.
[0146] Translation initiation sequence
[0193] In some embodiments, the cyclic polyribonucleotide encodes a polypeptide. In some embodiments, the translation initiation sequence may include a translation initiation sequence, e.g., a start codon. The sequence includes a Kozak or Shine-Dalgarno sequence. The polyribonucleotide may contain a translation initiation sequence, e.g., a Kozak sequence, adjacent to the expression sequence. In some embodiments, a translation initiation sequence, e.g., a Kozak sequence, is provided at the end of each expression In some embodiments, the sequences are located on one or both sides of the sequence, resulting in separation of the expression products. The circular polyribonucleotide comprises at least one translation initiation sequence adjacent to the expression sequence. .
[0147]
[0194] The native 5'-UTR may carry features that play a role in translation initiation The natural 5'-UTR is involved in the process by which the ribosome initiates translation of many genes. The resulting signature may be, for example, a Kozak sequence. CCR(A / G)CCAUGG (R is the 3 bases of the start codon (AUG) followed by another "G" The 5'-UTR has an upstream purine (adenine or guanine). Secondary structures involved in binding may also form.
[0148]
[0195] A circular polyribonucleotide may have two or more initiation codons, e.g., Not at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least At least 12, at least 13, at least 14, at least 15, at least 16, at least At least 17, at least 18, at least 19, at least 20, at least 25, at least At least 30, at least 35, at least 40, at least 50, at least 60, or A gene can contain more than 60 initiation codons. Translation begins on the first initiation codon or on the first It may begin downstream of the start codon.
[0149]
[0196] In some embodiments, the circular polyribonucleotide comprises an initial start codon, For example, it may begin at a codon that is not AUG. Alternative translation initiation sequences, including but not limited to, ACG, AGG, AAG, C TG / CUG, GTG / GUG, ATA / AUA, ATT / AUU, TTG / UUG In some embodiments, translation can be initiated under selective conditions, e.g., stress induction. As a non-limiting example, a circular polyribonucleic acid Translation of the nucleic acid may begin at an alternative translation initiation sequence, e.g., ACG. As a typical example, circular polyribonucleotide translation can be initiated by the alternative translation initiation sequence CTG / CUG As yet another non-limiting example, circular polyribonucleotide translation can begin at Alternatively, the translation may begin at the alternative translation initiation sequence GTG / GUG. Thus, the circular polyribonucleotide may contain repeat-associated non-AUG(RAN) sequences, e.g. Alternative translation initiation sequences, including short stretches of RNA, e.g., CGG, GGGGCC, C Translation can be initiated at AG or CTG.
[0150]
[0197] The nucleotides flanking the codon that initiates translation are circular polyribonucleic acid. The codon that initiates translation may affect the translation efficiency, length and / or structure of the nucleotide. Circular polyribonucleic acid can be produced by masking any of the nucleotides flanking the The location of the translation initiation, translation efficiency, length, and / or structure of the oxidase can be altered.
[0151]
[0198] In some embodiments, the masking agent is a nucleotide that occupies the start codon or an alternative start codon. A masked initiation codon or an alternative codon can be used nearby to mask or conceal the codon. It is possible to reduce the probability of translation initiation at the start codon. Examples include antisense locked nucleic acid (LNA) oligonucleotides and exon-dimers. In some embodiments, the masking agent may be an exonuclease junction complex (EJC). The start codon of a circular polyribonucleotide is masked using the This can increase the likelihood of initiation in the program.
[0152]
[0199] In some embodiments, translation occurs under selective conditions, e.g., limited Circular polyribonucleic acid (PC) is produced by selection in the presence of GRSF-1, but not by the virus. The otide contains a GRSF-1 binding site.
[0153]
[0200] In some embodiments, translation is mediated by eukaryotic initiation factor 4A (EIF4A) by rocagralate. Translation is initiated by eIF4A processing. Translation is inhibited by blocking 43S scanning. It represses the RocA-eIF4A target sequence, resulting in premature upstream translation initiation. Protein expression from the transcript can be reduced.
[0154] Termination sequence
[0201] In some embodiments, the circular polyribonucleotide comprises one or more expressed sequences. Each expression sequence may have a termination sequence. The ribonucleotides contain one or more expression sequences, the expression sequences lacking a termination sequence and As a result, circular polyribonucleotides are continuously translated. The removal of the termination sequence is accomplished by the ribosome Rolling circle translation or expression products, e.g., peptides, due to stalling or lack of shedding or continuous production of the polypeptide. Group circle translation produces continuous expression products via each expressed sequence.
[0155]
[0202] In some embodiments, the cyclic polyribonucleotide comprises a staggered sequence. While avoiding the production of continuous expression products, such as peptides or polypeptides, Staggered sequences are included to maintain ribosome positioning during translation to maintain translation circle. The staggered sequence can induce 2A-like or CHYSEL (systolic In some embodiments, the sequence may include a sequence of a sRNA or a sRNA. The tagger element is X1X2X3EX5NPGP (X1 is absent or G or H). X2 is absent or D or G, and X3 is D or V or I or S or M. and X5 is any amino acid. In some embodiments, the sequence encodes an alpha helical propensity. A non-conserved sequence of amino acids followed by the consensus sequence -D(V / I)ExNPGP(x= Some non-limiting examples of stagger elements include GDV ESNPGP, GDIEENPGP, VEPNPGP, IETNPGP, GDIESNP GP, GDVELNPGP, GDIETNPGP, GDVEPGP, GDVEENPG P,GDVEQNPGP,IESNPGP,GDIELNPGP,HDIETNPGP, HDVETNPGP, HDVEMNPGP, GDMESNPGP, GDVETNPGP, GDIEQNPGP, and DSEFNPGP.
[0156]
[0203] In some embodiments, the circular polyribonucleotide comprises one or more expressed sequences. In some embodiments, the one or more expression sequences include a termination sequence at the end of the Generally, a termination sequence lacks an in-frame nucleotide sequence that signals the end of translation. In some embodiments, the ribozyme comprises a ribozyme triplet, e.g., UAA, UGA, UAG. One or more of the termination sequences in the circular polyribonucleotide may be a frameshift termination sequence, e.g. including, but not limited to, off-frame or -1 and +1 shifts that can terminate translation reading frame (e.g., cryptic stop). As frameshift termination sequence is a nucleotide triplet occurring in the second and third reading frames of an expressed sequence These include TAA, TAG, and TGA. Frameshift termination sequences are harmful to cells. This may be important in preventing misleading mRNA sequences, which are often the case.
[0157]
[0204] In some embodiments, the stagger sequences described herein terminate translation. and / or the expression product can be cleaved between the G and P of the consensus sequence described herein. As one non-limiting example, circular polyribonucleotides can terminate translation and / or comprises at least one stagger sequence for cleaving the expression product. In the method of the present invention, the circular polyribonucleotide is a staggered polyribonucleotide flanking at least one expression sequence. In some embodiments, the circular polyribonucleotide comprises a respective expression In some embodiments, the circular polyribonucleotide comprises a stagger sequence after the sequence. Each of the expression sequences includes a stagger sequence on one or both sides of the expression sequence, It results in the translation of individual peptides and / or polypeptides from the expressed sequences.
[0158] PolyA sequence
[0205] In some embodiments, the circular polyribonucleotide comprises a polyA sequence. In some embodiments, the length of the polyA sequence is more than 10 nucleotides in length. In embodiments, the polyA sequence is more than 15 nucleotides in length (e.g., at least or about 10 , 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,20 0, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1, 900, 2,000, 2,500, and over 3,000 nucleotides. In the embodiment, the polyA sequence is about 10 to about 3,000 nucleotides (e.g., 30 to 50 , 30~100, 30~250, 30~500, 30~750, 30~1,000, 30 ~1,500, 30~2,000, 30~2,500, 50~100, 50~250, 5 0~500, 50~750, 50~1,000, 50~1,500, 50~2,000, 50~2,500, 50~3,000, 100~500, 100~750, 100~1, 000, 100~1,500, 100~2,000, 100~2,500, 100~3, 000, 500~750, 500~1,000, 500~1,500, 500~2,00 0, 500~2,500, 500~3,000, 1,000~1,500, 1,000~ 2,000, 1,000~2,500, 1,000~3,000, 1,500~2,000 0, 1,500~2,500, 1,500~3,000, 2,000~3,000, 2, 000~2,500 and 2,500~3,000).
[0159]
[0206] In some embodiments, the polyA sequence is the entire length of the circular polyribonucleotide. The design is based on the length of the coding region, the specific features or regions ( For example, based on the length of the first or flanking region, or on the length of the circular polyribonucleotide In this regard, the polyA sequence may be based on the length of the final product expressed from the 10, 20, 30, 40, 50, 60, 70 The polyA sequence may be greater than 100%, 80%, 90%, or 100% longer than the circular polyribonucleotide. In this regard, the polyA sequence may be designed as part of the entire construct or as part of the construct. 10%, 20%, 30%, 40%, 50%, 60% of the total length of the product minus the polyA sequence %, 70%, 80%, 90% or more. In addition, the gene for polyA binding protein Conjugation of engineered binding sites and circular polyribonucleotides enhances expression. It is possible.
[0160]
[0207] In some embodiments, the cyclic polyribonucleotide is a poly-AG quartet. G-quartets are designed to contain G-rich sequences in both DNA and RNA. In some embodiments, the cyclic hydrogen bond sequence of four guanine nucleotides can be formed by In this form, a G-quartet can be incorporated at the end of the polyA sequence. The circular polyribonucleotide constructs produced may be modified to improve stability, protein production, and / or other parameters. The assay can be performed at various time points, for example for half-life. In one embodiment, the polyAG quartet is a single polyA sequence of 120 nucleotides. This can result in protein production equivalent to at least 75% of that seen with the use of
[0161] Riboswitches
[0208] In some embodiments, the circular polyribonucleotide comprises one or more ribosomal Includes the switch.
[0162]
[0209] Riboswitches can bind directly to small target molecules, and their binding to the target is mediated by RNA A portion of a cyclic polyribonucleotide that affects translation and the stability and activity of the expressed product Thus, a circular polyribonucleotide containing a riboswitch can be The activity of the circular polyribonucleotide may be modulated depending on its presence or absence. In the literature, riboswitches are regions of aptamer-like affinity for discrete molecules. Any aptamer contained within the encoding nucleic acid can be used to sequester the molecule from the bulk volume. In some embodiments, "(ribo)switch" activity can be determined by the Can be used for downstream reporting.
[0163]
[0210] In some embodiments, the riboswitch can regulate transcription termination, inhibition of translation initiation, In eukaryotes, it monitors gene expression by self-cleavage of NA and by altering the splicing pathway. Riboswitches regulate gene expression through the binding or removal of trigger molecules. Thus, conditions that activate, deactivate, or block the riboswitch can be controlled. Providing a circular polyribonucleotide containing a riboswitch can alter gene expression For example, gene expression can occur as a result of the termination of transcription or the blocking of ribosome binding to RNA. The binding of the trigger molecule, or an analog thereof, can alter the properties of the riboswitch. Depending on the .
[0164]
[0211] In some embodiments, the riboswitch is adenosylcobalamin (vitamin It binds coenzyme form of B12 to regulate the biosynthesis and transport of cobalamin and similar metabolites. The cobalamin riboswitch (also known as the B12 element) controls transcription.
[0165]
[0212] In some embodiments, the riboswitch binds cyclic di-GMP. It is a cyclic di-GMP riboswitch that regulates various genes by inducing cyclic Two non-structurally related classes of di-GMP riboswitches: cyclic di-GMP-I and cyclic di-GMP-II Cyclic di-GMP-II exists.
[0166]
[0213] In some embodiments, the riboswitch is a flavin mononucleotide (FM FMN riboswitch (RFN) binds riboflavin to regulate riboflavin biosynthesis and transport (also called element).
[0167]
[0214] In some embodiments, the riboswitch comprises a sufficient concentration of glucosamine-6- The glmS riboswitch cleaves itself when phosphate is present.
[0215] In some embodiments, the riboswitch binds glutamine to form glutamine Glutamine riboswitches regulate genes involved in ATPase and nitrogen metabolism. Riboswitches can also bind short peptides of unknown function. They fall into two structurally related classes: the glnA RNA motif and the downstream peptide motif.
[0168]
[0216] In some embodiments, the riboswitch binds glycine and converts it to a glycine substitute. A glycine riboswitch that regulates genes. It consists of two adjacent It is the only known naturally occurring RNA that contains an aptamer domain and exhibits cooperative binding.
[0169]
[0217] In some embodiments, the riboswitch binds lysine to mediate lysine biosynthesis. lysine riboswitches (also called L-boxes) that regulate transcription, catabolism, and transport.
[0218] In some embodiments, the riboswitch binds prequeusine. The preQ1 ribosomal protein regulates genes involved in the synthesis or transport of the precursor of quercetin to quercetin. Two distinct classes of preQ1 riboswitches are the preQ1-I riboswitches. The binding domain of the preQ1-I riboswitch is Maine is one of the smallest naturally occurring riboswitches. occus and preQ1-I, which is found only in certain species of Lactococcus The I riboswitch has a completely different structure and is larger than the preQ1-I riboswitch. .
[0170]
[0219] In some embodiments, the riboswitch binds purines to regulate purine metabolism and The purine riboswitch is a purine riboswitch that regulates the transport of guanidine and guanidine. It binds guanine or adenine. The specificity for either guanine or adenine is Due to Watson-Crick interactions with a single pyrimidine in the riboswitch at Y74 In a guanine riboswitch, the single pyrimidine is a cytosine (i.e., C7 4). In an adenine riboswitch, the single pyrimidine is uracil (i.e., Homologous purine riboswitches can bind deoxyguanosine. However, there is a more significant difference than with a single nucleotide mutation.
[0171]
[0220] In some embodiments, the riboswitch encodes S-adenosylhomocysteine ( SAH) is bound to the methylation reaction to produce S-adenosylmethionine (SAM). This is a SAH riboswitch that regulates genes involved in the recycling of the SAH produced.
[0172]
[0221] In some embodiments, the riboswitch is S-adenosylmethionine (SA The SAM riboswitch binds methionine (M) to regulate the biosynthesis and transport of methionine and SAM There are three distinct SAM riboswitches: SAM-I (originally called S-box) SAM-I is a ubiquitous SAM protein that is widely distributed in bacteria. SAM-II is found only in α-, β-, and a few γ-proteobacteria. SMK box riboswitches are found in the Lactobacillales. These three riboswitch variants have no obvious sequence or structural similarity. A fourth variant, SAM-IV, has a ligand-binding core similar to that of SAM-I, but , are considered to have distinct scaffolding situations.
[0173]
[0222] In some embodiments, the riboswitch is similar to both SAM and SAH. This is an affinity binding SAM-SAH riboswitch.
[0223] In some embodiments, the riboswitch binds tetrahydrofolate to encode a residue. It is a tetrahydrofolate riboswitch that regulates gene synthesis and transport.
[0174]
[0224] In some embodiments, the riboswitch is a theophylline-binding riboswitch or is a thymine pyrophosphate-binding riboswitch.
[0225] In some embodiments, the riboswitch senses glucosamine-6-phosphate. Thermoanaerobacter tengcongens is the glmS catalytic riboswitch from
[0175]
[0226] In some embodiments, the riboswitch encodes thiamine pyrophosphate (TPP). TPP ribosomal protein binds to regulate thiamine biosynthesis and transport, as well as the transport of similar metabolites. The TPP riboswitch is found in eukaryotes. do.
[0176]
[0227] In some embodiments, the riboswitch binds a molybdenum cofactor. and biosynthesis and transport of enzymes that use molybdenum or its derivatives as cofactors. and Moco riboswitches that regulate genes involved in .
[0177]
[0228] In some embodiments, the riboswitch is a gene encoding a riboswitch encoding a gene encoding a Vibrio vulnificus. It was found in the 5'-UTR of the adenine deaminase (add)-encoding gene of O. vulnificus. The adenine-sensing add-A riboswitch is
[0178] Aptazymes
[0229] In some embodiments, the cyclic polyribonucleotide comprises an aptazyme. Aptazymes are compounds in which the aptamer domain is used as an allosteric control element to regulate the catalytic activity of a ligand. A switch for conditional expression that is bound to a region of a catalytic RNA ("ribozyme" below) In some embodiments, the aptazyme is active in cell type-specific translation. In some embodiments, the aptazyme is a cellular state specific translational target, e.g. It is active in virus-infected cells or in the presence of viral nucleic acids or viral proteins. .
[0179]
[0230] Ribozymes are RNA molecules that catalyze chemical reactions. Many natural ribozymes The ribozyme reacts with the phosphodiester bond of the ribozyme itself or with the phosphodiester bond of another RNA. Natural ribozymes can catalyze the hydrolysis of tert-linked ester bonds. Catalytic RNAs can also catalyze enzyme activity. Catalytic RNAs can be "evolved" using in vitro methods. Ribozymes and the products of the reactions of ribozymes can regulate gene expression. In this study, catalytic RNA or ribozymes are used to generate ligands for the chemical conversion of molecules from bulk volumes. Within larger non-coding RNAs, the ribozymes are present in many copies within the cell. In some embodiments, the aptamer and the ribozyme can be both can also be encoded in the same non-coding RNA.
[0180]
[0231] Non-limiting examples of ribozymes include hammerhead ribozymes, VL ribozymes, Examples of ribozymes include ribozymes, leadzymes, and hairpin ribozymes.
[0232] In some embodiments, the aptazyme is capable of cleaving an RNA sequence and or a ribozyme that can be regulated as a result of binding of a modulator. The ribozymes may be self-cleaving ribozymes. The properties of antibodies and aptamers may be combined.
[0181]
[0233] In some embodiments, the aptazyme is a cyclic polyribonucleic acid molecule as described herein. The aptamer in the absence of ligand / modulator The immunoreactive enzyme is inactive and allows expression of the transgene. Expression is stopped by the addition of a ligand. It can be downregulated or inhibited in response to the presence of a particular modulator. The aptazymes described herein are designed to regulate the expression of genes in response to modulators, where upregulation is desirable. It can be used in the control system.
[0182]
[0234] Aptazymes generate a system for autoregulation of circular polyribonucleotide expression For example, they can be used to inhibit the rate-limiting enzyme in the synthesis of certain small molecules. The protein products of the circular polyribonucleotides described herein are increased in the presence of small molecules. Synthesis of molecules engineered to contain aptazymes selected to have enhanced catalytic activity Alternatively, aptazymes can provide an autoregulatory feedback loop for The activity can be a protein product from a cyclic polyribonucleotide, or any other cellular macromolecule. It may be an accumulation of selected senses.
[0183]
[0235] In some embodiments, the cyclic polyribonucleotide comprises an aptamer sequence. Non-limiting examples of aptamers include RNA aptamers that bind lysozyme. , Toggle-25t (a 2'-fluoro thrombin complex that binds with high specificity and affinity to thrombin) Pyrimidine nucleotide-containing RNA aptamer), human immunodeficiency virus transactivator RNA-Tat binds the HIV response element (TAR), and hemin binds RNA aptamers that bind interferon-γ, and vascular endothelial growth factor receptor 1 (VEGF-1) RNA aptamers that bind VEGF and prostate-specific antigen (PSA) RNA aptamers that bind to ribosomal protein 1 (RIRP1), ribosomal protein 1 (RIP1), and heat shock factor 1 (HSF1) An example is an RNA aptamer that binds (HSF1).
[0184]
[0236] In some embodiments, the circRNAs described herein are For example, circRNAs can be used to detect non-coding RNAs, lncRNA, miRNA, tRNA, rRNA, snoRNA, ncRNA, siRN In some embodiments, the circR gene can encode a circA gene, or an shRNA. The NA may contain antisense miRNA and transcriptional elements. ircRNAs can produce functional linear miRNAs. Non-limiting examples of application areas are listed in Table 5.
[0185] [Table 4]
[0186] Duplicate Elements
[0237] Circular polyribonucleotides encode sequences and / or motifs useful for replication. Replication of the circular polyribonucleotide produces a complementary circular polyribonucleotide. In some embodiments, the circular polyribonucleotide may be generated by initiating transcription. The transcription is initiated by the endogenous cellular machinery (DNA-dependent RNA polymerase), which contains motifs for initiating transcription. RNA-dependent RNA polymerase encoded by circular polyribonucleotides The product of the rolling circle transcription event is a ribozyme. Either the complementary or the propagating circular polyribonucleotide at unit length is cut by the The ribozyme can generate a circular polyribonucleotide and its complementary strand. or can be encoded in trans by an RNA sequence. The encoded ribozyme exerts ribozyme activity to control circRNA spread. In some embodiments, the gene may include a regulating (inhibiting or promoting) sequence or motif. The unit length sequences can be ligated into a circular form by cellular RNA ligase. In some embodiments, the cyclic polyribonucleotide comprises a replication element that supports self-amplification. Examples of such replication elements include the HDV replication domain and the replication-competent domain. Capable circular RNA sense and / or antisense ribozymes, e.g. Antigenome 5'-CGGGUCGGCAUGGCAUCUCCACCUCCUCGC GGUCCGACCUGGGCAUCCGAAGGAGGACGCACGUCCACUC GGAUGGCUAAGGGAGAGCCA-3' (SEQ ID NO: 1), or Genome 5'-UGGCCGGCAUGGUCCCAGCCUCCUCGCUGGCGC CGGCUGGGCAACAUUCGAGGGGGACCGUCCCCUCGGUAAU GGCGAAUGGGACCCA-3' (sequence number 2).
[0187]
[0238] In some embodiments, the cyclic polyribonucleotide is The cleavage sequence in the circular polyribonucleotide comprises at least one of the cleavage sequences described herein. The cleft sequence cleaves the long transcript replicated from the circular polyribonucleotide into a defined length. This results in a complementary strand to the circular polyribonucleotide, which can then be circularized to form the complementary strand to the circular polyribonucleotide.
[0188]
[0239] In another embodiment, the cyclic polyribonucleotide is At least one ribozyme for cleaving long transcripts replicated from the DNA into defined lengths. The nucleic acid sequence includes a ribozyme that cleaves the transcript at the ribozyme sequence. Circularization forms a complementary strand to the circular polyribonucleotide.
[0189]
[0240] In some embodiments, the cyclic polyribonucleotide is, for example, an exonuclease. It is substantially resistant to degradation by enzymes.
[0241] In some embodiments, the circular polyribonucleotide replicates intracellularly. In some embodiments, the cyclic polyribonucleotide is about 10% to 20%, 20% to 3 0%, 30%~40%, 40%~50%, 50%~60%, 60%~70%, 70%~7 5%, 75%~80%, 80%~85%, 85%~90%, 90%~95%, 95%~9 9%, or any percentage therebetween. The polyribonucleotides are replicated within the cell and transferred to daughter cells. , the cell ingests at least one circular polyribonucleotide at least 25%, 5 Transfer with an efficiency of 0%, 60%, 70%, 80%, 85%, 90%, 95%, or 99%. In some embodiments, cells undergoing meiosis transfer circular polyribonucleotides to daughter cells. At least 25%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, or 9 In some embodiments, cells undergoing meiosis are transfected with the circular polyribonucleic acid (PPI) at an efficiency of 9%. Transfer nucleotides to daughter cells at least 25%, 50%, 60%, 70%, 80%, 85%, 9 Transfer with 0%, 95%, or 99% efficiency.
[0190]
[0242] In some embodiments, the circular polyribonucleotide is capable of replicating within a host cell. In some embodiments, the cyclic polyribonucleotide is expressed in a mammalian cell, e.g., a human It can replicate in mouse cells.
[0191]
[0243] In some embodiments, the circular polyribonucleotide is a polypeptide that replicates in a host cell. On the other hand, circular polyribonucleotides can be integrated into the genome of a host, for example by integrating with a host chromosome. In some embodiments, the cyclic polyribonucleotide does not regulate the expression of the host. In some embodiments, the circular polyribonucleic acid has a negligible recombination frequency with a chromosome. Reotide is, for example, about 1.0 cM / Mb, 0.9 cM / Mb, 0.8 cM / Mb, 0. 7cM / Mb, 0.6cM / Mb, 0.5cM / Mb, 0.4cM / Mb, 0.3cM / Mb, 0.2 cM / Mb, 0.1 cM / Mb, or less than that number, e.g. It has a recombination frequency with the main chromosome.
[0192] Other Arrays
[0244] In some embodiments, the circular polyribonucleotide further comprises another nucleic acid sequence. In some embodiments, the cyclic polyribonucleotide is DNA, RNA, or Other sequences may include, but are not limited to, genomic DNA. , cDNA, or tRNA, mRNA, rRNA, miRNA, gRNA, siRNA, or other RNAi molecule. In this case, the cyclic polyribonucleotide is a nucleotide sequence that is expressed by a gene located at a different locus than the cyclic polyribonucleotide or at the same locus as the cyclic polyribonucleotide. The nucleic acid sequence includes a sequence encoding an siRNA for targeting the locus of the same gene expression product. In some embodiments, the cyclic polyribonucleotide is a cyclic polyribonucleotide different from The gene expression product of the present invention includes a sequence encoding an siRNA for targeting the gene expression product of the present invention.
[0193]
[0245] In some embodiments, the circular polyribonucleotide lacks a 5'-UTR. In some embodiments, the circular polyribonucleotide lacks a 3'-UTR. In some embodiments, the circular polyribonucleotide lacks a polyA sequence. In some embodiments, the circular polyribonucleotide lacks a termination sequence. The polyribonucleotide lacks an internal ribosome entry site. Polyribonucleotides that are oriented in a circular fashion lack susceptibility to degradation by exonucleases. In this embodiment, the circular polyribonucleotide lacks binding to a cap-binding protein. In some embodiments, the circular polyribonucleotide lacks a 5' cap.
[0194]
[0246] In some embodiments, the cyclic polyribonucleotide has one or more of the following sequences: Top: Sequences encoding one or more miRNAs, sequences encoding one or more replication proteins sequences, sequences encoding exogenous genes, sequences encoding therapeutic agents, regulatory sequences (e.g., promoter sequences), motors, enhancers), and endogenous genes (siRNA, lncRNA, shRNA) A sequence encoding one or more regulatory sequences for targeting and coding for a therapeutic mRNA or protein. Contains the array to load.
[0195]
[0247] Other sequences include sequences of about 2 to about 5,000 nt, about 10 to about 100 nt, about 50 to about 15 0nt, about 100 to about 200nt, about 150 to about 250nt, about 200 to about 300nt, Approx. 250~350nt, approx. 300~500nt, approx. 10~1000nt, approx. 50~ Approx. 1000nt, Approx. 100~Approx. 1000nt, Approx. 1000~Approx. 2000nt, Approx. 2000 ~ about 3000nt, about 3000~ about 4000nt, about 4000~ about 5000nt, or more It may have any range of lengths therebetween.
[0196]
[0248] Circular polyribonucleotides are transformed into linear RNA as a result of their circularization. For example, circular polyribonucleotides may contain certain distinguishing features. Therefore, circular polyribonucleic acid (PRI) is less susceptible to degradation by enzymes than linear RNA. Nucleotides are converted to linear RNA, especially when incubated in the presence of exonucleases. A. Increased stability of circular polyribonucleotides compared to linear RNA. Due to their nature, circular polyribonucleotides are useful as cell transformation agents for producing polypeptides. It is more useful as an exogenous RNA and can be stored more easily and for longer than linear RNA. The stability of circular polyribonucleotides treated with nucleases is unclear, as RNA degradation occurs Using methods standard in the art (e.g., gel electrophoresis) to determine whether (by
[0197]
[0249] Furthermore, unlike linear RNA, circular polyribonucleotides are The nucleotide is incubated with a phosphatase, e.g., calf intestinal phosphatase. In this case, it is not susceptible to dephosphorylation.
[0198] Nucleotide spacer sequences
[0250] In some embodiments, the cyclic polyribonucleotide comprises a spacer sequence. nothing.
[0199]
[0251] The spacer may be arranged over the entire length of the spacer or at least 50 %, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96 %, 97%, 98% or 99% of the consecutive nucleic acid residues, e.g., 65%, 60%, 55%, %, 50%, 55%, 50%, 45%, 40%, 39%, 38%, 37%, 36%, 35 %, 34%, 33%, 32%, 31%, 30%, 29%, 28%, 27%, 26%, 25 %, 24%, 23%, 22%, 20%, 19%, 18%, 17%, 16%, 15%, 14 %, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2 In some embodiments, the nucleic acid molecule may have a low GC content of less than 1% or 2%. The spacer has substantially no secondary structure, e.g., less than 40 kcal / mol, -3 9, -38, -37, -36, -35, -34, -33, -32, -31, -30, -2 9, -28, -27, -26, -25, -24, -23, -22, -20, -19, -1 8, -17, -16, -15, -14, -13, -12, -11, -10, -9, -8, The spacer is less than -7, -6, -5, -4, -3, -2 or -1 kcal / mol. may comprise nucleic acid, for example DNA or RNA.
[0252] The spacer sequence is an RNA sequence, preferably a sequence including a secretory signal peptide. The nucleic acid sequence may encode a protein or peptide sequence.
[0200]
[0253] The spacer sequence may be non-coding. When the spacer is a non-coding sequence, In some embodiments, the initiation codon can be provided in the coding sequence of the flanking sequence. In this case, the first nucleic acid residue of the coding sequence may be the A residue of the start codon, e.g., AUG. It is envisaged that the spacer may encode an RNA or a protein or peptide sequence. In this case, the start codon can be provided in the spacer sequence.
[0201]
[0254] In some embodiments, the spacer is operable to another sequence as described herein. It is linked to function.
[0202] Non-nucleic acid linkers
[0255] The circular polyribonucleotides described herein can also include non-nucleic acid linkers. In some embodiments, the cyclic polyribonucleotides described herein are In some embodiments, the nucleic acid sequence includes a non-nucleic acid linker between one or more of the sequences or elements. In some embodiments, one or more of the sequences or elements described herein are connected with a linker. The nucleic acid linker can be a chemical bond, for example, one or more covalent or non-covalent bonds. In some embodiments, the non-nucleic acid linker is a peptide or protein linker. Such a linker may be 2 to 30 amino acids or longer. , flexible, rigid or cleavable linkers as described herein.
[0203]
[0256] The most commonly used flexible linkers consist mainly of Gly and Ser residues. The flexible linker has a sequence consisting of a stretch of the nucleotides ("GS" linker). These may be useful for binding domains that require a certain degree of movement or interaction, and are small and non-polar (e.g. It may contain amino acids such as Ser or T. The incorporation of hr stabilizes the linker in aqueous solution by forming hydrogen bonds with water molecules. The linker also maintains its binding affinity, thus reducing undesirable interactions between the linker and the protein moiety. do.
[0204]
[0257] The rigid linker is used to maintain a fixed distance between the domains and to facilitate their independent functions. Rigid linkers are useful for maintaining the stability of one or more components in the fusion. It is also useful when spatial separation of domains is important to preserve molecular weight or biological activity. The rigid linker may have an α-helical structure or a Pro-rich sequence (XP). n (X is any The amino acids may be Ala, Lys, or Glu.
[0205]
[0258] The cleavable linker may release the free functional domain in vivo. In embodiments, the linker undergoes cleavage under defined conditions, e.g., in the presence of a reducing agent or a protease. In vivo cleavable linkers allow for the reversible cleavage of disulfide bonds. As an example, a thrombin-sensitive sequence (e.g., In vitro thrombin treatment of CPRSCs resulted in the formation of thrombin-sensitive sequences. This results in cleavage of the nucleic acid sequence while leaving the reversible disulfide bond intact. In vivo cleavage of the linker in the IL-1 domain allows the IL-1 domain to be expressed in a specific cell or organelle under pathological conditions (e.g., cancer or inflammation). is a protease expressed in vivo in tissues or restricted in certain cellular compartments. The specificity of many proteases can also be achieved by the restriction of This provides slower cleavage of the linker.
[0206]
[0259] Examples of linking molecules include hydrophobic linkers, e.g., negatively charged sulfonic acid groups; lipids , for example, poly(-CH 2 -ipid, for example, poly(-CHe) PEG groups, their unsaturated variants, their hydroxylated variants, amidated or otherwise N-containing variants thereof; non-carbon linkers; carbohydrate linkers a phosphodiester linker or other molecule capable of covalently linking two or more polypeptides; Non-covalent linkers, for example, linkers that are linked to the polypeptide via a hydrophobic region of the polypeptide. Hydrophobic stretches of a region or polypeptide, such as leucine, isoleucine, valine, or can be alanine, phenylalanine, or even tyrosine, methionine, glycine or other Also included are hydrophobic lipid globules that are linked together via a series of hydrophobic residue-rich residues. The peptide uses charge-based chemistry to convert a positively charged portion of a polypeptide into a negatively charged portion of another polypeptide. The conjugation may be such that it binds to a peptide or a nucleic acid.
[0207] Circularization
[0260] In some embodiments, the linear circular polyribonucleotide is circularized or In some embodiments, linear circular polyribonucleic acid can be concatemerized. The otides can be formulated in vitro and / or cyclized prior to delivery. In this state, the linear circular polyribonucleotide can be circularized within the cell.
[0208] Extracellular cyclization
[0261] In some embodiments, linear circular polyribonucleotides are prepared using chemical methods. The ribonucleotides are then circularized or concatemerized to form circular polyribonucleotides. In the chemical method of the present invention, the 5' end and The 3' ends, when brought together, form a new covalent bond between the 5' and 3' ends of the molecule. The 5' end may contain an NHS ester reactive group and the 3' end may contain an NHS ester reactive group. , which may contain a 3' amino-terminated nucleotide, resulting in the synthesis of linear RNA molecules in organic solvents. The 3'-amino terminated nucleotide on the 3' end is catalyzed by the nucleophilic 5'-NHS-ester moiety. It is attacked and forms a new 5' or 3'-amide bond.
[0209]
[0262] In some embodiments, a DNA or RNA ligase is used to ligate the 5'-phosphate A nucleic acid molecule (e.g., a linear circular polyribonucleotide) is synthesized by cleaving a nucleic acid (e.g., a linear nucleic acid) at 3 It can enzymatically bind to the '-hydroxyl group of phosphodiester bonds to form new phosphodiester bonds. In one example reaction, linear circular polyribonucleotides are mixed with 1 to 10 units of T4RNA. Incubate for 1 hr at 37 °C with ligase according to manufacturer's protocol. The ligation reaction involves enzymatic ligation by base pairing with both the 5' and 3' regions of the flanking region. This may occur in the presence of linear nucleic acid which can assist the polymerization reaction.
[0210]
[0263] In some embodiments, the DNA or RNA ligase ligates the circular polyribonucleic acid. As a non-limiting example, the ligase can be used in the synthesis of otides. c ligase or circular ligase.
[0211]
[0264] In some embodiments, the 5' or 3' end of the linear circular polyribonucleotide Either of the above may encode a ligase ribozyme sequence, such that during in vitro transcription, The resulting linear circular polyribonucleotide is a linear circular polyribonucleotide having a 5' end. Contains an active ribozyme sequence that can be ligated to the 3' end of a linear circular polyribonucleotide The ligase ribozyme is a ribozyme that binds to group I introns, hepatitis delta virus, and hairpin ribozymes. The ligands can be derived from a single antibody or can be derived using SELEX (systematic evolution of ligands by exponential enrichment). can be selected by the atic evolution of ligands by exponential enrichment. The ribozyme ligase reaction may take 1 to 24 hours at a temperature of 0 to 37°C.
[0212]
[0265] In some embodiments, the linear circular polyribonucleotide comprises at least one The non-nucleic acid portion of the nucleic acid may be used to circularize or concatemerize the nucleic acid. In one embodiment, at least one non-nucleic acid moiety is a 5' React with regions or features near the termini and / or 3' termini to form linear circular polyribonucleic acid The nucleotides may be cyclized or concatemerized. The non-nucleic acid moieties are located within the 5' and / or 3' ends of the linear circular polyribonucleotide. Non-nucleic acid moieties contemplated As a non-limiting example, the non-nucleic acid moiety may be a bond, e.g., a hydrophobic bond. The bond may be a degradable bond, an ionic bond, a biodegradable bond and / or a cleavable bond. As another non-limiting example, the non-nucleic acid moiety is a ligation moiety. The nucleic acid portion may be an oligonucleotide or a peptide portion, such as an aptamer as described herein. The linker may be a nucleic acid or a non-nucleic acid linker.
[0213]
[0266] In some embodiments, the linear circular polyribonucleotide is a linear circular polyribonucleotide. Atoms at, near or attached to the 5' and 3' ends of polynucleotides; Circularization or concatemerization due to non-nucleic acid moieties that cause attraction between molecular surfaces As a non-limiting example, one or more linear circular polyribonucleotides can be Cyclization or concatemerization can be achieved by intermolecular or intramolecular forces. Non-limiting examples of the above include dipole-dipole forces, dipole-induced dipole forces, induced dipole-induced dipole forces, and Non-limiting examples of intramolecular forces include polar forces, van der Waals forces, and London dispersion forces. Examples include covalent bonds, metallic bonds, ionic bonds, resonance bonds, agonistic bonds, and dipole bonds. Conjugation, conjugation, hyperconjugation and anticonjugation are examples of such conjugation.
[0214]
[0267] In some embodiments, the linear circular polyribonucleotide has a 5′ end near the The ribozyme RNA sequence may include a ribozyme RNA sequence near the 3' end of the nucleic acid sequence. When exposed to the remainder of the endozyme, it can be covalently linked to a peptide. Peptides covalently linked to the ribozyme RNA sequence near the 3' and 4' ends of the peptides associate with each other. , which may cause circularization or concatemerization of linear circular polyribonucleotides. In the present invention, peptides are covalently linked to the ribozyme RNA sequence near the 5' and 3' ends. The bonds can be ligated using a variety of methods known in the art, including, but not limited to, However, it is not intended to be a linear primary construct or a linear construct after being subjected to protein ligation. This may result in circularization or concatamerization of the mRNA.
[0215]
[0268] In some embodiments, the linear circular polyribonucleotide can be, for example, a 5' tert-amino acid. Phosphate is then transported to RNA 5' pyrophosphohydrolase (RppH) or ATP diphosphohydrolase (ATPD). The 5' triphosphate of a nucleic acid that is converted to the 5' monophosphate by contact with an enzyme (apyrase) Alternatively, the 5' triphosphate of the linear circular polyribonucleotide may be substituted with the 5' monophosphate. Conversion can be achieved by (a) cleaving the 5' nucleotide of a linear circular polyribonucleotide with a phosphatase (e.g. For example, Antarctic phosphatase, shrimp alkaline phosphatase, or bovine small intestinal phosphatase. (b) contacting the phosphate buffer with a phosphate buffer to remove all three phosphates; and (b) after step (a). The 5' nucleotide of This can be produced by a two-step reaction involving contacting the enzyme with
[0216] Splicing elements
[0269] In some embodiments, the cyclic polyribonucleotide comprises at least one sequence. In some embodiments, the splicing element comprises In some embodiments, the circular polyribonucleic acid is flanked by at least one expression sequence. The octets contain splicing elements flanking each expressed sequence. In this embodiment, the splicing elements are present on one or both sides of each expression sequence. This results in the isolation of the expression products, e.g., peptides and / or polypeptides.
[0217]
[0270] In some embodiments, the circular polyribonucleotide is a sequence that, when replicated, Contains an internal splicing element that joins the ends to be spliced together. Examples include splice site sequences and short inverted repeats (30-40 nt), e.g., A luSq2, AluJr, and AluSz, inverted sequences in the flanking introns, flag Alu elements in the linking intron and sequences adjacent to backsplice events motifs found in sequence elements (suptable 4 enriched motifs), For example, 200 bp before (upstream) or after the back splice site with flanking exons Examples of such a sequence include small introns (<100 nt) that have a sequence downstream. In some embodiments, the circular polyribonucleotide comprises an internal splicing element and and at least one repeated nucleotide sequence as described elsewhere herein. In one embodiment, the repeated nucleotide sequence is a repeat from the Alu family of introns. In some embodiments, the splicing-associated ribosome binding domain may include a repeat sequence. Proteins are involved in the synthesis of circular polyribonucleotides, e.g., myelin and quaternary It can regulate the Quaking (QKI) splicing factor.
[0218]
[0271] In some embodiments, the cyclic polyribonucleotide is a It may contain canonical splice sites flanking the head-to-tail junction of the oxidase.
[0272] In some embodiments, the cyclic polyribonucleotide comprises two 3-nucleoside chains. A bulge-helix-bulge containing a four base pair stem flanked by helix bulges The cleavage occurs at a site in the bulge region and may include a terminal 5'-hydroxyl Circularization produces a characteristic fragment with a cyclic phosphate and a 2',3'-cyclic phosphate. It proceeds by nucleophilic attack of the 5'-OH group on the 2',3'-cyclic phosphate of the same molecule, It forms a 3',5'-phosphodiester bridge.
[0219]
[0273] In some embodiments, the cyclic polyribonucleotide comprises an HPR element. The HPR may comprise a multimeric repeat RNA sequence that contains 2',3'-cyclic HPR elements are linear, circular polyribonucleic acids and contain a 5'-OH terminus. The 5' and 3' ends of the peptide are self-processed, thereby ligating the ends together. do.
[0220]
[0274] In some embodiments, the circular polyribonucleotide is a self-ligating In some embodiments, the circular polyribonucleotide may include a sequence that mediates HDV sequences for self-ligation (e.g., HDV replication domain conserved sequences, GGCUCAUCUCGACAAGAGGCGGCAGUCCUCAGUACUCUUA CUCUUUUCUGUAAAGAGGAGACUGCUGGACUCGCCGCCCA AGUUCGAGCAUGAGCC (SEQ ID NO: 3) (Beeharry et al. 2 004) or GGCUAGAGGCGGCAGUCCUCAGUACUCUUACUCUUUUCUG UAAAGAGGAGACUGCUGGACUCGCCGCCCGAGCC (SEQ ID NO: 4 In some embodiments, the circular polyribonucleotide may comprise a self-ligating In another embodiment, the loop E sequence may be included to facilitate transcription of the genomic DNA. In the present invention, a circular polyribonucleotide can be a self-circularizing intron, e.g., a 5'- and 3'-ligand. junction, or self-circularizing catalytic intron, e.g., Group I, Group II or a group III intron. A non-limiting example of a sequence is a self-splicing sequence derived from the T4 bacteriophage gene td. Reverse intron-exon sequences and intervening sequences of Tetrahymena (IVS)rRNA can be mentioned.
[0221] Other cyclization methods
[0275] In some embodiments, the linear circular polyribonucleotide comprises individual introductory fragments. Phases containing either repetitive or non-repetitive nucleic acid sequences within or across the flanking introns. The repeated nucleic acid sequence may include a complementary sequence. In some embodiments, the circular polyribonucleotide comprises a repeating nucleic acid sequence. In some embodiments, the repetitive nucleotide sequence includes polyCA or polyUG. In some embodiments, the cyclic polyribonucleotide may include a cyclic polyribonucleotide having the sequence At least one repeating nucleic acid sequence that hybridizes to a complementary repeating nucleic acid sequence in another segment of the polynucleotide sequence. and the hybridized segments form an internal duplex. In some embodiments, the repeat nucleic acid sequence is composed of two distinct circular polyribonucleotides. and complementary repeated nucleic acid sequences hybridize to produce a single circularized polyribonucleotide. In some embodiments, the hybridized segments form an internal duplex. Thus, complementary sequences are found at the 5' and 3' ends of the linear circular polyribonucleotide. In some embodiments, the complementary sequence is about 3, 4, 5, 6, 7, 8, 9, 10, 11, 1 2, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 , 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, Contains 75, 80, 85, 90, 95, 100 or more paired nucleotides.
[0222] qualification
[0276] In some aspects, the invention described herein provides compositions and modified cyclic poly(Asp- ... Methods for using, making, and delivering modified circular polyribonucleotides The term "modified nucleotide" refers to a non-modified naturally occurring ribonucleotide, e.g., Natural unmodified nucleotides adenosine (A) and uridine (U) represented by the chemical formula 5 , guanidinium (G), cytidine (C), and monophosphate. Modified ribonucleic acid may refer to any nucleotide analog or derivative having a chemical modification of the formula: Chemical modifications of ribonucleotides can include modifying any one or more functional groups of the ribonucleotide, e.g., the sugar, Nucleobases or internucleoside linkages (e.g., phosphate / phosphodiester linkages) / phosphodiester backbone) modifications.
[0223] [Table 5]
[0224]
[0277] The circular polyribonucleotide is a polyribonucleotide with respect to a reference sequence, in particular a parent polyribonucleotide. The present invention may include one or more substitutions, insertions and / or additions, deletions, and covalent modifications, which may be In some embodiments, the cyclic polyribonucleotide comprises one The above post-transcriptional modifications (e.g., capping, cleavage, polyadenylation, splicing, polyadenylation, etc.) A sequence, methylation, acylation, phosphorylation, methylation of lysine and arginine residues, acylation nitrosylation of thiol groups and tyrosine residues, etc. Nucleotides can be, for example, any one of a sugar, a nucleobase, or an internucleoside linkage (e.g., a linking phosphorus Any useful modification (of the acid / of the phosphodiester bond / of the phosphodiester backbone) may be included. One or more atoms of the pyrimidine nucleobase may be an optionally substituted amino, thiols, optionally substituted alkyl (e.g., methyl or ethyl) substituted or substituted by aryl, aryl (e.g., chloro or fluoro), or halo (e.g., chloro or fluoro); In certain embodiments, the modification (e.g., one or more modifications) may be at the sugar and nucleoside. The modification occurs at each of the intersidic bonds. Acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LN A) or a hybrid thereof). is described herein.
[0225]
[0278] In some embodiments, the cyclic polyribonucleotide increases translation efficiency. The compound contains at least one N(6) methyladenosine (m6A) modification to enhance the synthesis of ribozymes.
[0279] In some embodiments, the modifications include chemical or cell-derived modifications. For example, some non-limiting examples of intracellular RNA modifications can be found in Lewis and Pan, “RNAmodifications and structures cooperate to guide RNA-protein interactions” from NatReviews Mol Cell Biol, 2017, 18: 202-210.
[0226]
[0280] In another embodiment, "pseudouridine" is 1 acp 3 Ψ(1-Methion The term refers to uridine-3-(3-amino-3-carboxypropyl) pseudouridine. In this embodiment, the term 1 It refers to Ψ (1-methylpseudouridine). In the present embodiment, the term refers to Ψm (2'-O-methylpseudouridine. In another embodiment, the term refers to m5D (5-methyldihydrouridine). In this context, the term 3 In another embodiment, it refers to Ψ(3-methylpseudouridine). In another embodiment, the term refers to a pseudouridine moiety that is not further modified. In the present context, the term refers to any monophosphate, diphosphate, or triphosphate of any of the pseudouridines listed above. In another embodiment, the term refers to any other sh Each possibility represents a separate embodiment of the present invention.
[0227]
[0281] In some embodiments, the ribonucleotides of the cyclic polyribonucleotide are Chemical modifications can enhance immune evasion. Modifications include, for example, terminal modifications, e.g., 5' Terminal modifications (phosphorylation (mono, di and tri), conjugation, inverted linkage, etc.), 3' Terminal modifications (conjugation, DNA nucleotides, inverted bonds, etc.), base modifications (e.g. For example, stabilizing bases, destabilizing bases, or bases that base pair with the extension repertoire of the partner. replacement by nucleotides), removal of bases (non-basic nucleotides), or conjugated bases. Modified ribonucleotide bases include 5-methylcytidine and pseudouridine. In some embodiments, the base modification has some functional effect. These include modulating the expression, immune response, stability, and intracellular localization of circular polyribonucleotides. In some embodiments, the modifications include bio-orthogonal. nal) nucleotides, e.g., unnatural bases.
[0228]
[0282] In some embodiments, the sugar modifications (e.g., 2' or at the 4' or 5' position) or one or more sugar replacements of ribonucleotides, Modifications of the backbone include modifications or replacements of phosphodiester bonds. Non-limiting examples of nucleotides include those with modified backbones or non-natural nucleoside linkages, e.g., Examples include cyclic polyribonucleotides with modifications or replacements of phosphodiester bonds. Examples of cyclic polyribonucleotides having modified backbones include those having a cyclic ribonucleotide having a ribonucleotide in the backbone. For the purposes of this application, and as is sometimes referred to in the art, As a reference, modified RNA that does not have a phosphorus atom in the internucleoside linkage can also be used. In certain embodiments, a cyclic polyribonucleoside may be considered a polyribonucleoside. A ribonucleotide contains a ribonucleotide which has a phosphorus atom in its internucleoside backbone.
[0229]
[0283] Modified cyclic polyribonucleotide backbones include, for example, phosphorothioates, Chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyls methyl and other alkyl phosphonates, e.g., 3'-alkyl chiral phosphonates, phosphinates, phosphoramidates, e.g. 3'-Aminophosphoramidates and aminoalkylphosphoramidates, thionophosphoramidates dates, thionoalkylphosphonates, thionoalkylphosphotriesters, and borate phosphates having the normal 3'-5' bond, their 2'-5' bond Analogs, and adjacent pairs of nucleoside units from 3'-5' to 5'-3' or 2'-5 Examples of the salts include those having the opposite polarity bonded from 5'-2' to 5'-2'. In some embodiments, the circular polyribonucleic acid may be a cyclic polyribonucleic acid. The bonds may be negatively or positively charged.
[0230]
[0284] Modified nucleotides that can be incorporated into circular polyribonucleotides include nucleosides, Modifications can be made at the internucleotide linkage (e.g., the phosphate backbone). With respect to the leutidine backbone, the terms "phosphate" and "phosphodiester" are used interchangeably. The backbone phosphate group can be modified by replacing one or more of the oxygen atoms with different substituents. Additionally, modified nucleosides and nucleotides can be modified with an unmodified phosphate moiety. Modified ribozymes may include large-scale replacement of the internucleoside linkages described herein with alternative internucleoside linkages. Examples of phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenate, phosphates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoranes amides, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriamides. Phosphorodithioates include esters in which both are replaced by sulfur. The phosphate linker has a nitrogen (bridging phosphoramidate) at the linking oxygen, a sulfur Yellow (bridged phosphorothioate) and carbon (bridged methylene-phosphonate) replacement It can also be modified by
[0231]
[0285] The α-thio substituted phosphate moiety is linked to RNase I via a non-natural phosphorothioate backbone linkage. A and serves to provide stability to the DNA polymer. Phosphorothioate DNA and RNA has increased nuclease resistance and subsequently a long half-life in the cellular environment Phosphorothioates attached to cyclic polyribonucleotides are involved in the regulation of cellular innate immune molecules. It is predicted to reduce the innate immune response through weaker binding / activation.
[0232]
[0286] In some embodiments, the modified nucleosides include α-thio-nucleosides. 5'-O-(l-thiophosphate)-adenosine, 5'-O-(l-thio 5'-O-(l-thiophosphate)-cytidine (α-thio-cytidine), 5'-O-(l-thiophosphate) )-guanosine, 5'-O-(l-thiophosphate)-uridine, or 5'-O-(1 Other internucleoside linkages include α-thiophosphate and α-pseudouridine. Examples include internucleoside linkages that do not contain a phosphorus atom.
[0233]
[0287] In some embodiments, the cyclic polyribonucleotide comprises one or more cytotoxic For example, the cytotoxic nucleoside may be a cyclic polyribonucleotide. For example, bifunctional modifications can be incorporated into the nucleoside. Although not commonly used, adenosine arabinoside, 5-azacytidine, 4'-thio-arabinoside, Cytidine, cyclopentenylcytosine, cladribine, clofarabine, cytarabine, Tosine arabinoside, l-(2-C-cyano-2-deoxy-β-D-arabino-pentaerythroyl) (furanosyl)-cytosine, decitabine, 5-fluorouracil, fludarabine, floxacin Combination of uridine, gemcitabine, tegafur and uracil, tegafur ((R,S)- 5-Fluoro-l-(tetrahydrofuran-2-yl)pyrimidine-2,4(lH,3H )-dione), troxacitabine, tezacitabine, 2'-deoxy-2'-methylidene Additional examples include dimethyldimethacrylate (DMDC), and 6-mercaptopurine. is fludarabine phosphate, N4-behenoyl-l-β-D-arabinofuranosylcytosine , N4-Octadecyl-1-β-D-arabinofuranosylcytosine, N4-Palmitoyl -l-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)cytosine and P-4055 (cytarabine 5'-elaidate).
[0234]
[0288] Circular polyribonucleotides can be uniformly modified along the entire length of the molecule. For example, one or more or all types of nucleotides (e.g., naturally occurring nucleotides) may be present. , purine or pyrimidine, or one or more of A, G, U, C, I, pU (all) are uniformly modified in the circular polyribonucleotide or in a given predetermined sequence region thereof In some embodiments, the cyclic polyribonucleotide can be a pseudocyclic polyribonucleotide. In some embodiments, the cyclic polyribonucleotide comprises a lysine. Characterizing cyclic polyribonucleotides as endogenous to the immune system Contains inosine. Incorporation of inosine also mediates improved RNA stability / reduced degradation possible.
[0235]
[0289] In some embodiments, in a circular polyribonucleotide (or a given sequence thereof), In some embodiments, all nucleotides in the region are modified. m6A, which may increase expression; inosine, which may attenuate immune responses; RNA stability, or translational readiness. Pseudouridine, which can increase the dosing rate (stop codon = coding possibility), increases stability m5C, which can mediate intracellular translocation (e.g., nuclear localization); and 2, which supports intracellular translocation (e.g., nuclear localization). It may contain 2,7-trimethylguanosine.
[0236]
[0290] Different sugar and nucleotide modifications can be found at various positions in the circular polyribonucleotide. The skilled artisan will appreciate that cyclic structures, such as cyclic nucleotides, cyclic nucleotides, and / or internucleoside linkages (e.g., backbone structures) may be present. Nucleotide analogs or other compounds may be used so that the function of the polyribonucleotide is not substantially reduced. It is recognized that the modification can be located at any position of the circular polyribonucleotide. The modification can also be a non-coding region modification. Circular polyribonucleotides contain from about 1% to about 100% modified nucleotides (relative to the total nucleotide content or one or more of the nucleotides) (for any one or more of the above types, i.e., A, G, U, or C) or any The percentage between them (e.g. 1%~20%>, 1%~25%, 1%~50%, 1%~60%) , 1%~70%, 1%~80%, 1%~90%, 1%~95%, 10%~20%, 10% ~25%, 10%~50%, 10%~60%, 10%~70%, 10%~80%, 10% ~90%, 10%~95%, 10%~100%, 20%~25%, 20%~50%, 20 %~60%, 20%~70%, 20%~80%, 20%~90%, 20%~95%, 20 %~100%, 50%~60%, 50%~70%, 50%~80%, 50%~90%, 5 0%~95%, 50%~100%, 70%~80%, 70%~90%, 70%~95%, 70%~100%, 80%~90%, 80%~95%, 80%~100%, 90%~95 %, 90%-100%, and 95%-100%).
[0237]
[0291] In some embodiments, the cyclic polyribonucleotides provided herein are , a modified cyclic polyribonucleotide. For example, a fully modified cyclic polyribonucleotide is all or substantially all modified adenosine residues, all or substantially all modified uridyline residues, all or substantially all modified siro residues; all or substantially all modified guanine residues; all or substantially all modified siro residues; In some embodiments, the amino acid sequence provided herein comprises a cysteine residue, a cysteine residue, a cysteine residue, or any combination thereof. The provided cyclic polyribonucleotide is a hybrid modified cyclic polyribonucleotide. A hybrid modified circular polyribonucleotide comprises at least one modified nucleotide. and may have a portion of consecutive unmodified nucleotides. The unmodified portion of the nucleotide is at least about 5, 10, 15, or 20 consecutive unmodified nucleotides. In some embodiments, the hybrid modification may have a nucleotide sequence, a nucleotide sequence, a nucleotide sequence, a nucleotide sequence, or any number in between. The unmodified portion of the modified circular polyribonucleotide may be at least about 30, 40, 60, 70 , 80, 90, 100, 110, 120, 130, 140, 150, 160, 180, 2 00, 220, 250, 280, 300, 320, 350, 380, 400, 420, 4 50, 500, 550, 600, 650, 700, 750, 800, 850, 900, or 1000 contiguous unmodified nucleotides, or any number therebetween. In the hybrid modified circular polyribonucleotide, 1, 2, 3, 4, 5, 6, 7 In some embodiments, the hybrid modification The cyclic polyribonucleotide may be at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 30, 40, 50, 70, 80, 100, 120, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000 or more In some embodiments, the hybrid modified circular polyribonucleic acid (HPA) is Cleotides should be at least 1%, 2%, 5%, 7%, 8%, 10%, 12%, 15%, 1 8%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 6 5%, 70%, 80%, 90%, 95%, or 99% but less than 100% qualified In some embodiments, the unmodified portion comprises a binding site. In some embodiments, the non-modifying portion binds a protein, DNA, RNA, or cellular target. In some embodiments, the unmodified portion comprises a binding site configured to bind to an IRE Contains S.
[0238]
[0292] In some embodiments, the hybrid modified cyclic polyribonucleotide is In some embodiments, the modified cyclic polyribonucleotide has a lower immunogenicity than the corresponding unmodified cyclic polyribonucleotide. In the present invention, the hybrid modified circular polyribonucleotide is a corresponding unmodified circular polyribonucleotide. At least about 1.1, 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4. 5, 4.8, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9. In some embodiments, the antibodies described herein have a 0, 9.5, or 10.0 fold lower immunogenicity. The immunogenicity described in is RIG-I, TLR-3, TLR-7, TLR-8, MDA-5, Expression or signal transduction of at least one of LGP-2, OAS, OASL, PKR, and IFN-β In some embodiments, the level of hybridization or activation is evaluated. Modified cyclic polyribonucleotides have longer chain lengths than the corresponding unmodified cyclic polyribonucleotides. In some embodiments, the hybrid modified circular polyribonucleic acid has a short half-life. The modified circular polyribonucleotides have at least about 1.1, 1.2, 1 .3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.3, 3 .5, 3.8, 4.0, 4.2, 4.5, 4.8, 5.0, 5.5, 6.0, 6.5, 7 .0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times longer half-life. In some embodiments, the half-life is determined by the cyclic polyribonucleotide or the corresponding cyclic polyribonucleotide. The polyribonucleotide is introduced into the cell, and the introduced circular polyribonucleotide or This is measured by measuring the levels of the corresponding cyclic polyribonucleotide.
[0239]
[0293] In some embodiments, the hybrid modified cyclic polyribonucleotide is In some embodiments, the hybrid modified circular polyribonucleic acid One or more of the expression sequences of the nucleotides are similar to the corresponding unmodified circular polyribonucleotides. or higher translation efficiency. In some embodiments, the hybrid modified cyclic One or more of the expression sequences of the polyribonucleotide may be a corresponding unmodified circular polyribonucleotide. At least about 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1. 5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, or 3 times higher translation efficiency. In some embodiments, one or more expression sequences of the hybrid modified circular polyribonucleotides are The string may include a portion that includes a modified nucleotide (e.g., a portion that includes a hybrid modified circular polyribonucleic acid (e.g., The modified cyclic polyribonucleotides have a higher In some embodiments, one or more of the circular polyribonucleotides have a high translation efficiency. The expressed sequences are more than 10%, or at least 20%, 30%, 40%, 50%, 60%, 70%, %, 80%, 90%, or 100% of the modified nucleotides. In some embodiments, the cyclic polyribonucleotide has a higher translation efficiency than the cyclic polyribonucleotide. In one embodiment, one or more expression sequences of the hybrid modified circular polyribonucleotide are modified. A portion containing modified nucleotides (e.g., a portion is a hybrid modified circular polyribonucleic acid at least one cyclic polyribonucleotide having a Approximately 1.1, 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3 , 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5, 4.8, 5.0, 5.5 , 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times As described herein, in some embodiments, the translation efficiency is in a cell containing a cyclic polyribonucleotide or a corresponding cyclic polyribonucleotide or in an in vitro translation system (e.g., rabbit reticulocyte lysate). .
[0240]
[0294] In some embodiments, the hybrid modified cyclic polyribonucleotide is a non- In some embodiments, the binding site has no modifications, e.g., no modified nucleotides. Thus, the hybrid modified circular polyribonucleotide may be a mixture of unmodified, e.g. configured to bind to proteins, DNA, RNA, or cellular targets without In some embodiments, the hybrid modified circular polyribonucleic acid The ribosome entry site is an internal ribosome entry site (IRE) that is unmodified, e.g., has no modified nucleotides. In some embodiments, the hybrid modified cyclic polyribonucleotide has In some embodiments, the nucleotide sequence is 10% or less of the nucleotides in the binding site that are modified nucleotides. In the form of a hybrid modified circular polyribonucleotide, the modified nucleotide , in a binding site configured to bind to a protein, DNA, RNA, or cellular target. In some embodiments, the hybrid modified circular polynucleotide has 10% or less nucleotides. Ribonucleotides are modified nucleotides in internal ribosome entry sites (IRES). In some embodiments, the hybrid modified cyclic The polyribonucleotide contains modified nucleotides throughout, except at the binding sites. In an embodiment, the hybrid modified cyclic polyribonucleotide is a protein, a DNA A, RNA, or a cellular target is bound to the binding site. In some embodiments, the hybrid modified circular polyribonucleic acid The nucleic acid has modified nucleotides throughout, except for the IRES element. In an embodiment, the hybrid modified circular polyribonucleotide comprises an IRES element and and one or more other portions. Although not bundled, the unmodified IRES element is a hybrid modified circular polyribonucleic acid (PCR) nucleotides that are translatable, e.g., to the corresponding nucleotides that do not have any modified nucleotides. For one or more expressed sequences similar to or higher than the circular polyribonucleotides It has high translation efficiency.
[0241]
[0295] In some embodiments, the hybrid modified cyclic polyribonucleotide is RES elements or proteins, DNA, RNA, or cellular targets The modified nucleotides are contained throughout the entire circular polyribonucleotide except for the binding site. For example, 5' methylcytidine and pseudouridine. The red modified cyclic polyribonucleotide contains 5' methylcytidine and pseudouridine. The cyclic polyribonucleotides may have higher or lower immunogenicity than the corresponding non-cyclic cyclic polyribonucleotides. In one embodiment, the hybrid modified cyclic polyribonucleotide is a corresponding unmodified cyclic polyribonucleotide. At least about 1.1, 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5, 4.8, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times less immunogenic. The immunogenicity described herein is based on RIG-I, TLR-3, TLR-7, TLR-8, At least one of MDA-5, LGP-2, OAS, OASL, PKR, and IFN-β In some embodiments, the expression or signaling or activation of a hybridoma is evaluated. The lid-modified cyclic polyribonucleotide may be a cyclic polyribonucleotide having a corresponding unmodified cyclic polyribonucleotide, e.g. For example, the corresponding circular polyribonucleic acid that does not contain 5' methylcytidine and pseudouridine. In some embodiments, the hybrid modified cyclic poly(Asp-Tyr) has a longer half-life than the oxidase. The ribonucleotides have a length at least about 1.0 times that of the corresponding unmodified circular polyribonucleotides. 1, 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3, 3. 2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5, 4.8, 5.0, 5.5, 6. 0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times longer, In some embodiments, the half-life is longer than that of a circular polyribonucleotide. The corresponding cyclic polyribonucleotide is introduced into the cell, and the introduced cyclic polyribonucleotide inside the cell is by measuring the levels of ribonucleotides or the corresponding cyclic polyribonucleotides To be measured.
[0242]
[0296] In some instances, the hybrid modified circular polyribonucleoside described herein The peptide is a corresponding circular polyribonucleic acid peptide which is otherwise identical but fully modified. For example, it has similar immunogenicity to the IRES element. Hybrid modified circular polyribonucleic acid containing 5'-methylcytidine and pseudouridine. Leutidine is otherwise identical but contains 5'-methylcytidine and pseudouridine throughout. and a corresponding cyclic polyribonucleotide having unmodified cytidines and no unmodified uridines. In some embodiments, the immunogenicity of the I Contains 5' methylcytidine and pseudouridine throughout except for the RES element The hybrid modified circular polyribonucleotide is otherwise identical but has 5 throughout. 'Has methylcytidine and pseudouridine, and no unmodified cytidine or uridine The translation efficiency is similar to or higher than that of the corresponding circular polyribonucleotide. Yes.
[0243] Conjugation of cyclic polyribonucleotides
[0297] circRNAs of the present disclosure can be used to bind, for example, compounds (e.g., small molecules), antibodies, or The compound may be conjugated to a fragment thereof, a peptide, a protein, an aptamer, a drug, or a combination thereof. In some embodiments, small molecules can be conjugated to circRNAs. The small molecule can be induced to express circRNAs by condensation, thereby generating circRNAs that contain the small molecule.
[0244]
[0298] The circRNAs of the present disclosure can be used as conjugates to facilitate conjugation. The conjugation moiety may include, for example, a circular polyribonucleoside. at an internal site of a peptide, or at the 5' end, 3' end, or internal site of a linear polynucleotide The conjugation moiety can be incorporated chemically or enzymatically. For example, the conjugation moiety can be simultaneously synthesized during solid phase oligonucleotide synthesis. The gene may be expressed transcriptionally (e.g., by a permissive RNA polymerase) or post-transcriptionally (e.g., by an RNA polymerase The conjugation moiety can be incorporated into the modified It may be a modified nucleotide or nucleotide analog, e.g., bromodeoxyuridine. The conjugation moiety contains a reactive group or functional group, such as an azide group or an alkyne group. The conjugation moiety may undergo a chemoselective reaction. Molecules include, for example, digoxigenin, 2,4-dinitrophenyl, biotin, and avidin. It may be a haptenic group, or may be an azole, a nitroaryl compound, a benzofurazan, a triterpene, Pen, urea, thiourea, rotenone, oxazole, thiazole, coumarin, cycloligna azoaryl compounds or benzodiazepines. The conjugation moiety can be a diaryl group capable of undergoing reversible electrocyclic rearrangement. Conjugation moieties may include nucleophiles, carbanions, and and / or α,β-unsaturated carbonyl compounds.
[0245]
[0299] circRNAs can be synthesized via chemical reactions, e.g., click chemistry, Staudi ligation, Pd-catalyzed C-C bond formation (e.g., Suzuki-Miyaura reaction), Michael Addition, olefin metathesis, or inverse electron demand Diels-Alder synthesis of conjugates Click chemistry allows the rapid and rapid synthesis of two or more cyclic amines under suitable reaction conditions. Pairs of selectively reacting (clicking) functional groups may be utilized. Non-limiting click chemistry Reactions include azide-alkyne cycloaddition and copper-catalyzed 1,3-dipolar azide-alkyne addition. Cyclization (CuAAC), Strain-Promoted Azide-Alkyne Click Chemistry (SPAAC), and and tetrazine-alkene ligation.
[0246]
[0300] Non-limiting examples of functionalized nucleotides include azide-modified UTP analogs, 5 -Azidomethyl-UTP, 5-azido-C3-UTP, 5-azido-PEG4-UTP, 5-Ethynyl-UTP, DBCO-PEG4-UTP, Vinyl-UTP, 8-Azide-A TP, 3'-azido-2',3'-ddATP, 5-azido-PEG4-CTP, 5-D BCO-PEG4-CTP, N6-azidohexyl-3'-dATP, 5-DBCO-P EG4-dCpG, and 5-azidopropyl-UTP. In this study, circRNAs contained at least one 5-azidomethyl-UTP, 5-azido-C 3-UTP, 5-azido-PEG, 4-UTP, 5-ethynyl-UTP, DBCO-PEG 4-UTP, vinyl-UTP, 8-azido-ATP, 5-azido-PEG4-CTP, 5 -DBCO-PEG4-CTP, or 5-azidopropyl-UTP.
[0247]
[0301] Selected single modified nucleotide (e.g., modified A containing an azide at the 2' position) , C, G, U, or T) are synthesized under optimized conditions (e.g., via solid-phase chemical synthesis) to provide site-specific Multiple nucleotides containing an azide at the 2' position can be incorporated heterologously. For example, to substitute nucleotides during an in vitro transcription reaction (e.g., UTP for 5-azide). It can be incorporated by substituting 1-C3-UTP.
[0248]
[0302] circRNA conjugates can be synthesized by copper-catalyzed click reactions, e.g., by coupling the alkyne moiety to the Copper-catalyzed 1,3-dipolar azide-alkyne addition of functionalized small molecules and azide-functionalized polyribonucleic acid Linear RNA can be generated using cyclization (CuAAC). For example, linear RNA can be cleaved by poly(A) polymerase. The azide can be modified at its 3' end with a derivatized nucleotide. Conjugated to small molecules via copper-catalyzed or strain-promoted azide-alkyne click reactions and the linear RNA can be circularized.
[0249]
[0303] circRNA conjugates are generated using the Staudinger reaction. For example, a circular RNA containing an azide-functionalized nucleotide can be synthesized by the reaction of a triphenyl Alkyne functionalization in the presence of phosphine-3,3',3''-trisulfonic acid (TPPTS) The antibody can be conjugated to a small molecule.
[0250]
[0304] circRNA conjugates can be generated using the Suzuki-Miyaura reaction For example, circRNAs containing halogenated nucleotide analogs can be synthesized by In the presence of a reactive partner, it can undergo Suzuki-Miyaura reaction. For example, 5-iodo Uridine triphosphate (IUTP)-containing circRNAs were isolated by Pd(OAc) 2 and 2-Ami Nopyrimidine-4,6-diol (ADHP) or dimethylamino-substituted ADHP (DMA DHP) to produce iodine in the presence of various boronic acid and ester substrates. Uridine-labeled circRNA can be functionalized. CircRNAs containing anosine were analyzed by Pd(OAc) 2 and water-soluble triphenylphosphane -3,3',3''-trisulfonate ligands in the presence of a catalytic system It can be reacted with boronic acid.
[0251]
[0305] CircRNA conjugates can be synthesized using Michael addition, e.g., electron transfer The Michael donor is reacted with an α,β-unsaturated compound (Michael acceptor) to form a It is possible.
[0252] structure
[0306] In some embodiments, the cyclic polyribonucleotide has a higher order structure, e.g., In some embodiments, the complementary structure of the circular polyribonucleotide comprises a The segment folds upon itself into a double-stranded segment, which is a pair, e.g., A- In some embodiments, the terminal loop is held together by hydrogen bonds between U and CG. A helix, also known as a stem, with a connecting double-stranded segment is formed within the molecule. In some embodiments, the cyclic polyribonucleotide forms a quasi-duplex secondary structure. In some embodiments, the at least one segment has a quasi-duplex secondary structure. The segments having the structure are at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 2 6, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 , 80, 85, 90, 95, 100 or more paired nucleotides. In the present invention, the cyclic polyribonucleotide is composed of one or more segments having a quasi-duplex secondary structure. In some embodiments, the segment The numbers are 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, and 17. , 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 1 100 or more nucleotides apart.
[0253]
[0307] There are 16 possible base pairings, of which 6 (AU, GU , GC, UA, UG, CG) can form realistic base pairs. The rest are called mismatches. , which occur at very low frequency in helices. The structure of the octide cannot be easily disrupted without affecting its function and without fatal consequences. This provides an option for maintaining secondary structure. In some embodiments, the primary structure of the stem While the structure (i.e., their nucleotide sequence) can still vary, the helical regions The nature of the bases is not critical to the conformation; they Substitutions are possible as long as the structure is preserved. In some embodiments, the cyclic polyribonucleotide has a quasi-helical structure. has at least one segment having a quasi-helical structure. In the present study, the number of segments having a quasi-helical structure is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 2 3, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60 , 65, 70, 75, 80, 85, 90, 95, 100 or more nucleotides. In some embodiments, the cyclic polyribonucleotide comprises one or more cyclic ribonucleotides having a quasi-helical structure. In some embodiments, the segment may have more than one segment (e.g., 2, 3, 4, 5, 6 or more segments). The segments are 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 , 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 9 In some embodiments, the cyclic nucleotides are separated by 0, 95, 100 or more nucleotides. The polyribonucleotide has at least one U-rich or A-rich sequence or a combination thereof. In some embodiments, the U-rich and / or A-rich sequences include triple quasi-helix sequences. In some embodiments, the circular polyribonucleic acid is arranged to produce a circular structure. The oxidase has a double quasi-helical structure. An oxidase is a peptide that is a peptide that consists of one or more segments (e.g., 2, 3, 4, 5) with a double quasi-helical structure. In some embodiments, the cyclic polyribonucleotide has a C In some embodiments, the nucleic acid sequence comprises at least one of a C-rich sequence, a C-rich sequence, a G-rich sequence, and / or a G-rich sequence. and / or the G-rich sequence is arranged to produce a triple quasi-helical structure. In embodiments, the cyclic polyribonucleotide contains an intramolecular triple quasi-helix that aids in stabilization. It has a hex structure.
[0254]
[0308] In some embodiments, the cyclic polyribonucleotide is a cyclic polyribonucleotide (e.g., It has two quasi-helical structures (separated by an ester bond) so that their terminals The end base pairs are stacked, the quasi-helical structures are collinear, and the “coaxially stacked” This results in a "reduced" substructure.
[0255]
[0309] In some embodiments, the cyclic polyribonucleotide comprises at least one m iRNA binding site, at least one lncRNA binding site, and / or at least one It has a tRNA motif of
[0256] delivery
[0310] The cyclic polyribonucleotides described herein can be used in pharmaceutical compositions with delivery vehicles. can be included within.
[0257]
[0311] For example, by formulating the pharmaceutical compositions described herein with a pharmaceutical excipient or carrier. The pharmaceutical carrier may be a membrane, a lipid bilayer, and / or a polymeric carrier, e.g., a liposome. The nanoparticles may be particles, such as nanoparticles, e.g., lipid nanoparticles, which may be prepared by known methods. subjects for whom the Such methods can be used to deliver the drug to animals, such as cattle, dogs, cats, horses, and poultry. Examples include, but are not limited to, transfection (e.g., lipid-mediated, cationic polymer , calcium phosphate; electroporation or other methods of membrane disruption (e.g., nuclease inofection), fusion, and viral delivery (e.g., lentivirus, retrovirus , adenovirus, AAV).
[0258]
[0312] The present invention further relates to a host or In some embodiments, the host or host cell is a plant, insect, cell. The organism may be a bacteria, a fungus, a vertebrate, a mammal (eg, human), or other organism or cell.
[0259]
[0313] In some embodiments, the cyclic polyribonucleotide is non-immunogenic in a host. In some embodiments, the cyclic polyribonucleotide is a reference compound, e.g., Linear polynucleotides corresponding to the circular polyribonucleotides described herein, unmodified circular polyribonucleotides, Induced by cyclic polyribonucleotides lacking nucleotides or encryptogens The immune system of the host may have a reduced response compared to, or may be unable to produce, a response. Some immune responses include, but are not limited to, humoral immune responses (e.g., antigen-specific These include immune responses (e.g., production of specific antibodies) and cell-mediated immune responses (e.g., lymphocyte proliferation).
[0260]
[0314] In some embodiments, the host or host cell is treated with a cyclic polyribonucleotide. In some embodiments, the host is contacted with (e.g., delivered to or administered to) , a mammal, such as a human. Both amounts can be measured at any time after administration. The time course of host growth in culture is then determined. If growth is increased or decreased in the presence of a circular polyribonucleotide or expression product thereof, Both have been identified as being effective in increasing or decreasing host growth.
[0261] Production method
[0315] In some embodiments, the cyclic polyribonucleotide is non-naturally occurring: Deoxyribonucleic acid sequences that can be produced using recombinant DNA technology or chemical synthesis Includes.
[0262]
[0316] The DNA molecule used to generate the RNA circle is the original naturally occurring nucleic acid sequence. The DNA sequence of the present invention may be modified versions thereof, or synthetic polypeptides not normally found in nature (e.g., For example, the present invention may include a DNA sequence encoding a chimeric molecule or a fusion protein. It is within the scope of the invention. DNA molecules can be synthesized using a variety of techniques, including but not limited to: , classical mutagenesis techniques and recombinant DNA techniques, e.g., site-directed mutagenesis, Chemical treatment of nucleic acid molecules to induce mutations, restriction enzyme cleavage of nucleic acid fragments, lamination of nucleic acid fragments igation, polymerase chain reaction (PCR) amplification and / or protrusion of selected regions of a nucleic acid sequence for natural mutagenesis, synthesis of oligonucleotide mixtures, and "constructing" mixtures of nucleic acid molecules The modifications can be made using ligation of mixtures of the above and combinations thereof.
[0263]
[0317] Cyclic polyribonucleotides can be prepared, for example, by chemical synthesis and enzymatic synthesis. In some embodiments, the linear primary construct or linear mRNA can be circularized. or concatemerizing to produce the circular polyribonucleotides described herein. The mechanism of cyclization or concatemerization can be, but is not limited to, chemical, enzymatic, etc. This can occur via methods such as enzyme- or ribozyme-catalyzed methods. The 3'-linkage can be an intramolecular linkage or an intermolecular linkage.
[0264] Pharmaceutical Compositions
[0318] The present invention includes compositions in combination with one or more pharma- ceutically acceptable excipients. The pharmaceutical compositions optionally contain one or more additional active agents, e.g., agents having therapeutic and / or prophylactic activity. The pharmaceutical compositions of the present invention may be sterile and / or pyrogen-free. General considerations in the formulation and / or manufacture of pharmaceutical agents are found, for example, in US Pat. Remington: The Science and Practice of Pharmacy 21st ed., Lippinco tt Williams & Wilkins, 2005. In one aspect, the present invention relates to cyclic A method for producing a pharmaceutical composition as described herein, comprising producing a polyribonucleotide. Includes the law.
[0265]
[0319] The description of pharmaceutical compositions provided herein primarily refers to pharmaceutical compositions suitable for administration to humans. Although the present invention is directed to compositions, such compositions may generally be used in any other animal, e.g., non-human animals. It will be understood by those skilled in the art that the pharmaceutical compositions are suitable for administration to human and non-human mammals. Modification of pharmaceutical compositions suitable for administration to humans to make them suitable for administration to a variety of animals is sufficient. It is understood that such Modifications may be designed and / or made with no more than routine experimentation. Subjects to which the pharmaceutical compositions are intended to be administered include, but are not limited to, humans and / or Other primates; mammals, e.g., commercially relevant mammals, e.g., cattle, pigs, horses, sheep and / or birds, e.g. commercially relevant birds. , e.g., poultry, chickens, ducks, geese, and / or turkeys .
[0266]
[0320] The formulations of the pharmaceutical compositions described herein may be prepared in any manner known or hereafter proposed in the pharmacological art. The preparation may be carried out by any method developed. Generally, such preparation methods include those that are The ingredient is brought into association with the excipient and / or one or more other accessory ingredients, and then optionally and / or Optionally, this includes portioning, shaping and / or packaging the product.
[0267]
[0321] The pharmaceutical compositions described herein are available in unit dosage forms suitable for single administration of precise dosage amounts. In unit dosage form, the formulation may be a unit-sized formulation containing an appropriate amount of one or more compounds. The unit dose is in the form of a package containing discrete amounts of the formulation. Examples of suitable formulations are packaged injections, vials, or ampoules. The pharmaceutical composition may be packaged in a multi-dose non-reclosable container. Multi-dose reclosable containers may be packaged in, for example, The injectable formulations may be used alone, in combination with a preservative, or without a preservative. and providing the composition in a dosage form, for example in ampoules or in multi-dose containers with a preservative. can be done.
[0268]
[0322] In one aspect, the present invention provides a method for detecting a target, e.g., an RNA, DNA, protein, (b) a cyclic polyribonucleotide that contains a binding site for binding a drug, a substance, a cell membrane, or the like; and A pharmaceutical composition comprising a target and a circular polyribonucleic acid. The leutide forms a complex and the target comprises a pharmaceutical composition that is not a microRNA.
[0269]
[0323] In some embodiments, the binding site is a first binding site and the target is a first In some embodiments, the circular polyribonucleotide binds to a second target. The antibody further comprises a second binding site which binds to the antibody.
[0270]
[0324] In one aspect, the present invention provides a method for the preparation of a nucleic acid molecule comprising: (a) (i) a first binding molecule that binds a first target; and (ii) a second binding site that binds a second target. and (b) a pharma- ceutical composition comprising a first the binding site of the first target is different from the second binding site, and the first target and the second target are microRNAs. The pharmaceutical composition includes
[0271]
[0325] In some embodiments, the first target is a first circular polyribonucleotide ( In some embodiments, the second target comprises a second circRNA binding motif. In some embodiments, the ribonucleotide sequence includes a circular polyribonucleotide (circRNA) binding motif. In this case, the first target, the second target, and the circular polyribonucleotide form a complex. In some embodiments, the first target and the second target interact with one another. In embodiments, the complex, when contacted with a cell, modulates a cellular process. In some embodiments, the formation of a complex modulates a cellular process when contacted with a cell. In such embodiments, the cellular process is associated with the pathogenesis of the disease or condition. To connect.
[0272]
[0326] In some embodiments, the cyclic polyribonucleotide, when contacted with a cell, In some embodiments, the antibody modulates a cellular process associated with the first or second target. In some embodiments, the first and second targets interact with each other in a complex. In some embodiments, the cellular process is associated with the pathogenesis of a disease or condition. In some embodiments, the first process is different from the translation of the circular polyribonucleotide. Targets include deoxyribonucleic acid (DNA) molecules, and targets include proteins. In an embodiment, the complex is capable of directing transcription of a DNA molecule, epigenetic modification of a DNA molecule, or the like. Modulates the modeling or degradation of DNA molecules.
[0273]
[0327] In some embodiments, the first target comprises a first protein and the second target In such an embodiment, the complex comprises a first protein and a second protein. The degradation of the protein, the translocation of the first protein, or the signal transduction A complex formed by a direct interaction between a first and a second protein. The compound may modulate the formation of the complex (e.g., inhibit or promote the formation of the complex).
[0274]
[0328] In some embodiments, the first target comprises a first ribonucleic acid (RNA) molecule. and the second target comprises a second RNA molecule. The degradation of the first RNA molecule may be modulated.
[0275]
[0329] In some embodiments, the target comprises a protein and the second target comprises an RNA In such an embodiment, the complex comprises a molecule that is involved in protein translocation. They modulate the expression of ribonuclease, or are formed by direct interactions between proteins and RNA molecules. It inhibits the formation of the complex that is involved in the synthesis of ribosomal proteins.
[0276]
[0330] In some embodiments, the first target is a receptor and the second target is a receptor. In such an embodiment, the complex inhibits activation of the receptor. As used herein, a "receptor" refers to a receptor that receives a chemical signal from outside a cell. Chemical signals may refer to, but are not limited to, small molecules. Organic compounds (e.g., amino acids and their derivatives, e.g., glutamic acid, glycine, gamma-butyric acid, acids), lipids, proteins or polypeptides, DNA and RNA molecules, and ions. The receptor may be located on the cell membrane, in the cytoplasm, or in the cell nucleus. The chemical signal that binds can generally be referred to as the "substrate" of the receptor. Upon binding to a signal, a receptor initiates one or more cellular processes, e.g., a signaling pathway. The receptors provided herein may trigger some form of cellular response by initiating a signal transduction. The bodies can be of any type recognized by those of skill in the art, for example: (1) ion channels; -type receptors, which are receptors for fast neurotransmitters such as acetylcholine (nicotinic) and G They may be targets of ABA; activation of these receptors results in changes in ion transport across membranes. These are proteins in which each subunit contains an extracellular ligand-binding domain and a transmembrane domain. It may have a heteromeric structure in that it is composed of four transmembrane domains. The ligand-binding cavity may be located at the interface between the subunits; ) G protein-coupled receptors, which are the receptors that bind some hormones and slow neurotransmitters, e.g. These include receptors for dopamine and metabotropic glutamate. The α-helices may be composed of transmembrane α-helices. The loops connecting the α-helices may be extracellular and intracellular. (3) kinase-binding and -associated receptors (or receptor tyrosine kinases) that can form the intracellular domain; It has an extracellular domain containing a ligand-binding site and an enzymatic function. It may consist of an intracellular domain rich in α-helix and connected by a single transmembrane α-helix. The insulin receptor is an example of this type of receptor; insulin reacts with its corresponding (4) Nuclear receptors at https: / / en.wikipedia.org / wiki / Nuclear_receptor They are localized in the nucleus or cytoplasm and translocate to the nucleus after binding to their ligands. These include a C-terminal ligand-binding region, a core DNA-binding domain (DBD) and an AF It may be composed of an N-terminal domain containing the activation function 1 (activation function 1) domain. Glandular hormone receptors are examples of such receptors, and their corresponding substrates include: Various steroids and hormones may be mentioned.
[0277]
[0331] In one aspect, the present invention provides a cyclic polynucleotide comprising: (a) a binding moiety that binds a target; and (b) a pharma- ceutical composition comprising a ribonucleotide; and (b) a pharma- ceutically acceptable carrier or excipient. Thus, the circular polyribonucleotide is non-translatable or translation-deficient, and the target is a microRNA. Includes pharmaceutical compositions that are not NA.
[0278]
[0332] In one aspect, the invention provides a method for the preparation of a peptide comprising: (a) a binding moiety that binds a target; (b) a circular polyribonucleotide comprising a first ribonucleic acid (RNA) binding motif; and A pharmaceutical composition comprising a pharma- ceutical carrier or excipient, The method includes the steps of: (a) administering to a subject a pharmaceutical composition comprising administering to said subject a gene that is non-translatable or translation-deficient and wherein the target is a microRNA.
[0279]
[0333] In such embodiments, the target comprises a DNA molecule. In this state, binding of the target to the circular polyribonucleotide is monitored to interfere with the transcription of the DNA molecule. In such an embodiment, the target comprises a protein. In embodiments, binding of targets to circular polyribonucleotides is achieved by the synthesis of proteins and other molecules. In such an embodiment, the protein is a receptor and Binding of the target to the cyclic polyribonucleotide activates the receptor. In this embodiment, the protein is a first enzyme and the cyclic polyribonucleotide is a second enzyme. and a second binding site for binding to the first and second nucleic acid fragments of the circular polyribonucleotide. The binding of the first and second enzymes modulates the enzymatic activity of the first and second enzymes. In certain embodiments, the target comprises a messenger RNA (mRNA) molecule. In this embodiment, binding of the target to the circular polyribonucleotide interferes with the translation of the mRNA molecule. In such an embodiment, the target comprises a ribosome. In certain embodiments, binding of the target to the circular polyribonucleotide results in interference with the translation process. In such an embodiment, the target comprises a circular RNA molecule. In such embodiments, binding of the target to the circular polyribonucleotide is achieved by the binding of a circular RNA molecule. In such an embodiment, binding of the target to the circular polyribonucleotide isolates the target.
[0280]
[0334] In one aspect, the present invention provides a method for detecting a target cell comprising: (a) detecting a binding site that binds the cell membrane of a target cell; and the plasma membrane of the target cell is bound to a circular polyribonucleic acid (RNA) binding motif. and (b) a pharma- ceutically acceptable carrier or excipient.
[0281]
[0335] In some embodiments, the circular polyribonucleic acid penetrates a second membrane of a second target cell. The second target cell further comprises a second binding site for binding to the second RNA. In some embodiments, the cyclic polyribonucleotide comprises a binding motif for a target cell. and binding to both the cell membrane of the first target cell and the second cell membrane of the second target cell, Cell fusion of the cells is modulated.
[0282]
[0336] In some embodiments, the circular polyribonucleotide is linked to a second target. and a second binding site for binding both the first and target to the circular polyribonucleotide. The binding induces a conformational change in the first target, thereby inhibiting the upregulation of the first target in the first cell. In some embodiments, the cyclic polyribonucleotide induces a signal transduction of the current. Untranslatable or translation defective.
[0283]
[0337] In some embodiments, the circular polyribonucleic acid comprises: a) an encryptogen; b) splicing elements; c) regulatory sequences; d) replication sequences; e) quasi-duplex secondary structures; and f) further comprising at least one structural element selected from the expression sequence. In an embodiment, the quasi-helical structure is a small molecule having at least one non-double-stranded segment. In such an embodiment, the quasi-helical RNA segment comprises at least one double-stranded RNA segment. The loop structure comprises a first sequence and a second sequence linked by a repeating sequence, e.g., an A-rich sequence. In some embodiments, the encryptogen comprises a splicing element. include.
[0284]
[0338] In some embodiments, the circular polyribonucleic acid comprises at least one modified nucleic acid. In such an embodiment, at least one modified nucleic acid comprises 2'-O-methyl, 2'-O-Methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-de Oxy, T-deoxy-2'-fluoro, 2'-O-aminopropyl (2'-O-AP) , 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylamino 2'-O-DMAP, TO-Dimethylaminoethyloxyethyl (2' -O-DMAEOE), 2'-ON-methylacetamide (2'-O-NMA), LNA, Ethylene Nucleic Acid (ENA), Peptide Nucleic Acid (PNA), 1',5'-Amino Acid Hydrohexitol nucleic acid (HNA), morpholino, methylphosphonate nucleotides, Thiol phosphonate nucleotides and 2'-fluoro N3-P5'-phosphoramidiates The circular polyribonucleotide is selected from the group consisting of fully modified circular polyribonucleotides. In some embodiments, the administered cyclic polyribonucleotide may be In some embodiments, the cyclic polyribonucleotide is a hybrid modified cyclic polyribonucleotide. Ribonucleotides include modified nucleotides and unmodified IRES.
[0285]
[0339] In some embodiments, the encryptogen comprises at least one modified nucleic acid, Examples include pseudouridine and N(6) methyladenosine (m6A). In the form, the encryptogen has a protein binding site, e.g., a ribonucleic acid binding protein (RNA-binding protein). In some embodiments, the cryptogen comprises a protein that, for example, evades a CTL response. The antibody contains an immunity protein binding site for binding to the antibody.
[0286]
[0340] In some embodiments, the circular polyribonucleic acid is a nucleic acid that binds RIG-I, TLR-3, T LR-7, TLR-8, MDA-5, LGP-2, OAS, OASL, PKR, and IF Encryption as assessed by expression, signaling, or activation of at least one of N-β In some embodiments, the antigen-binding domain is at least two-fold less immunogenic than its counterpart lacking the antigen. In some embodiments, the circular polyribonucleic acid has a size ranging from about 20 bases to about 20 kb. In this situation, circular polyribonucleic acid is synthesized via circularization of a linear polynucleotide. In some embodiments, the circular polyribonucleic acid is substantially resistant to degradation.
[0287] Purpose
[0341] The cyclic polyribonucleotides described herein can be used in cells, tissues, and the like where they are needed. and administering to a cell, tissue or subject, e.g., to enhance a cellular function or process, e.g., to a cell, tissue or subject. The present invention can also be used to modulate gene expression in cell functions or cells. A method of modulating a process, e.g., gene expression, in a cell in need thereof. administering to a cell, tissue or subject a cyclic polyribonucleotide as described herein. The administered cyclic polyribonucleotide is a modified cyclic polyribonucleotide. In some embodiments, the administered cyclic polyribonucleotide may be a fully modified In some embodiments, the administered circular polyribonucleotide is The nucleotide is a hybrid modified circular polyribonucleotide. In the present invention, the cyclic polyribonucleotide administered is an unmodified cyclic polyribonucleotide. .
[0288] EMBODIMENT PARAGRAPH [1] (a) Bind a target, e.g., RNA, DNA, protein, cell membrane, etc. A circular polyribonucleotide comprising a binding site; and (b) A pharma- ceutically acceptable carrier or excipient. A pharmaceutical composition comprising: The target and the circular polyribonucleotide form a complex, The pharmaceutical composition wherein the target is not a microRNA.
[0289] [2](a) (i) a first binding site that binds a first target, and (ii) a second binding site that binds a second target; a cyclic polyribonucleotide comprising (b) A pharma- ceutically acceptable carrier or excipient. A pharmaceutical composition comprising: the first binding site is different from the second binding site; The pharmaceutical composition, wherein the first target and the second target are both microRNAs.
[0290] [3] The pharmaceutical composition of paragraph [1], wherein the binding site comprises an aptamer sequence. [4] The first binding site comprises a first aptamer sequence and the second binding site comprises a second aptamer sequence. The pharmaceutical composition of paragraph [2], comprising a ptamer sequence.
[0291] [5] The aptamer sequence is a pharmaceutical composition according to item [3], which has a secondary structure that binds to a target. Composition. [6] The first aptamer sequence has a secondary structure that binds the first target and the second aptamer sequence has a secondary structure that binds the first target. The pharmaceutical composition of item [4], wherein the tamers have a secondary structure that binds a second target.
[0292] [7] The binding site is a first binding site, and the target is a first target, item [1] A pharmaceutical composition comprising: [8] The circular polyribonucleotide further comprises a second binding site that binds to a second target. A pharmaceutical composition according to any one of paragraphs [3], [5], and [7].
[0293] [9] The first target is the first circular polyribonucleotide (circRNA)-binding motif. Any one of the pharmaceutical compositions in paragraphs [2], [4], [6], [7], and [8], thing.
[0294]
[10] The second target is a second circular polyribonucleotide (circRNA)-binding motif. Any one of the pharmaceutical compositions in paragraphs [2], [4], [6], and [7] to [9], including Composition.
[0295]
[11] The first target, the second target, and the circular polyribonucleotide form a complex. The pharmaceutical composition of any one of paragraphs [2], [4], [6], and [7] to
[10] .
[12] The first and second targets interact with each other, paragraphs [2], [4], and [6]; And any one of the pharmaceutical compositions [7] to
[11] .
[0296]
[13] The complex modulates cellular processes, paragraphs [1], [3], [5], And any one of the pharmaceutical compositions [7] to
[12] .
[14] The first and second targets are the same, and the first and second binding sites are binding sites for the first target. and a different binding site on the second target, paragraphs [2], [4], [6], and [ 7] to
[13] .
[0297]
[15] The primary and secondary targets are different, see paragraphs [2], [4], [6] and [7 ]~
[13] .
[16] The circular polyribonucleotide may be a polyribonucleotide having one or more additional targets that bind a third or more targets. Any of paragraphs [2], [4], [6], and [7] to
[15] further comprising a binding site. One pharmaceutical composition.
[0298]
[17] One or more of the targets are the same, and one or more additional binding sites are linked to one or more of the targets. Combining the different binding sites above, paragraphs [2], [4], [6], and [7] to
[16] 13. The pharmaceutical composition of claim 12,
[0299]
[18] The formation of the complex modulates cellular processes, paragraphs [1], [3], [ 5] and any one of [7] to
[17] .
[19] The cyclic polyribonucleotide, when contacted with a first or second target, modulates a cellular process associated with a second target, paragraphs [2], [4], and [6] and any one of the pharmaceutical compositions [7] to
[18] .
[0300]
[20] The first and second targets interact with each other in a complex, paragraphs [2], [4] , [6], and any one of [7] to
[19] .
[21] The cellular process is related to the pathogenesis of a disease or pathological condition, Any one of the pharmaceutical compositions.
[0301]
[22] The cellular process is different from the translation of circular polyribonucleic acid, paragraphs
[13] to
[21] 13. The pharmaceutical composition of claim 12,
[23] The first target comprises a deoxyribonucleic acid (DNA) molecule and the second target comprises a protein. Any one of paragraphs [2], [4], [6], and [7] to
[22] , including the Pharmaceutical composition.
[0302]
[24] The complex is involved in the directed transcription of DNA molecules, epigenetic remodeling of DNA molecules, and Paragraphs [1], [3], [5] and [ 7] to
[23] .
[0303]
[25] The first target comprises a first protein and the second target comprises a second protein. The pharmaceutical composition according to any one of paragraphs [2], [4], [6], and [7] to
[24] , .
[0304]
[26] The complex is involved in the degradation of the first protein, the translocation of the first protein, and or modulates signal transduction or modulates natural protein function. inhibits the formation of a complex formed by direct interaction between the first and second proteins. Paragraphs [1], [3], [5], and [7] to
[25] of Any one of the pharmaceutical compositions.
[0305]
[27] The first target or the second target is a ubiquitin ligase, paragraphs [2] and [4 ], [6], and any one of [7] to
[26] .
[28] The first target comprises a first ribonucleic acid (RNA) molecule and the second target comprises a second Any one of paragraphs [2], [4], [6], and [7] to
[27] , including an RNA molecule A pharmaceutical composition comprising:
[0306]
[29] The pharmaceutical composition of paragraph
[28] , wherein the complex modulates degradation of the first RNA molecule. composition.
[30] The first target comprises a protein and the second target comprises an RNA molecule, 2], [4], [6], and [7] to
[29] .
[0307]
[31] The complex modulates protein translocation or inhibiting the formation of a complex formed by direct interaction between the protein and the RNA molecule; A pharmaceutical composition comprising any one of the following: [1], [3], [5], and [7] to
[30] .
[0308]
[32] The first target is a receptor and the second target is a substrate of the receptor, paragraph [2 ], [4], [6], and [7] to
[31] .
[33] The complex inhibits receptor activation, paragraphs [1], [3], [5], and [ 7] to
[32] .
[0309]
[34] (a) a circular polyribonucleotide comprising a binding site for binding a target; and (b) A pharma- ceutically acceptable carrier or excipient. A pharmaceutical composition comprising: The circular polyribonucleotides are non-translatable or translation-deficient and target microRNAs. Not a pharmaceutical composition.
[0310]
[35] (a) a binding site that binds a target, the target being a ribonucleic acid (RNA)-binding molecule; Circular polyribonucleic acid containing the chief; and (b) A pharma- ceutically acceptable carrier or excipient. A pharmaceutical composition comprising: The circular polyribonucleotides are non-translatable or translation-deficient and target microRNAs. A pharmaceutical composition.
[0311]
[36] the binding site comprises an aptamer sequence having a secondary structure that binds the target, A pharmaceutical composition according to any one of
[34] and
[35] .
[37] The pharmaceutical composition of any one of paragraphs
[34] and
[36] , wherein the target comprises a DNA molecule. composition.
[0312]
[38] Binding of targets to circular polyribonucleotides modulates the interference with transcription of DNA molecules. The pharmaceutical composition of any one of paragraphs
[34] to
[37] .
[39] The target is any of paragraphs
[34] and
[36] to
[38] , including a protein. One pharmaceutical composition.
[0313]
[40] Target binding to circular polyribonucleotides is a key step in the interaction of proteins with other molecules. The pharmaceutical composition of paragraph
[39] , which modulates the activity of
[41] The protein is a receptor, and the binding of the target to the cyclic polyribonucleotide is A pharmaceutical composition according to any one of paragraphs
[39] to
[40] , which activates a receptor.
[0314]
[42] The protein is the first enzyme, and the cyclic polyribonucleotide is the second enzyme. and a second binding site that binds to the first and second binding sites to the circular polyribonucleotide. The pharmaceutical composition of any one of paragraphs
[39] to
[0041] , wherein the binding of the enzymes modulates the enzymatic activity of the first and second enzymes.
[0315]
[43] The protein is a ubiquitin ligase. Any one of the pharmaceutical compositions.
[44] The pharmaceutical composition of any one of paragraphs
[34] ,
[0036] , and
[38] , wherein the target comprises a messenger RNA (mRNA) molecule.
[0316]
[45] Binding of targets to circular polyribonucleotides monitors the interference with the translation of mRNA molecules. The pharmaceutical composition of paragraph
[44] .
[46] The pharmaceutical composition of any one of paragraphs
[34] ,
[36] ,
[39] and
[0040] , wherein the target comprises a ribosome.
[0317]
[47] Binding of targets to circular polyribonucleotides modulates the interference with the translation process. The pharmaceutical composition according to any one of paragraphs
[34] to
[46] ,
[48] Any of paragraphs
[34] ,
[36] and
[38] , wherein the target comprises a circular RNA molecule. Any one of the pharmaceutical compositions.
[0318]
[49] Binding of the target to the circular polyribonucleotide sequesters the circular RNA molecule. A pharmaceutical composition comprising the compound
[48] .
[50] Binding of targets to circular polyribonucleotides sequesters microRNA molecules. , any one of paragraphs
[35] ,
[36] ,
[38] and
[47] .
[0319]
[51] (a) A binding site that binds to a cell membrane (e.g., cell wall membrane, organelle membrane, etc.) and the membrane of the cell contains a circular polyribonucleotide that contains a ribonucleic acid (RNA) binding motif. and (b) A pharma- ceutically acceptable carrier or excipient. 23. A pharmaceutical composition comprising:
[0320]
[52] The binding site binds the membrane of the cell (e.g., the cell wall membrane, organelle membrane, etc.). The pharmaceutical composition of paragraph
[51] , comprising an aptamer sequence having a secondary structure.
[53] The circular polyribonucleotide further comprises a second binding site that binds to a second target. and the second target comprises a second RNA-binding motif. Any one of the pharmaceutical compositions.
[0321]
[54] The pharmaceutical composition of paragraph
[0053] , wherein the cyclic polyribonucleotide binds to a membrane of a cell and a second target.
[55] The cyclic polyribonucleotide further comprises a second binding site that binds to a second cellular target. and wherein the binding of the cellular target and the second cellular target to the circular polyribonucleotide comprises binding to the cellular target. and inducing a conformational change in the cellular target, thereby inducing downstream signaling of the cellular target. The pharmaceutical composition of any one of
[51] to
[54] .
[0322]
[56] The pharmaceutical composition of any one of paragraphs [1] to
[0055] , wherein the cyclic polyribonucleotide is non-translatable or translation-deficient.
[57] Cyclic polyribonucleotides are a) Encryptogen; b) splicing elements; c) regulatory sequences; d) Replicated sequences; e) quasi-double-stranded secondary structure; f) quasi-helical structure; and g) Expression sequences Paragraphs [1] to [5] further comprising at least one structural element selected from the group consisting of:
[56] Any one of the pharmaceutical compositions.
[0323]
[58] A quasi-helical structure is one that has at least one non-double-stranded segment. The pharmaceutical composition of paragraph
[57] , comprising one double-stranded RNA segment.
[59] A quasi-helical structure is a structure in which a first sequence and a second sequence are connected by a repeat sequence. The pharmaceutical composition of any one of paragraphs
[57] and
[58] ,
[0324]
[60] The pharmaceutical composition of any one of paragraphs
[57] to
[0059] , wherein the encryptogen contains a splicing element.
[61] The pharmaceutical composition of any one of paragraphs [1] to
[0060] , wherein the circular polyribonucleic acid comprises at least one modified nucleic acid.
[0325]
[62] At least one modified nucleic acid is 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, T-deoxy-2 '-Fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylamino Noethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-OD MAP), TO-Dimethylaminoethyloxyethyl (2'-O-DMAEOE), 2 '-O-Methylacetamide (2'-O-NMA), Locked Nucleic Acid (LNA), Ethyl Enzyme Nucleic Acid (ENA), Peptide Nucleic Acid (PNA), 1',5'-Anhydrohexitol Nucleic Acid (HNA), morpholino, methylphosphonate nucleotides, thiolphosphonate nucleotides and 2'-fluoro N3-P5'-phosphoramidites. The pharmaceutical composition of paragraph
[61] .
[0326]
[63] The pharmaceutical composition of any one of paragraphs
[57] to
[0062] , wherein the encryptogen comprises at least one modified nucleic acid.
[64] The encryptogen is a compound according to paragraphs
[57] to
[63] which contains a protein binding site. Any one of the pharmaceutical compositions.
[0327]
[65] The pharmaceutical composition of any one of paragraphs
[57] to
[0064] , wherein the encryptogen comprises an immune protein binding site.
[66] Circular polyribonucleic acid binds RIG-I, TLR-3, TLR-7, TLR-8, and M At least one of DA-5, LGP-2, OAS, OASL, PKR, and IFN-β less than their counterparts lacking the cryptogen as assessed by expression, signaling or activation. The pharmaceutical composition according to any one of paragraphs
[57] to
[65] , having at least 2-fold lower immunogenicity. .
[0328]
[67] The circular polyribonucleic acid has a size of about 20 bases to about 20 kb, paragraph [1] ~
[66] Any one of the pharmaceutical compositions.
[68] Circular polyribonucleic acid is synthesized via circularization of a linear polynucleotide. 4. A pharmaceutical composition according to any one of [1] to
[67] .
[0329]
[69] The circular polyribonucleic acid of paragraphs [1] to
[68] , which is substantially resistant to degradation. Any one of the pharmaceutical compositions.
[70] (a) a binding site that binds to a target, the target having a ribonucleic acid (RNA)-binding moiety; cyclic polyribonucleotides containing (b) A pharma- ceutically acceptable carrier or excipient. A pharmaceutical composition comprising: The cyclic polyribonucleotide comprises at least one modified nucleotide and at least about 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800 , 900, or 1000 consecutive unmodified nucleotides. .
[0330]
[71] (a) a binding site that binds to a target, the target having a ribonucleic acid (RNA) binding moiety; cyclic polyribonucleotides containing (b) A pharma- ceutically acceptable carrier or excipient. A pharmaceutical composition comprising: The cyclic polyribonucleotide comprises at least one modified nucleotide and at least about 5, 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800 , 900, or 1000 contiguous nucleotides, the first portion comprising: A pharmaceutical composition that lacks both pseudouridine and 5'-methylcytidine.
[0331]
[72] the binding site comprises an aptamer sequence having a secondary structure that binds the target,
[70] and
[71] any one of the pharmaceutical compositions.
[73] Cyclic polyribonucleotides are more efficient than the corresponding unmodified cyclic polyribonucleotides. The pharmaceutical composition of any one of paragraphs
[70] to
[72] , having as low an immunogenicity as possible.
[0332]
[74] Cyclic polyribonucleotides bind to RIG-I, TLR-3, TLR-7, and TLR -8, MDA-5, LGP-2, OAS, OASL, PKR, and IFN-β The corresponding unmodified cyclic nucleotides are evaluated by expression or signaling or activation of at least one of At least about 1.1, 1.2, 1.3, 1.5, 1.6, 1 .8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4 .2, 4.5, 4.8, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8 Paragraphs
[70] to
[72] , which refer to a compound having a lower immunogenicity than the compound of the present invention. 13. The pharmaceutical composition of claim 12,
[0333]
[75] Cyclic polyribonucleotides are more efficient than the corresponding unmodified cyclic polyribonucleotides. The pharmaceutical composition of any one of paragraphs
[70] to
[74] , having a long half-life.
[76] Cyclic polyribonucleotides are more efficient than the corresponding unmodified cyclic polyribonucleotides. Also at least about 1.2, 1.3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8 , 3, 3.2, 3.3, 3.5, 3.8, 4.0, 4.2, 4.5, 4.8, 5.0, 5 .5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10. The pharmaceutical composition of any one of paragraphs
[70] to
[74] , having a half-life that is 0 times longer.
[0334]
[77] The half-life of cyclic polyribonucleotide or the corresponding unmodified cyclic polyribonucleic acid The nucleotide is introduced into the cell, and the introduced circular polyribonucleotide or the corresponding nucleotide is introduced into the cell. Paragraph
[75] , which is measured by measuring the level of cyclic polyribonucleotides; and
[76] Any one of the pharmaceutical compositions.
[0335]
[78] At least one modified nucleotide is N(6) methyladenosine (m6A). The pharmaceutical composition of any one of paragraphs
[0070] to
[77] , wherein the uridine is selected from the group consisting of 5'-methylcytidine and pseudouridine.
[0336]
[79] At least one modified nucleic acid is 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, T-deoxy-2 '-Fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylamino Noethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-OD MAP), TO-Dimethylaminoethyloxyethyl (2'-O-DMAEOE), 2 '-O-Methylacetamide (2'-O-NMA), Locked Nucleic Acid (LNA), Ethyl Enzyme Nucleic Acid (ENA), Peptide Nucleic Acid (PNA), 1',5'-Anhydrohexitol Nucleic Acid (HNA), morpholino, methylphosphonate nucleotides, thiolphosphonate nucleotides and 2'-fluoro N3-P5'-phosphoramidites. The pharmaceutical composition of any one of paragraphs 70 to
[77] .
[0337]
[80] At least about 10%, 20%, 3 0%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% are qualified The pharmaceutical composition of any one of paragraphs
[70] to
[79] , which is a nucleotide.
[0338]
[81] Cyclic polyribonucleotides are proteins composed of unmodified nucleotides. Any of paragraphs
[70] to
[80] , which includes a binding moiety that binds to a NA, RNA, or cellular target. Any one of the pharmaceutical compositions.
[0339]
[82] Cyclic polyribonucleotides are internal ribosomal nucleotide sequences composed of unmodified nucleotides. The pharmaceutical composition of any one of paragraphs
[70] to
[81] , comprising an IRES.
[83] The modified site is any one of paragraphs
[70] to
[80] , which is made up of unmodified nucleotides. or a pharmaceutical composition.
[0340]
[84] The binding site is a therapeutic agent according to paragraph
[83] , comprising an IRES consisting of unmodified nucleotides. Pharmaceutical composition.
[85] The first portion is a bond that binds a protein, DNA, RNA, or a cellular target. A pharmaceutical composition according to any one of paragraphs
[70] to
[84] , comprising a site.
[0341]
[86] The first part is a medical device that includes an IRES, as described in any one of paragraphs
[70] to
[85] . Pharmaceutical composition.
[87] A pharmaceutical composition according to any one of paragraphs
[70] to
[0086] , wherein the cyclic polyribonucleotide comprises one or more expression sequences.
[0342]
[88] A circular polyribonucleotide is a polyribonucleotide that contains one or more expression sequences and an IRES. The polyribonucleotide may contain 5'-methylcytidine, pseudouridine, or or a combination thereof.
[0343]
[89] One or more of the expression sequences of a circular polyribonucleotide may be a corresponding unmodified circular polyribonucleotide. A pharmaceutical composition according to any one of paragraphs
[70] to
[0088] , configured to have a higher translation efficiency than ribonucleotides.
[0344]
[90] One or more expression sequences of a circular polyribonucleotide may be a corresponding unmodified circular polyribonucleotide. At least about 0.7, 0.8, 0.9, 1.0, 1.1, 1.2 , 1.3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, or 3 times higher translation efficiency The pharmaceutical composition of any one of paragraphs
[70] to
[89] , having a rate of
[0345]
[91] One or more of the expression sequences of the circular polyribonucleotide may contain modified nucleotides. a first portion having a higher translation efficiency than a corresponding circular polyribonucleotide having a second portion; A pharmaceutical composition according to any one of
[70] to
[90] .
[0346]
[92] One or more of the expression sequences of the circular polyribonucleotide contains more than 10% modified nucleosides. and a corresponding circular polyribonucleotide having a first portion containing a tide, The pharmaceutical composition of any one of paragraphs
[70] to
[90] ,
[0347]
[93] One or more of the expression sequences of the circular polyribonucleotide may contain modified nucleotides. At least about 1.2, 1. 3, 1.5, 1.6, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.3, 3. 5, 3.8, 4.0, 4.2, 4.5, 4.8, 5.0, 5.5, 6.0, 6.5, 7. have 0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 times higher translation efficiency; A pharmaceutical composition according to any one of paragraphs
[70] to
[92] .
[0348]
[94] The translation efficiency is in cells containing otides or in in vitro translation systems (e.g., rabbit reticulocyte lysates) The pharmaceutical composition of any one of paragraphs
[89] to
[93] , wherein the pharmaceutical composition is measured according to any one of the following methods:
[0349]
[95] A cyclic polyribonucleotide is a cyclic polyribonucleotide that is any one of items 0 to
[69] . The pharmaceutical composition of any one of paragraphs
[70] to
[94] , which is a ribonucleotide.
[96] A method for treating a patient, comprising administering to the patient a pharmaceutical composition according to any one of paragraphs [1] to
[95] . or to a subject having a disease or condition.
[0350]
[97] Generate any one of the circular polyribonucleotides described in paragraphs [1] to
[95] . A method for producing a pharmaceutical composition comprising:
[98] Any of paragraphs [1] to
[95] , which is formulated in a carrier, e.g., a membrane or lipid bilayer. Any one of the circular polyribonucleotides.
[0351]
[99] A linear polyribonucleotide having a nucleic acid sequence as a circular polyribonucleotide. The method according to any one of paragraphs [1] to
[95] , comprising circularizing the Methods for making leotides.
[0352]
[0100] A genetically engineered cell comprising any one of the compositions of items [1] to
[95] . A method for binding a target in a cell, comprising: an untranslatable molecule that includes an aptamer sequence, the aptamer sequence having a secondary structure that binds the target; Providing a circular polyribonucleotide; and Delivering untranslatable circular polyribonucleotides to cells and form detectable complexes with the target at least 5 days after delivery. The method includes:
[0353] A method for binding a target in a cell, comprising: Delivering untranslatable circular polyribonucleotides to cells and The non-translatable circular polyribonucleotide comprises an aptamer sequence that binds a target. The complex formed detectable with the target at least 5 days after the transfer. The method includes:
[0354] The target may be selected from the group consisting of nucleic acid molecules, small molecules, proteins, carbohydrates, and lipids. Any one of the methods described in paragraphs
[0101] and
[0102] , selected from the above.
[0104] Any of paragraphs
[0101] to
[0103] , in which the target is a gene regulatory protein One way.
[0355]
[0105] The method of paragraph 104, wherein the gene regulatory protein is a transcription factor.
[0106] The method of paragraph
[0103] , wherein the nucleic acid molecule is a DNA molecule or an RNA molecule.
[0107] The complex according to paragraphs
[0101] to
[0106] , which modulates gene expression. Either one of the methods.
[0356] The complex is involved in the directed transcription of DNA molecules, epigenetic remodeling of DNA molecules, and Any of paragraphs
[0101] to
[0107] that modulates the degradation of a ring or DNA molecule. One way.
[0357] The complex may be involved in target degradation, target translocation, or target signal transduction. Any one of the methods described in paragraphs
[0101] to
[0108] for modulating the
[0110] Any one of the methods of paragraphs
[0107] to
[0109] , wherein gene expression is associated with the etiology of a disease or condition.
[0358] The complex is detectable at least 7, 8, 9, or 10 days after delivery. Use one of the following methods: paragraphs
[0101] to
[0110] .
[0112] Untranslatable circular polyribonucleotides are present at least 5 days after delivery , any one of paragraphs
[0101] to
[0111] .
[0359]
[0113] The non-translatable circular polyribonucleotide may be at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 Or any one of the methods described in paragraphs
[0101] to
[0112] that exists 10 days later.
[0114] The untranslatable circular polyribonucleotide is an unmodified untranslatable circular polyribonucleotide. A punch line can be any one of paragraphs
[0101] to
[0113] .
[0360]
[0115] The method of any one of paragraphs
[0101] to
[0114] , wherein the untranslatable circular polyribonucleotide has a quasi-double-stranded secondary structure.
[0116] The method of any one of paragraphs
[0101] to
[0115] , wherein the aptamer sequence further has a tertiary structure that binds the target.
[0361]
[0117] The cell is a eukaryotic cell. Law.
[0118] Any one of the methods of paragraph
[0117] , wherein the eukaryotic cell is a human cell.
[0362] A method for binding a transcription factor in a cell, comprising the steps of: A non-translatable circular polyribonucleotide containing an aptamer sequence that binds a transcription factor is provided. and Delivering untranslatable circular polyribonucleotides to cells and forms complexes with transcription factors and modulates gene expression The method includes:
[0363] A method for binding a transcription factor in a cell, comprising the steps of: Delivering untranslatable circular polyribonucleotides to cells and contains an aptamer sequence that binds a transcription factor, and the untranslatable circular polyribonucleotide is , forming complexes with transcription factors and modulating gene expression The method includes:
[0364] A method for sequestering a transcription factor in a cell, comprising: A non-translatable circular polyribonucleotide containing an aptamer sequence that binds a transcription factor is provided. and Delivering untranslatable circular polyribonucleotides to cells and It is believed that the transcription factor sequestering occurs by binding the transcription factor to form a complex in cells. The method includes:
[0365] A method for sequestering a transcription factor in a cell, comprising: Delivering untranslatable circular polyribonucleotides to cells and contains an aptamer sequence that binds a transcription factor, and the untranslatable circular polyribonucleotide is sequestering transcription factors by binding them to form complexes The method includes:
[0366]
[0123] Any one of the methods of paragraphs
[0121] and
[0122] , wherein cell viability is decreased after formation of the complex. A method of sensitizing a cell to a cytotoxic agent, comprising: A non-translatable circular polyribonucleotide containing an aptamer sequence that binds a transcription factor is provided. and A cytotoxic agent and an untranslatable circular polyribonucleotide are delivered to a cell, and the untranslatable circular polyribonucleotide is Polynucleotides form complexes with transcription factors in cells; This makes the cells more resistant to cytotoxic agents than cells lacking non-translatable circular polyribonucleotides. Sensitizing cells The method includes:
[0367] A method of sensitizing a cell to a cytotoxic agent, comprising: A cytotoxic agent and an untranslatable circular polyribonucleotide are delivered to a cell, and the untranslatable circular polyribonucleotide is The polynucleotide contains an aptamer sequence that binds a transcription factor; Nucleotides form complexes with transcription factors in cells; This makes the cells more resistant to cytotoxic agents than cells lacking non-translatable circular polyribonucleotides. Sensitizing cells The method includes:
[0368] Sensitization of cells to cytotoxic agents is achieved by the use of cytotoxic agents and non-translatable circular polyribonucleic acid. Paragraphs
[0124] and
[0125] , which result in reduced cell viability after delivery of nucleotides Either one of the methods.
[0369] Decreased cell viability is associated with cytotoxic agents and untranslatable cyclic polyribonucleotides. The method of paragraph
[0126] , wherein the concentration of α-aminobutyric acid in the blood is reduced by 40% or more at least two days after delivery. A method for binding a pathogenic protein in a cell, comprising the steps of: Untranslatable circular polyribonucleotides containing aptamer sequences that bind pathogenic proteins To provide; and Delivering untranslatable circular polyribonucleotides to cells and forms a complex with virulence proteins for their degradation The method includes:
[0370] A method for binding a pathogenic protein in a cell, comprising the steps of: Delivering untranslatable circular polyribonucleotides to cells and contains an aptamer sequence that binds a pathogenic protein; Otides form complexes with pathogenic proteins for their degradation. The method includes:
[0371] A method for binding a ribonucleic acid molecule in a cell, comprising the steps of: providing an untranslatable circular polyribonucleotide comprising a sequence complementary to the sequence of the ribonucleic acid molecule; and Delivering untranslatable circular polyribonucleotides to cells and forms a complex with a ribonucleic acid molecule in a cell. The method includes:
[0372] A method for binding a ribonucleic acid molecule in a cell, comprising the steps of: Delivering untranslatable circular polyribonucleotides to cells and comprises an aptamer sequence that binds a ribonucleic acid molecule; The peptides form complexes with ribonucleic acid molecules in cells. The method includes:
[0373] A method for combining genomic deoxyribonucleic acid molecules in a cell, comprising the steps of: A non-translatable circular polyribonucleic acid molecule containing an aptamer sequence that binds a genomic deoxyribonucleic acid molecule. Providing nucleotides; and Delivering untranslatable circular polyribonucleotides to cells and It forms complexes with genomic deoxyribonucleic acid molecules and modulates gene expression. and The method includes:
[0374] A method for combining genomic deoxyribonucleic acid molecules in a cell, comprising the steps of: Delivering untranslatable circular polyribonucleotides to cells and comprises an aptamer sequence that binds a genomic deoxyribonucleic acid molecule; Ribonucleotides form complexes with genomic deoxyribonucleic acid molecules and monitor gene expression. To aggregate The method includes:
[0375] A method for binding a small molecule in a cell, comprising: To provide an untranslatable circular polyribonucleotide that contains an aptamer sequence that binds a small molecule and Delivering untranslatable circular polyribonucleotides to cells and They form complexes with small molecules and mediate cellular processes (e.g., protein degradation, cell signaling, etc.). Modulating various physiological functions (e.g., immune function, immune system ... The method includes:
[0376] A method for binding a small molecule in a cell, comprising: Delivering untranslatable circular polyribonucleotides to cells and comprises an aptamer sequence that binds a small molecule; They form complexes with small molecules and mediate cellular processes (e.g., protein degradation, cell signaling, etc.) , gene expression, etc. The method includes:
[0377]
[0136] Small molecules are organic compounds having a molecular weight of 900 Daltons or less that are capable of acting as cellular promoters. A method according to any one of paragraphs
[0134] and
[0135] for modulating a process.
[0137] The method of any one of paragraphs
[0134] to
[0136] , wherein the small molecule is a drug. .
[0378]
[0138] Any of paragraphs
[0134] and
[0135] , wherein the small molecule is a fluorophore. Or one way.
[0139] Any one of paragraphs
[0134] to
[0136] , wherein the small molecule is a metabolite. method.
[0379]
[0140] The aptamer sequence includes a secondary structure that binds a target. A composition comprising an untranslatable circular polyribonucleotide.
[0141] The aptamer sequence includes a secondary structure that binds a target. and a pharma- ceutically acceptable carrier or excipient. Pharmaceutical compositions.
[0380]
[0142] Any one of paragraphs
[0101] to
[0141] of an untranslatable circular polyribonucleic acid Cells containing otides.
[0143] A method for treating a subject in need of treatment, comprising administering any one of the compositions of paragraphs
[0101] to
[0140] or the pharmaceutical composition of paragraph
[0141] . .
[0381]
[0144] Any one of paragraphs
[0101] to
[0141] of an untranslatable circular polyribonucleic acid A polynucleotide encoding an otide.
[0145] Any one of paragraphs
[0101] to
[0141] of an untranslatable circular polyribonucleic acid A method for producing otides.
[0382]
[0342] All references and publications cited herein are hereby incorporated by reference. Be absorbed.
[0343] The following examples are illustrative of some embodiments of the present invention using model elements. These are provided to further illustrate aspects of the invention, but are not intended to limit the scope of the invention; Due to the exemplary nature of the present invention, other procedures, methods, or techniques known to those skilled in the art may be alternatively used. It is understood that this is possible. EXAMPLES
[0383] Example 1: Circular RNA that binds DNA to regulate gene expression This example describes circular RNA that binds to DNA to regulate gene expression. do.
[0384] A model target gene, in this case the dihydrofolate reductase (DHFR) gene The non-naturally occurring circular RNA is engineered to contain a sequence within the As can be seen, DHFR plays an important role in regulating the amount of tetrahydrofolate in cells. Tetrahydrofolic acid and its derivatives play an important role in the synthesis of purines and acetylcholine, which are important for cell proliferation and growth. DHFR plays a central role in the synthesis of nucleic acid precursors. As shown in the Examples below, the circular RNA binds to the DHFR gene and mediates its transcription. Suppress.
[0385]
[0346] The circular RNA has the DHFR binding sequence 5'-ACAAAUGGGGACGAGG It is designed to contain the sequence GGGGCGGGGCGGCC-3' (SEQ ID NO:5).
[0347] A DNA segment containing the above DHFR binding sequence is subjected to T7 RNA polymerase. Synthesize unmodified linear RNA by in vitro transcription using R. The DNA was purified using the QIAGEN purification system and treated with alkaline phosphatase (ThermoFi Sher Scientific, EF0652) according to the manufacturer's instructions. and purify again using an RNA purification system.
[0386]
[0348] T4 DNA ligase (New England Bio, Inc., M020 2M) or T4 RNA ligase 2 (New England Bio, Inc., M02 Splints were prepared by processing transcribed linear RNA and DNA splints using 39S Ligation produces circular RNA, which is then isolated after enrichment by RNase R treatment. RNA quality was assessed by agarose gel or via automated electrophoresis (Agilent). and evaluate.
[0387] As shown in FIG. 5C, one circular RNA binding to DHFR genomic DNA Several methods, e.g., CHAR, evaluate RNA binding directly to genomic DNA. T-qPCR, DHFR transcript-specific qPCR, and cell proliferation and growth assays Active binding of circular RNA to the DHFR gene was assessed via reduced DHFR transcription. This results in decreased purine and thymidylate synthesis, as well as decreased cell proliferation and growth. It is predicted that...
[0388] Example 2: Circular RNA that binds dsDNA to regulate gene expression
[0350] This example describes a method for producing circular RNA that binds to dsDNA to regulate gene expression. Write down.
[0389] As shown in FIG. 5D, the model target gene, in this case, transformin The non-naturally occurring circular RNA was prepared so as to contain a sequence that binds to a transforming growth factor beta (TGF-β) target sequence. TGF-β is secreted by many cell types. After binding to the receptor, the receptor is phosphorylated, activating a signaling cascade that leads to various This results in the activation of various downstream substrates and regulatory proteins. We describe circular RNAs that bind to TGF-β target genes to induce TGF-β expression.
[0390] The circular RNA contains the TGF-β target binding sequence 5'-CGGAGAGCAGAGA It is designed to contain GGGAGCG-3' (SEQ ID NO:6).
[0353] T7 RNA polymerase is synthesized from a DNA segment having a TGF-β binding sequence. Synthesize unmodified linear RNA by in vitro transcription using RNase A. The cells were purified using the QIAGEN A purification system and then purified using alkaline phosphatase (ThermoFis Her Scientific, EF0652) according to the manufacturer's instructions. Then, purify again using an RNA purification system.
[0391]
[0354] T4 DNA ligase (New England Bio, Inc., M020 2M) or T4 RNA ligase 2 (New England Bio, Inc., M02 Splints were prepared by processing transcribed linear RNA and DNA splints using 39S Ligation produces circular RNA, which is then isolated after enrichment by RNase R treatment. RNA quality was assessed by agarose gel or via automated electrophoresis (Agilent). and evaluate.
[0392] Circular RNA binding to dsDNA is determined via a triplex immunocapture assay Here, biotin-labeled triplex-forming oligonucleotide (TFO) ssRNA molecules (control Sequence or targeting sequence 5'-CGGAGAGCAGAGAGGGAGCG-3' (SEQ ID NO: 7) to obtain target DNA sequences from cells or nuclei isolated from cells. Assay for RNA-DNA triplex formation by pulling down biotinylated target or control The DNA pulled down by TFO was sequenced to confirm the RNA-dsDNA pulldown. The enriched DNA sequence is then determined.
[0393]
[0356] Alternative methods for demonstrating RNA-DNA binding include CHART-qPCR and gel electrophoresis. The antibody is a nucleic acid mobility shift assay, in which a targeting ssRNA oligo (5'-CGGAG AGCAGAGAGGGAGCG-3' (SEQ ID NO: 7) is a target dsDNA oligo (5 '-AGAGAGAGGGAGAGAG-3' (SEQ ID NO: 8) and 3'-TCTCTCT CCCTCTCTC-5' (SEQ ID NO: 9)) but not with the control DNA oligo. Doesn't work.
[0394]
[0357] Additional assessment of functional changes induced after target RNA binding can be performed using qPCR. TGF-β target genes measured by, for example, TGFB2, TGFBR1, and / or Examples include changes in SMAD2.
[0395] Example 3: Circular RNA that binds DNA to regulate gene expression This example describes circular RNA that binds to DNA to inhibit transcription factor binding. Will be posted.
[0396]
[0359] A binding sequence for a target sequence, in this case, a gamma globin transcription factor binding sequence, The non-naturally occurring circular RNA is engineered to produce a circulating RNA that is specific for the foetal hemoglobin during development in the womb. It is the major oxygen-transporting protein in the human fetus during the last 7 months and is bioavailable in the newborn. Fetal hemoglobin has a greater affinity for hemoglobin than adult hemoglobin. This allows the developing fetus better access to oxygen from the mother's bloodstream. In live infants, fetal hemoglobin is almost completely replaced by adult hemoglobin by approximately 6 months of age. It will be completely replaced.
[0397]
[0360] GATA-1 is -567 G γ / -566 A γ-globin GATA motif It is a component of the repressor complex GATA-1-FOG-1-Mi2b that binds at The following example illustrates the use of -567 to prevent binding of inhibitory transcription factor / repressor complexes. G γ / -566 A γ-globin GATA motif (accession file GI455025) et al., GenBank coordinates 33992 to 33945 and accession file GI455 025 (GenBank coordinates 38772 to 38937, respectively) bound to cyclic R Enter NA.
[0398] Circular RNA binds the inhibitory transcription factor complexes GATA1, Mi2b, and FOG1. The nucleic acid sequence is designed to contain a non-deleted binding sequence that
[0362] Using T7 RNA polymerase to generate a DNA segment containing a transcription factor binding sequence Synthesize unmodified linear RNA by in vitro transcription using the . Purified using a purification system (QIAGEN) and alkaline phosphatase (ThermoFish (Fujikura Scientific, EF0652) according to the manufacturer's instructions. Purify again using an RNA purification system.
[0399]
[0363] T4 DNA ligase (New England Bio, Inc., M020 2M) or T4 RNA ligase 2 (New England Bio, Inc., M02 Splints were prepared by processing transcribed linear RNA and DNA splints using 39S Ligation produces circular RNA, which is then isolated after enrichment by RNase R treatment. RNA quality was assessed by agarose gel or via automated electrophoresis (Agilent). and evaluate.
[0400] Binding of circular RNA to DNA can be achieved using direct DNA binding methods, such as CHART-q Assess via PCR and function via methods such as activation and expression of fetal hemoglobin Active binding of circular RNA to regulatory elements upstream of the γ-globin gene inhibits transcription. It activates HbF transcription by providing competitive inhibition of the factor BCL11A or other inhibitory transcription factors. The changes in HbF levels were measured by HPLC analysis and flow cytometry. The expression level can be measured via quantitative PCR and / or qPCR.
[0401] Example 4: Circular RNA binding to DNA duplexes
[0365] This example describes circular RNA binding to DNA duplexes.
[0402]
[0366] Non-naturally occurring circular RNAs can be engineered to contain DNA binding sequences for the major groove. Short (15-mer) RNA oligonucleotides (triple-stranded oligos) can be used to TNF-α (transferase oligonucleotides (TFOs)) can form stable triple helical RNA:DNA complexes. The third strand of the triplex structure (i.e., the TFO) follows a path through the major groove of the duplex DNA. The specificity and stability of the triplex structure are due to the classical Watson-Crick base pairing in duplex DNA. This is achieved through Hoogsteen hydrogen bonds that are different from those formed by pairing. , which binds to the purine-rich strand of the target duplex through the major groove.
[0403]
[0367] A DNA segment containing a 10-15 base polypurine sequence is synthesized using T7RNA fragments. Unmodified linear RNA is synthesized by in vitro transcription using ribosomal RNA. RNA was purified using an RNA purification system (QIAGEN) and purified using alkaline phosphatase (The rmoFisher Scientific, EF0652) according to the manufacturer's instructions Treat accordingly and purify again using an RNA purification system.
[0404]
[0368] T4 DNA ligase (New England Bio, Inc., M020 2M) or T4 RNA ligase 2 (New England Bio, Inc., M02 Processing of transcribed linear RNA and DNA splints using 39S The ligation generated circular RNA, which was then concentrated by RNase R treatment and purified to a single RNA. RNA quality was assessed by agarose gel or via automated electrophoresis (Agilent). and evaluate.
[0405] Binding of circular RNA to DNA can be achieved by direct DNA binding methods, e.g., to genomic DNA. The direct RNA binding of the dsDNA was assessed via CHART-qPCR. Alternative methods for determining circular RNA binding include triplex immunocapture assays and gel mobility shift assays. Examples of such assays include
[0406] Example 5: Circul...
Claims
[Claim 1] The invention described in this specification.
